Determinations under Sections 85, 85A and 88 (No. PB 24 of 2006)
as amended
made under the
National Health Act 1953
This compilation was prepared on 20 June 2006
taking into account amendments up to No. PB 25 of 2006
Prepared by the Office of Legislative Drafting and Publishing,
Attorney-General’s Department, Canberra
- These Determinations commence on 1 June 2006.
2. The Determinations (No. PB 16 of 2006) under sections 85, 85A and 88 of the National Health Act 1953 made on 24 March 2006 with effect from 1 April 2006 are repealed.
3. In these Determinations:
“Act” means the National Health Act 1953;
“base-priced drug” means —
(a) in relation to cimetidine hydrochloride or ranitidine hydrochloride (tablet, effervescent, equivalent to 150 mg ranitidine or syrup equivalent to 150 mg ranitidine per 10 mL, 300 mL): cimetidine or famotidine or nizatidine or ranitidine hydrochloride (tablet equivalent to 150 mg ranitidine or tablet equivalent to 300 mg ranitidine); or
(b) in relation to amlodipine besylate or lercanidipine hydrochloride or nifedipine (tablet 20 mg (controlled release)): felodipine or nifedipine (tablet 10 mg or tablet 20 mg or tablet 30 mg (controlled release) or tablet 60 mg (controlled release)); or
(c) in relation to ramipril (capsule 10 mg): captopril or enalapril maleate or fosinopril sodium or lisinopril or perindopril erbumine or quinapril hydrochloride or ramipril (tablet 1.25 mg or tablet 2.5 mg or tablet 5 mg) or trandolapril;
“CFC” means chlorofluorocarbon;
“CFU” means colony forming unit;
“electronic communication” has the meaning given by subsection 5(1) of the Electronic Transactions Act 1999;
“g” means gram;
“I.M.” means intramuscular;
“I.U.” means international unit;
“I.V.” means intravenous;
“kg” means kilogram;
“L” means litre;
“m” means metre;
“Medicare Australia CEO” means the Chief Executive Officer of Medicare Australia;
“mg” means milligram;
“mL” means millilitre;
“mm” means millimetre;
“mmol” means millimole;
“PBS” means Pharmaceutical Benefits Scheme;
“Regulations” means the National Health (Pharmaceutical Benefits) Regulations 1960 made under the Act.
4. For the purposes of subsection 85(3) of the Act, where the strength, type of unit, size of unit or other particulars of form are specified in the column headed “Form” in the First or Second Schedule to these Determinations in relation to a drug or medicinal preparation referred to in subsection 85(2) of the Act the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of the Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a pharmaceutical benefit when prescribed by a medical practitioner.
4A. For the purposes of subsection 85(3) of the Act, where a form is specified in the column headed “Form” in the Fourth Schedule to these Determinations, that particular refers to the form of a medicinal preparation, which is composed of one or more of the drugs or medicinal preparations specified in Schedule 4 to the Declaration under subsection 85(2) of the Act with or without the addition of one or more of the substances specified in Schedule 5 to that Declaration, that is allowable for the purposes of Part VII of the Act to the effect that the medicinal preparation in that form is a pharmaceutical benefit when prescribed by a medical practitioner.
5. For the purposes of subsection 88(1A) of the Act, where the strength, type of unit, size of unit or other particulars of form are specified in the column headed “Form” in the Third Schedule to these Determinations in relation to a drug or medicinal preparation referred to in subsection 85(2) of the Act the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of the Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a pharmaceutical benefit referred to in subsection 88(1A) of the Act for the supply of which a participating dental practitioner is authorised to write a prescription.
6. The purposes set out in the column headed “Purposes” in Part 2 of the First or Second Schedule to these Determinations are the only purposes for which a medical practitioner may prescribe the maximum quantities and numbers of repeats specified in that Part in relation to those pharmaceutical benefits specified in that same Part.
7. The purposes set out in the column headed “Purposes” in Part 2 of the Third Schedule to these Determinations are the only purposes for which a participating dental practitioner may prescribe the maximum quantities specified in that Part in relation to those pharmaceutical benefits specified in that same Part.
8. For the purposes of subsection 85A(2)(c) of the Act, the manner of administration, if any, set out in the column headed “Manner of administration” in relation to a pharmaceutical benefit, the name of which is specified in:
(a) the First or Second Schedule to these Determinations, is the only manner in which a medical practitioner may, in a prescription, direct the pharmaceutical benefit to be administered; or
(b) the Third Schedule to these Determinations, is the only manner in which a participating dental practitioner may, in a prescription, direct the pharmaceutical benefit to be administered.
9. For the purposes of subsection 85A(2)(a) of the Act, the maximum quantity or number of units of a pharmaceutical benefit that may, in one prescription, be directed to be supplied on any one occasion is:
(a) where the name of the pharmaceutical benefit is specified —
(i) in Part 1 of the First Schedule to these Determinations — the quantity or number, if any, specified in that Part of the Schedule in the column headed “Maximum quantity” in relation to the pharmaceutical benefit; or
(ii) in Part 2 of the First Schedule to these Determinations and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed “Purposes” — the quantity or number, if any, specified in that Part of the Schedule in the column headed “Maximum quantity” in relation to the pharmaceutical benefit; or
(iii) in Part 1 of the Second Schedule to these Determinations — the quantity or number, if any, specified in that Part of the Schedule in the column headed “Maximum quantity” in relation to the pharmaceutical benefit; or
(iv) in Part 2 of the Second Schedule to these Determinations and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed “Purposes” — the quantity or number, if any, specified in that Part of the Schedule in the column headed “Maximum quantity” in relation to the pharmaceutical benefit; or
(v) in Part 1 of the Third Schedule to these Determinations — the quantity or number, if any, specified in that Part of the Schedule in the column headed “Maximum quantity” in relation to the pharmaceutical benefit; or
(vi) in Part 2 of the Third Schedule to these Determinations and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed “Purposes” — the quantity or number, if any, specified in that Part of the Schedule in the column headed “Maximum quantity” in relation to the pharmaceutical benefit; or
(b) in any other case — the quantity or number, if any, specified in the column headed “Maximum quantity” in the Fourth Schedule to these Determinations in relation to the form of the pharmaceutical benefit.
10. For the purposes of subsection 85A(2)(b) of the Act, the maximum number of occasions, if any, on which the supply of a pharmaceutical benefit may, in one prescription, be directed by a medical practitioner to be repeated is:
(a) where the name of the pharmaceutical benefit is specified —
(i) in Part 1 of the First Schedule to these Determinations — the quantity or number, if any, specified in that Part of the Schedule in the column headed “Maximum number of repeats” in relation to the pharmaceutical benefit; or
(ii) in Part 2 of the First Schedule to these Determinations and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed “Purposes” — the quantity or number, if any, in that Part of the Schedule in the column headed “Maximum number of repeats” in relation to the pharmaceutical benefit; or
(iii) in Part 1 of the Second Schedule to these Determinations — the quantity or number, if any, specified in that Part of the Schedule in the column headed “Maximum number of repeats” in relation to the pharmaceutical benefit; or
(iv) in Part 2 of the Second Schedule to these Determinations and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed “Purposes” — the quantity or number, if any, in that Part of the Schedule in the column headed “Maximum number of repeats” in relation to the pharmaceutical benefit; or
(b) in any other case — the number, if any, specified in the column headed “Maximum number of repeats” in the Fourth Schedule to these Determinations in relation to the form of the pharmaceutical benefit.
11. The following purposes are specified in relation to each pharmaceutical benefit the name of which is specified in Part 2 of the First or Second Schedule to these Determinations:
(a) where a class of persons is specified in the column headed “Purposes” — that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;
(b) where a disease or condition is specified in the column headed “Purposes” —
(i) if subsubparagraph (ii) does not apply — that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or
(ii) if the disease or condition is specified in relation to a specified class of persons — that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;
(c) where a purpose is specified in the column headed “Purposes” — that the pharmaceutical benefit is to be supplied for that purpose;
(d) where it is specified in the column headed “Purposes” that compliance with authority procedures set out in subparagraph 11(d) is required — that a medical practitioner has submitted to the Medicare Australia CEO a prescription for the supply of the pharmaceutical benefit:
(i) by preparing and signing the prescription:
(A) in a form approved by the Secretary and completed by the medical practitioner in ink in his or her own handwriting; or
(B) in a form, prepared by means of a computer, that is in accordance with the form approved by the Secretary under subsubsubparagraph (A); or
(C) in a form, prepared by means of a computer, approved in writing for the purpose by the Secretary and in the format approved in writing by the Secretary; or
(D) by a method approved in writing by the Secretary; or
(ii) by submitting the prescription by giving the Medicare Australia CEO by telephone, details of the prescription which has been prepared and signed by the medical practitioner in accordance with subsubparagraph (i); or
(iii) where the medical practitioner has attempted to obtain an authorisation by submitting details of the prescription to the Medicare Australia CEO in accordance with subsubparagraph (ii) but has been unable to do so because of a failure or other form of unavailability in the telephone system established by the Medicare Australia CEO for the provision of such authorisations, by submitting the prescription in accordance with the instructions stipulated in an emergency telephone message provided to the medical practitioner by the Medicare Australia CEO; or
(iv) by submitting the prescription by giving the Medicare Australia CEO, by means of an electronic communication of a kind approved in writing by the Medicare Australia CEO, details of the prescription which has been prepared and signed by the medical practitioner in accordance with subsubparagraph (i).
11A. For the purposes of subsubparagraph 11(d)(i), a prescription that has been prepared and signed by the medical practitioner in accordance with that subparagraph is taken to have been submitted by him or her if it is submitted by one of his or her employees.
12. Subject to paragraph 12B, the authorisation of a prescription submitted under subparagraph 11(d) may be made:
(a) if the prescription was submitted in accordance with subsubparagraph 11(d)(i) — by the Medicare Australia CEO signing his or her authorisation of the prescription on it and:
(i) if the Medicare Australia CEO requires the medical practitioner to alter the prescription — by returning it to the medical practitioner for alteration before the medical practitioner gives it to the person in respect of whom it was prepared; or
(ii) in any other case:
(A) by returning it to the medical practitioner; or
(B) by sending it to the person in respect of whom it was prepared; or
(b) if the prescription was submitted in accordance with subsubparagraph 11(d)(ii) — orally, at the time the Medicare Australia CEO is given details of the prescription; or
(c) if the prescription was submitted in accordance with subsubparagraph 11(d)(iv) — by the Medicare Australia CEO sending his or her authorisation, by electronic communication, to the medical practitioner.
12A. If the Medicare Australia CEO authorises a prescription in accordance with subparagraph 12(b) or (c):
(a) the Medicare Australia CEO must tell the medical practitioner, orally or by electronic communication, the number that has been allotted to the authorised prescription; and
(b) the medical practitioner must:
(i) mark that number on the prescription; and
(ii) retain a copy of the prescription for 1 year from the date on which the prescription was authorised.
12B. Notwithstanding paragraph 12, if the prescription was submitted in accordance with subsubparagraph 11(d)(iii), authorisation shall be deemed to have been granted upon completion by the medical practitioner of the prescription in accordance with the instructions stipulated in the emergency telephone message provided to the medical practitioner by the Medicare Australia CEO.
12C. Where a prescription is authorised, or deemed to be authorised, in accordance with paragraph 12, and an authorisation is also granted in accordance with subregulation 13(5) of the Regulations increasing the maximum quantity or number of units of the pharmaceutical benefit that may, in the prescription, be directed to be supplied on any one occasion, or the maximum number of occasions on which the supply of the pharmaceutical benefit may, in the prescription, be directed to be repeated, the authorisation in accordance with paragraph 12 is taken to be for the prescription of the increased quantity, number, or occasions, as the case may be.
13. The following purposes are specified in relation to each pharmaceutical benefit the name of which is specified in Part 2 of the Third Schedule to these Determinations:
(a) where a class of persons is specified in the column headed “Purposes” — that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;
(b) where a disease or condition is specified in the column headed “Purposes” —
(i) if subsubparagraph (ii) does not apply — that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or
(ii) if the disease or condition is specified in relation to a specified class of persons — that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;
(c) where a purpose is specified in the column headed “Purposes” — that the pharmaceutical benefit is to be supplied for that purpose.
14. For the purposes of subsection 85(6) of the Act, the name of the manufacturer or the names of manufacturers denoted in accordance with the following table by letters appearing in the column headed “Brand” in the First, Second or Third Schedule to these Determinations in relation to a drug or medicinal preparation the name of which is specified in that Schedule is or are the brand or brands under which the drug or medicinal preparation may be supplied under Part VII of the Act as a pharmaceutical benefit:
Letters | Manufacturer's Name | Letters | Manufacturer's Name |
AB | Abbott Australasia Pty Ltd |
AE | AFT Pharmaceuticals Pty Limited |
AF | Alphapharm Pty Limited |
AG | Allergan Australia Pty Ltd |
AH | Altana Pharma Pty Ltd |
AL | Alphapharm Medical A Division of Alphapharm Pty Limited |
AN | Amgen Australia Pty Ltd |
AP | AstraZeneca Pty Ltd |
AQ | Alcon Laboratories (Australia) Pty Ltd |
AS | Aspen Pharmacare Australia Pty Ltd |
AV | Aventis Pharma Pty Limited |
AW | Arrow Pharmaceuticals Limited |
AX | Aventis Pasteur Pty Limited |
BC | Bristol Laboratories A Division of Bristol-Myers Squibb Australia Pty Ltd |
BD | Biogen Idec Australia Pty Ltd |
BF | Bellwether Pharma Limited |
BG | Biochemie Australia A Division of Sandoz Pty Ltd |
BN | Bayer Australia Limited |
BP | British Pharmaceuticals |
BQ | Bristol-Myers Squibb Pharmaceuticals A Division of Bristol-Myers Squibb Australia Pty Ltd |
BR | B. Braun Australia Pty Ltd |
BU | Bausch & Lomb Surgical A Division of Bausch & Lomb (Australia) Pty Ltd |
BX | Baxter Healthcare Pty Limited |
BY | Boehringer Ingelheim Pty Limited |
CH | Chem mart Pty Limited |
CO | Chemists' Own Pty Ltd A member of Sigma Group of Companies |
CS | CSL Limited |
CV | Ciba Vision Australia Pty Ltd |
CX | Contact Lens Centre Australia Ltd |
DG | Douglas Medication Systems A Division of Douglas Pharmaceuticals Australia Ltd |
DK | Dakota Pharmaceuticals A Division of Sanofi-Synthelabo Australia Pty Limited |
DP | Douglas Pharmaceuticals Australia Ltd |
DR | DiaCare International Pty Ltd |
DT | DermaTech Laboratories Pty Ltd |
EO | Ego Pharmaceuticals Pty Ltd |
EP | EpiPharm Pty Ltd |
EX | Essex Laboratories |
FA | F.H. Faulding & Co. Limited |
FB | Pierre Fabre Medicament Australia Pty Limited |
FL | C. B. Fleet Co. (Aust.) Pty Ltd |
FM | Fawns and McAllan Pty Ltd A member of Sigma Group of Companies |
FP | Ferring Pharmaceuticals Pty Ltd |
FR | Charles E. Frosst Division of Merck Sharp & Dohme (Australia) Pty Ltd |
GC | GlaxoSmithKline Consumer Healthcare |
GD | General Diabetes Services |
GK | GlaxoSmithKline Australia Pty Ltd |
GN | Genepharm Australasia Limited |
GP | GP Laboratories A Division of Pfizer Pty Limited |
GX | GenRx Pty Ltd |
HA | Hamilton Laboratories Pty Ltd |
HP | Hoechst Division of Aventis Pharma Pty Limited |
HX | Hexal Australia Pty Ltd |
IQ | Ioquin A Division of Alcon Laboratories (Australia) Pty Ltd |
IT | InterPharma Pty Ltd |
JC | Janssen-Cilag Pty Ltd |
JT | Johnson & Johnson Pacific Pty Limited |
KN | Knoll A Division of Abbott Australasia Pty Ltd |
KR | Kenral Division of Pharmacia Australia Pty Limited |
KY | Key Pharmaceuticals Pty Ltd |
LB | Life Bioscience Pty Ltd |
LF | Laboratoires Fournier S.A. |
LM | Link Medical Products Pty Ltd |
LN | Lennon Healthcare A Division of Aspen Pharmacare Australia Pty Ltd |
LU | Lundbeck Australia Pty Ltd |
LY | Eli Lilly Australia Pty Limited |
MD | Macarthur Research Division of Roche Products Pty Ltd |
ME | Menley & James Division of GlaxoSmithKline Australia Pty Ltd |
MF | Mundipharma Pty Ltd |
MG | McGloins Classic Brands |
MK | Merck Sharp & Dohme (Australia) Pty Ltd |
ML | Marion Division of Aventis Pharma Pty Limited |
MM | 3M Pharmaceuticals Australia Pty Ltd |
MQ | Merck Pharmaceuticals |
MS | Abbott Diagnostics Division (MediSense Products) |
MX | Mayne Pharma Pty Ltd |
NA | National Diagnostic Products (Aust) Pty Limited |
NE | Norgine Pty Limited |
NF | FlexPen Products of Novo Nordisk Pharmaceuticals Pty Ltd |
NI | InnoLet Products of Novo Nordisk Pharmaceuticals Pty Ltd |
NL | NovoLet Products of Novo Nordisk Pharmaceuticals Pty Ltd |
NM | Novartis Medicines A Division of Novartis Pharmaceuticals Australia Pty Ltd |
NO | Novo Nordisk Pharmaceuticals Pty Ltd |
NT | Nestlé Australia Ltd |
NU | Nutricia Australia Pty Limited |
NV | Novartis Pharmaceuticals Australia Pty Ltd |
OA | Orphan Australia Pty Ltd |
OR | Organon (Australia) Pty Limited |
PC | Pfizer Consumer Healthcare Pty Ltd |
PD | Parke Davis Pty Ltd |
PE | Pacific EyeCare A Division of Allergan Australia Pty Ltd |
PF | Pfizer Pty Limited |
PH | Pharmacia Australia Pty Limited |
PK | Pharmatel Fresenius Kabi Pty Ltd |
PL | Pharmalab |
PM | PMC Pharma A Division of AstraZeneca Pty Ltd |
PP | Petrus Pharmaceuticals Pty Ltd |
PU | Pharmacia & Upjohn Pty Limited |
PX | Point of Care Diagnostics Australia Pty Ltd |
QM | Qualimed Division of Aventis Pharma Pty Limited |
RC | Reckitt Benckiser (Australia) Pty Limited |
RD | Roche Diagnostics Australia Pty Ltd |
RE | Real-RL Division of GlaxoSmithKline Australia Pty Ltd |
RO | Roche Products Pty Ltd |
SB | Scientific Hospital Supplies Australia Products |
SC | Schering Pty Ltd Australian Subsidiary of Schering AG, Berlin |
SE | Servier Laboratories (Aust.) Pty Ltd |
SG | Serono Australia Pty Ltd |
SH | Schering-Plough Pty Ltd |
SI | Sigma Pharmaceuticals Pty Ltd |
SJ | Sharpe Laboratories Pty Ltd |
SL | SBPA A Division of Sandoz Pty Ltd |
SM | Solvay Pharmaceuticals Division of Solvay Biosciences Pty Ltd |
SN | Smith & Nephew Healthcare |
SU | Sauter Laboratories (Aust.) Pty Ltd |
SW | Sanofi-Synthelabo Australia Pty Limited |
SY | Schering AG |
SZ | Sandoz Pty Ltd |
TH | Richard Thomson Pty Ltd |
TM | Technipro Marketing Pty Ltd |
TW | Terry White Chemists |
UC | UCB Pharma A Division of UCB Australia Pty Ltd |
UW | United Works of Pharmaceutical and Dietetic Products, Hungary |
VF | Vitaflo Australia Pty Ltd |
VT | Valeant Pharmaceuticals Australasia Pty Ltd |
WT | Wyeth Consumer Healthcare Pty Ltd |
WW | Wm R. Warner |
WX | Wyeth Australia Pty Limited |
WY | Wyeth Pharmaceuticals Division of Wyeth Australia Pty Limited |
Abciximab | I.V. injection 10 mg in 5 mL vial | Injection | 3 | .. | LY | |||
Acamprosate Calcium | Tablet 333 mg (enteric coated) | Oral | 180 | 1 | AF | |||
Acarbose | Tablet 50 mg | Oral | 90 | 5 | BN | |||
| Tablet 100 mg | Oral | 90 | 5 | BN | |||
Acetazolamide | Tablet 250 mg | Oral | 100 | 3 | SI | |||
Acetylcysteine Sodium | Inhalation solution equivalent to 200 mg acetylcysteine per mL, 5 mL | Inhalation | 30 | 3 | BQ | |||
Aciclovir | Tablet 200 mg | Oral | 50 | .. | AF, DP, GK, GX, HX | |||
| Tablet 800 mg | Oral | 35 | .. | AF, DP, GK, GX, HX | |||
| Eye ointment 30 mg per g, 4.5 g | Application to the eye | 1 | .. | GK | |||
Acitretin | Capsule 10 mg | Oral | 100 | 2 | RO | |||
| Capsule 25 mg | Oral | 100 | 2 | RO | |||
Adalimumab | Injection 40 mg in 0.8 mL pre-filled syringe | Injection | 2 | 3 | AB | |||
Adrenaline | I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector | Injection | 1 | .. | CS | |||
| I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector | Injection | 1 | .. | CS | |||
Adrenaline Acid Tartrate | Injection equivalent to adrenaline 1 in 1,000, 1 mL | Injection | 5 | 1 | AP | |||
Albendazole | Tablet 200 mg | Oral | 6 | 1 | GK | |||
| Tablet 400 mg | Oral | 60 | 2 | GK | |||
Alendronate Sodium | Tablet equivalent to 70 mg alendronic acid | Oral | 4 | 5 | AW, MK | |||
| Tablet equivalent to 40 mg alendronic acid | Oral | 30 | 5 | MK | |||
"Alfaré" | Oral powder 400 g | Oral | 8 | 5 | NT | |||
Allopurinol | Tablet 100 mg | Oral | 200 | 2 | AF, CH, FM, GX, HX, SI, TW | |||
| Tablet 300 mg | Oral | 60 | 2 | AF, CH, FM, GX, HX, SI, TW | |||
Alprazolam | Tablet 250 micrograms | Oral | 50 | .. | AF, AW, HX, PH | |||
| Tablet 500 micrograms | Oral | 50 | .. | AF, AW, HX, PH | |||
| Tablet 1 mg | Oral | 50 | 2 | AF, AW, CH, DP, GX, HX, PH, TW | |||
| Tablet 2 mg | Oral | 50 | 2 | AF, AW, CH, DP, GX, HX, PH, TW | |||
Aluminium Hydroxide - Dried with Magnesium Hydroxide | Tablet 200 mg-200 mg | Oral | 200 | 5 | PC, WW | |||
| Oral suspension 200 mg-200 mg per 5 mL, 500 mL | Oral | 2 | 5 | PC, WW | |||
Aluminium Hydroxide - Dried with Magnesium Trisilicate and Magnesium Hydroxide | Oral suspension 250 mg-120 mg-120 mg per 5 mL, 500 mL | Oral | 2 | 5 | FM | |||
Amantadine Hydrochloride | Capsule 100 mg | Oral | 100 | 5 | NV | |||
Amiloride Hydrochloride | Tablet 5 mg | Oral | 100 | 1 | AF | |||
Aminoglutethimide | Tablet 250 mg | Oral | 100 | 5 | NV | |||
Amiodarone Hydrochloride | Tablet 100 mg | Oral | 30 | 5 | AF, AW, GX, HX, SW | |||
| Tablet 200 mg | Oral | 30 | 5 | AF, AW, CH, GX, HX, SW, TW | |||
Amisulpride | Tablet 100 mg | Oral | 30 | 5 | SW | |||
| Tablet 200 mg | Oral | 60 | 5 | SW | |||
| Tablet 400 mg | Oral | 60 | 5 | SW | |||
| Oral solution 100 mg per mL, 60 mL | Oral | 2 | 5 | SW | |||
Amitriptyline Hydrochloride | Tablet 10 mg | Oral | 50 | 2 | AF | |||
| Tablet 25 mg | Oral | 50 | 2 | AF, MK | |||
| Tablet 50 mg | Oral | 50 | 2 | AF | |||
Amlodipine Besylate | Tablet equivalent to 5 mg amlodipine | Oral | 30 | 5 | PF | |||
| Tablet equivalent to 10 mg amlodipine | Oral | 30 | 5 | PF | |||
Amoxycillin Trihydrate | Tablet, chewable, equivalent to 250 mg amoxycillin | Oral | 20 | 1 | GK | |||
| Tablet equivalent to 1 g amoxycillin | Oral | 14 | 1 | BG, GK, SZ | |||
| Capsule equivalent to 250 mg amoxycillin | Oral | 20 | 1 | AF, CH, CS, DG, DP, GK, GX, HX, SI, TW | |||
| Capsule equivalent to 500 mg amoxycillin | Oral | 20 | 1 | AF, CH, CS, DG, DP, GK, GX, HX, SI, TW | |||
| Sachet containing oral powder equivalent to 3 g amoxycillin | Oral | 1 | .. | GK | |||
Amoxycillin Trihydrate with Potassium Clavulanate | Tablet equivalent to 500 mg amoxycillin-125 mg clavulanic acid | Oral | 10 | 1 | AL, AW, GK, HX, SL, SZ | |||
| Tablet equivalent to 875 mg amoxycillin-125 mg clavulanic acid | Oral | 10 | 1 | AL, AW, CH, GK, GX, HX, SL, SZ, TW | |||
Amoxycillin Trihydrate with Potassium Clavulanate and Water - Purified BP | Powder for oral suspension equivalent to 125 mg amoxycillin-31.25 mg clavulanic acid per 5 mL, 75 mL | Oral | 1 | 1 | AL, AW, GK, HX | |||
| Powder for oral suspension equivalent to 400 mg amoxycillin-57 mg clavulanic acid per 5 mL, 60 mL | Oral | 1 | 1 | AL, AW, GK, HX | |||
Amoxycillin Trihydrate with Water - Purified BP | Powder for paediatric oral drops equivalent to 100 mg amoxycillin per mL, 20 mL | Oral | 1 | 1 | GK | |||
| Powder for oral suspension equivalent to 125 mg amoxycillin per 5 mL, 100 mL | Oral | 1 | 1 | AF, CH, CS, DP, GK, GX, HX, SI, TW | |||
| Powder for oral suspension equivalent to 250 mg amoxycillin per 5 mL, 100 mL | Oral | 1 | 1 | AF, CH, CS, DP, GK, GX, HX, SI, TW | |||
| Powder for oral suspension equivalent to 500 mg amoxycillin per 5 mL, 100 mL | Oral | 1 | 1 | SZ | |||
Amphotericin | Lozenge 10 mg | Oral | 20 | 1 | BQ | |||
| Powder for injection 50 mg | Injection | 1 | .. | BQ | |||
Ampicillin Sodium | Powder for injection equivalent to 500 mg ampicillin | Injection | 5 | 1 | CS, DP | |||
| Powder for injection equivalent to 1 g ampicillin | Injection | 5 | 1 | AS, CS, DP | |||
Ampicillin Trihydrate | Capsule equivalent to 250 mg ampicillin | Oral | 24 | 1 | AF | |||
| Capsule equivalent to 500 mg ampicillin | Oral | 24 | .. | AF | |||
Anakinra | Injection 100 mg in 0.67 mL single use pre-filled syringe | Injection | 28 | 3 | AN | |||
Anastrozole | Tablet 1 mg | Oral | 30 | 5 | AP | |||
Apraclonidine Hydrochloride | Eye drops equivalent to 5 mg apraclonidine per mL, 10 mL | Application to the eye | 1 | 2 | AQ | |||
Aprepitant | Pack containing 1 capsule 125 mg and 2 capsules 80 mg | Oral | 1 | .. | MK | |||
Aripiprazole | Tablet 10 mg | Oral | 30 | 5 | BQ | |||
| Tablet 15 mg | Oral | 30 | 5 | BQ | |||
| Tablet 20 mg | Oral | 30 | 5 | BQ | |||
| Tablet 30 mg | Oral | 30 | 5 | BQ | |||
Aspirin | Tablet 100 mg | Oral | 112 | 1 | FA, MX | |||
| Tablet, dispersible, 300 mg | Oral | 96 | 1 | RC | |||
Atenolol | Tablet 50 mg | Oral | 30 | 5 | AF, AP, CH, DP, GX, HX, SI, TW | |||
Atorvastatin Calcium | Tablet equivalent to 10 mg atorvastatin | Oral | 30 | 5 | PF | |||
| Tablet equivalent to 20 mg atorvastatin | Oral | 30 | 5 | PF | |||
| Tablet equivalent to 40 mg atorvastatin | Oral | 30 | 5 | PF | |||
| Tablet equivalent to 80 mg atorvastatin | Oral | 30 | 5 | PF | |||
Atovaquone | Oral suspension 750 mg per 5 mL, 210 mL | Oral | 1 | .. | GK | |||
Atropine Sulfate | Injection 600 micrograms in 1 mL ampoule | Injection | 10 | 1 | AP | |||
| Eye drops 10 mg per mL, 15 mL | Application to the eye | 1 | 2 | SI | |||
Auranofin | Tablet 3 mg | Oral | 60 | 5 | LM | |||
Azathioprine | Tablet 25 mg | Oral | 100 | 2 | GK, HX | |||
| Tablet 50 mg | Oral | 100 | 2 | AF, AW, DP, GK, GX, HX | |||
Azithromycin Dihydrate | Tablet equivalent to 500 mg azithromycin | Oral | 2 | .. | PF | |||
Azithromycin Dihydrate with Water - Purified BP | Powder for oral suspension equivalent to 200 mg azithromycin per 5 mL, 15 mL | Oral | 1 | .. | PF | |||
Baclofen | Tablet 10 mg | Oral | 100 | 5 | AF, AW, CH, DP, GX, HX, NV, TW | |||
| Tablet 25 mg | Oral | 100 | 5 | AF, AW, CH, DP, GX, HX, NV, TW | |||
Balsalazide Sodium | Capsule 750 mg | Oral | 180 | 5 | PK | |||
"BCG Immunotherapeutic" (Bacillus Calmette-Guérin/ Connaught strain) | Single dose set comprising 1 vial powder for intravesical administration containing 6.6 to 19.2 x 108 CFU and 1 vial diluent 3 mL | Intravesical administration | 3 | 1 | AV | |||
"BCG-Tice" (Bacillus Calmette-Guérin/ Tice strain) | Vial containing powder for intravesical administration approximately 5 x 108 CFU | Intravesical administration | 3 | 1 | OR | |||
Beclomethasone Dipropionate | Pressurised inhalation 50 micrograms per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | MM | |||
| Pressurised inhalation 100 micrograms per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | MM | |||
| Pressurised inhalation in breath actuated device 50 micrograms per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | MM | |||
| Pressurised inhalation in breath actuated device 100 micrograms per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | MM | |||
Benzathine Penicillin | Injection 900 mg in 2 mL cartridge-needle unit (for use with Tubex Injector) | Injection | 1 | .. | AS | |||
| Powder for injection 900 mg | Injection | 1 | .. | AS | |||
Benzhexol Hydrochloride | Tablet 2 mg | Oral | 200 | 2 | SI | |||
| Tablet 5 mg | Oral | 200 | 1 | SI | |||
Benztropine Mesylate | Tablet 2 mg | Oral | 60 | 2 | PL | |||
| Injection 2 mg in 2 mL ampoule | Injection | 5 | .. | MK | |||
Benzydamine Hydrochloride | Mouth and throat rinse 22.5 mg per 15 mL, 500 mL | Oral application | 1 | 1 | MM | |||
Benzyl Benzoate | Application 50 g in 200 mL | Application | 1 | 2 | MG | |||
Benzylpenicillin Sodium | Powder for injection equivalent to 600 mg benzylpenicillin | Injection | 10 | 1 | CS | |||
| Powder for injection equivalent to 3 g benzylpenicillin | Injection | 10 | .. | CS | |||
Betamethasone Acetate with Betamethasone Sodium Phosphate | Injection 3 mg-3.9 mg in 1 mL ampoule | Injection | 5 | .. | SH | |||
Betamethasone Dipropionate | Cream equivalent to 500 micrograms betamethasone per g, 15 g | Application | 1 | 1 | EX, SH | |||
| Ointment equivalent to 500 micrograms betamethasone per g, 15 g | Application | 1 | 1 | EX, SH | |||
Betamethasone Valerate | Cream equivalent to 200 micrograms betamethasone per g, 100 g | Application | 2 | .. | EX, FM, SH, SI | |||
| Cream equivalent to 500 micrograms betamethasone per g, 15 g | Application | 1 | 1 | FM, SI | |||
| Ointment equivalent to 200 micrograms betamethasone per g, 100 g | Application | 2 | .. | EX, SH | |||
| Ointment equivalent to 500 micrograms betamethasone per g, 15 g | Application | 1 | 1 | FM, SI | |||
Betaxolol Hydrochloride | Eye drops, suspension, equivalent to 2.5 mg betaxolol per mL, 5 mL | Application to the eye | 1 | 5 | AQ | |||
| Eye drops, solution, equivalent to 5 mg betaxolol per mL, 5 mL | Application to the eye | 1 | 5 | AQ, IQ | |||
Bethanechol Chloride | Tablet 10 mg | Oral | 100 | 2 | HA | |||
Bicalutamide | Tablet 50 mg | Oral | 28 | 5 | AP | |||
Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | Application to the eye | 1 | 5 | AG | |||
Biperiden Hydrochloride | Tablet 2 mg | Oral | 200 | 2 | AB | |||
Bisacodyl | Tablet 5 mg | Oral | 200 | 2 | AE, AS | |||
| Suppositories 10 mg, 10 | Rectal | 3 | 5 | BY, PP | |||
| Suppositories 10 mg, 12 | Rectal | 3 | 4 | FL, PP | |||
| Enemas 10 mg in 5 mL, 25 | Rectal | 1 | 2 | AS | |||
Bisoprolol Fumarate | Tablet 2.5 mg | Oral | 28 | 5 | AL | |||
| Tablet 5 mg | Oral | 28 | 5 | AL | |||
| Tablet 10 mg | Oral | 28 | 5 | AL | |||
Bivalirudin Trifluoroacetate | Powder for I.V. injection equivalent to 250 mg bivalirudin, vial | Injection | 1 | .. | CS | |||
Bleomycin Sulfate | Powder for injection 15,000 I.U. | Injection | 10 | .. | BQ, MX, SI | |||
Brimonidine Tartrate | Eye drops 2 mg per mL, 5 mL | Application to the eye | 1 | 5 | AG, PE | |||
Brimonidine Tartrate with Timolol Maleate | Eye drops 2 mg brimonidine tartrate with timolol maleate equivalent to 5 mg timolol per mL, 5 mL | Application to the eye | 1 | 5 | AG | |||
Brinzolamide | Eye drops 10 mg per mL, 5 mL | Application to the eye | 1 | 5 | AQ, IQ | |||
Bromocriptine Mesylate | Tablet equivalent to 2.5 mg bromocriptine | Oral | 30 | .. | AF, HX, NV | |||
| Capsule equivalent to 5 mg bromocriptine | Oral | 60 | 5 | AF, HX, NV | |||
| Capsule equivalent to 10 mg bromocriptine | Oral | 100 | 5 | AF, NV | |||
Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | Inhalation | 1 | 5 | AP | |||
| Nebuliser suspension 1 mg in 2 mL single dose units, 30 | Inhalation | 1 | 5 | AP | |||
| Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses | Inhalation by mouth | 1 | 5 | AP | |||
| Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | Inhalation by mouth | 1 | 5 | AP | |||
| Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses | Inhalation by mouth | 1 | 5 | AP | |||
Budesonide with Eformoterol Fumarate Dihydrate | Powder for oral inhalation in breath actuated device 100 micrograms-6 micrograms per dose, 120 doses | Inhalation by mouth | 1 | 5 | AP | |||
| Powder for oral inhalation in breath actuated device 200 micrograms-6 micrograms per dose, 120 doses | Inhalation by mouth | 1 | 5 | AP | |||
| Powder for oral inhalation in breath actuated devices 400 micrograms-12 micrograms per dose, 60 doses, 2 | Inhalation by mouth | 1 | 5 | AP | |||
Buprenorphine | Transdermal patch 5 mg | Transdermal | 2 | .. | MF | |||
| Transdermal patch 10 mg | Transdermal | 2 | .. | MF | |||
| Transdermal patch 20 mg | Transdermal | 2 | .. | MF | |||
Bupropion Hydrochloride | Tablet 150 mg (sustained release) | Oral | 30 | .. | GK, HX, RE | |||
Busulfan | Tablet 2 mg | Oral | 100 | .. | GK | |||
Cabergoline | Tablet 500 micrograms | Oral | 2 | .. | PH | |||
| Tablet 1 mg | Oral | 30 | 5 | PU | |||
| Tablet 2 mg | Oral | 30 | 5 | PU | |||
| Tablet 4 mg | Oral | 30 | 5 | PU | |||
Calcipotriol | Ointment 50 micrograms per g, 30 g | Application | 1 | 1 | CS | |||
Calcitriol | Capsule 0.25 microgram | Oral | 100 | 3 | AF, AW, DP, GX, HX, RO | |||
Calcium Carbonate | Tablet, chewable, 1.25 g (equivalent to 500 mg calcium) | Oral | 120 | 1 | MM | |||
| Tablet 1.5 g (equivalent to 600 mg calcium) | Oral | 120 | 1 | WT | |||
Calcium Citrate | Tablet equivalent to 250 mg calcium | Oral | 120 | 1 | KY | |||
Calcium Folinate | Tablet equivalent to 15 mg folinic acid | Oral | 10 | .. | MX | |||
| Injection equivalent to 50 mg folinic acid in 5 mL | Injection | 5 | 5 | IT, MX, PF | |||
| Injection equivalent to 100 mg folinic acid in 10 mL | Injection | 10 | 1 | IT, PF | |||
Candesartan Cilexetil | Tablet 4 mg | Oral | 30 | 5 | AP | |||
| Tablet 8 mg | Oral | 30 | 5 | AP | |||
| Tablet 16 mg | Oral | 30 | 5 | AP | |||
| Tablet 32 mg | Oral | 30 | 5 | AP | |||
Candesartan Cilexetil with Hydrochlorothiazide | Tablet 16 mg-12.5 mg | Oral | 30 | 5 | AP | |||
Capecitabine | Tablet 150 mg | Oral | 60 | 2 | RO | |||
| Tablet 500 mg | Oral | 120 | 2 | RO | |||
"Caprilon" | Oral powder 420 g | Oral | 8 | 5 | SB | |||
Captopril | Tablet 12.5 mg | Oral | 90 | 5 | AF, BQ, CH, DP, FM, GX, HX, TW | |||
| Tablet 25 mg | Oral | 90 | 5 | AF, BQ, CH, DP, FM, GX, HX, TW | |||
| Tablet 50 mg | Oral | 90 | 5 | AF, BQ, CH, DP, FM, GX, HX, TW | |||
| Oral solution 5 mg per mL, 95 mL | Oral | 1 | 5 | BQ | |||
Carbamazepine | Tablet 100 mg | Oral | 200 | 2 | BG, NV, SZ | |||
| Tablet 200 mg | Oral | 200 | 2 | AF, BG, NV, SZ | |||
| Tablet 200 mg (controlled release) | Oral | 200 | 2 | NV | |||
| Tablet 400 mg (controlled release) | Oral | 200 | 2 | NV | |||
| Oral suspension 100 mg per 5 mL, 300 mL | Oral | 1 | 5 | NV | |||
Carbimazole | Tablet 5 mg | Oral | 200 | 2 | RO | |||
"Carbohydrate Free Mixture" | Oral powder 225 g | Oral | 24 | 5 | SB | |||
Carbomer 974 | Ocular lubricating gel 3 mg per g, single dose units 0.5 g, 30 | Application to the eye | 3 | 5 | AQ | |||
Carbomer 980 | Ocular lubricating gel 2 mg per g, 10 g | Application to the eye | 1 | 5 | BU, CV, NV | |||
| Eye drops 2 mg per g, single dose units 0.6 mL, 30 | Application to the eye | 3 | 5 | NV | |||
Carboplatin | Solution for I.V. injection 50 mg in 5 mL vial | Injection | 2 | .. | MX, PU | |||
| Solution for I.V. injection 150 mg in 15 mL vial | Injection | 6 | .. | MX, PU | |||
| Solution for I.V. injection 450 mg in 45 mL vial | Injection | 2 | .. | MX, PU | |||
Carmellose Sodium | Eye drops 5 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG | |||
| Eye drops 10 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG | |||
| Eye drops 2.5 mg per mL, single dose units 0.6 mL, 24 | Application to the eye | 4 | 5 | CX | |||
| Eye drops 5 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | 3 | 5 | AG | |||
| Eye drops 10 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | 3 | 5 | AG | |||
| Ocular lubricating gel 10 mg per mL, single dose units 0.6 mL, 28 | Application to the eye | 3 | 5 | CX | |||
Carmustine | Implants 7.7 mg, 8 | Intracranial | 1 | .. | OA | |||
Carvedilol | Pack containing 30 tablets 3.125 mg, 30 tablets 6.25 mg and 10 tablets 12.5 mg | Oral | 1 | .. | RO | |||
| Tablet 3.125 mg | Oral | 30 | .. | MD, RO | |||
| Tablet 6.25 mg | Oral | 60 | 5 | MD, RO | |||
| Tablet 12.5 mg | Oral | 60 | 5 | MD, RO | |||
| Tablet 25 mg | Oral | 60 | 5 | MD, RO | |||
|
|
|
|
|
| |||
|
|
|
|
|
| |||
|
|
|
|
|
| |||
Cefaclor Monohydrate | Tablet (sustained release) equivalent to 375 mg cefaclor | Oral | 10 | 1 | AF, AS, CH, DG, DP, GX, LN, TW | |||
Cefaclor Monohydrate with Water - Purified BP | Powder for oral suspension equivalent to 125 mg cefaclor per 5 mL, 100 mL | Oral | 1 | 1 | AF, AS, AW, CH, GX, TW | |||
| Powder for oral suspension equivalent to 250 mg cefaclor per 5 mL, 75 mL | Oral | 1 | 1 | AF, AS, AW, CH, GX, TW | |||
Cefepime Hydrochloride | Powder for injection equivalent to 1 g cefepime | Injection | 10 | .. | BQ | |||
| Powder for injection equivalent to 2 g cefepime | Injection | 10 | .. | BQ | |||
Cefotaxime Sodium | Powder for injection equivalent to 1 g cefotaxime | Injection | 10 | .. | MX, SZ | |||
| Powder for injection equivalent to 2 g cefotaxime | Injection | 10 | .. | MX, SZ | |||
Ceftriaxone Sodium | Powder for injection equivalent to 250 mg ceftriaxone | Injection | 1 | .. | RO | |||
| Powder for injection equivalent to 500 mg ceftriaxone | Injection | 5 | .. | RO | |||
| Powder for injection equivalent to 1 g ceftriaxone | Injection | 5 | .. | MX, RO, SZ | |||
| Powder for injection equivalent to 2 g ceftriaxone | Injection | 5 | .. | MX, RO, SZ | |||
Cefuroxime Axetil | Tablet equivalent to 250 mg cefuroxime | Oral | 14 | 1 | GK | |||
Celecoxib | Capsule 100 mg | Oral | 60 | 3 | PH | |||
| Capsule 200 mg | Oral | 30 | 3 | PH | |||
Cephalexin | Capsule 250 mg (anhydrous) | Oral | 20 | 1 | AF, AS, CH, DP, GX, HX, LN, TW | |||
| Capsule 500 mg (anhydrous) | Oral | 20 | 1 | AF, AS, CH, DP, GX, HX, LN, TW | |||
Cephalexin with Water - Purified BP | Granules for oral suspension 125 mg per 5 mL, 100 mL | Oral | 1 | 1 | AF, AS, CH, DP, GX, LN, TW | |||
| Granules for oral suspension 250 mg per 5 mL, 100 mL | Oral | 1 | 1 | AF, AS, CH, DP, GX, LN, TW | |||
Cephalothin Sodium | Powder for injection equivalent to 1 g cephalothin | Injection | 10 | 1 | AS, MX | |||
Cephazolin Sodium | Powder for injection equivalent to 500 mg cephazolin | Injection | 10 | .. | MX | |||
| Powder for injection equivalent to 1 g cephazolin | Injection | 10 | .. | AS, MX, SZ | |||
Chlorambucil | Tablet 2 mg | Oral | 100 | 2 | GK | |||
Chloramphenicol | Ear drops (aqueous) 5 mg per mL, 5 mL | Application to the ear | 1 | 2 | PF | |||
| Eye drops 5 mg per mL, 10 mL | Application to the eye | 1 | 2 | PF, SI | |||
| Eye ointment 10 mg per g, 4 g | Application to the eye | 1 | .. | PF, SI | |||
Chlorpromazine Hydrochloride | Tablet 10 mg | Oral | 100 | 5 | AV | |||
| Tablet 25 mg | Oral | 100 | 5 | AV | |||
| Tablet 100 mg | Oral | 100 | 5 | AV | |||
| Oral solution 25 mg per 5 mL, 100 mL | Oral | 1 | 5 | AV | |||
| Injection 50 mg in 2 mL ampoule | Injection | 10 | .. | AV | |||
Chlorthalidone | Tablet 25 mg | Oral | 100 | 1 | NV | |||
Cholestyramine | Sachets containing 4.7 g oral powder (equivalent to 4 g cholestyramine), 50 | Oral | 2 | 5 | BQ | |||
| Sachets containing 9.4 g oral powder (equivalent to 8 g cholestyramine), 50 | Oral | 1 | 5 | BQ | |||
Chorionic Gonadotrophin | Injection set containing 3 ampoules powder for injection 500 units and 3 ampoules solvent 1 mL | Injection | 1 | 5 | OR | |||
| Injection set containing 3 ampoules powder for injection 1,500 units and 3 ampoules solvent 1 mL | Injection | 1 | 5 | OR | |||
Ciclesonide | Pressurised inhalation 80 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | AH | |||
| Pressurised inhalation 160 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | AH | |||
Cimetidine | Tablet 200 mg | Oral | 120 | 5 | AF, GK | |||
| Tablet 400 mg | Oral | 60 | 5 | AF, GK, GX | |||
| Tablet 800 mg | Oral | 30 | 5 | AF, GK, GX | |||
Cimetidine Hydrochloride | Tablet, effervescent, equivalent to 800 mg cimetidine | Oral | 30 | 5 | GK | |||
Ciprofloxacin Hydrochloride | Tablet equivalent to 500 mg ciprofloxacin | Oral | 14 | .. | AL, AW, BG, BN, DP, GN, GX, HX | |||
| Tablet equivalent to 750 mg ciprofloxacin | Oral | 14 | .. | AL, AW, BN, DP, GN, GX, HX | |||
| Tablet equivalent to 250 mg ciprofloxacin | Oral | 2 | .. | BN | |||
| Eye drops equivalent to 3 mg ciprofloxacin per mL, 5 mL | Application to the eye | 2 | .. | AQ, IQ | |||
Cisplatin | I.V. injection 10 mg in 10 mL vial | Injection | 1 | .. | PU | |||
| I.V. injection 50 mg in 50 mL vial | Injection | 1 | .. | MX, PU | |||
| I.V. injection 100 mg in 100 mL vial | Injection | 1 | .. | MX | |||
Citalopram Hydrobromide | Tablet equivalent to 10 mg citalopram | Oral | 28 | 5 | AF | |||
| Tablet equivalent to 20 mg citalopram | Oral | 28 | 5 | AF, AW, CH, DP, GX, HX, LU, TW | |||
| Tablet equivalent to 40 mg citalopram | Oral | 28 | 5 | AF, GX, HX | |||
Cladribine | Injection 10 mg in 5 mL vial | Injection | 7 | .. | OA | |||
| Solution for I.V. infusion 10 mg in 10 mL single use vial | Injection | 7 | .. | JC | |||
Clarithromycin | Tablet 250 mg | Oral | 14 | 1 | AB, AF, CH, DP, GX, HX, TW | |||
Clindamycin Hydrochloride | Capsule equivalent to 150 mg clindamycin | Oral | 25 | .. | KR, PH | |||
Clomiphene Citrate | Tablet 50 mg | Oral | 10 | 5 | AV, AW, GX, HX, SG | |||
Clomipramine Hydrochloride | Tablet 25 mg | Oral | 50 | 2 | AF, CH, GX, NV, TW | |||
Clonazepam | Tablet 500 micrograms | Oral | 200 | 2 | AF, RO | |||
| Tablet 2 mg | Oral | 200 | 2 | AF, RO | |||
| Oral liquid 2.5 mg per mL, 10 mL | Oral | 2 | .. | RO | |||
| Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent) | Injection | 5 | .. | RO | |||
Clonidine Hydrochloride | Tablet 100 micrograms | Oral | 100 | 5 | BY | |||
| Tablet 150 micrograms | Oral | 100 | 5 | BY | |||
Clopidogrel Hydrogen Sulfate | Tablet equivalent to 75 mg clopidogrel | Oral | 28 | 5 | BQ, SW | |||
Coal Tar - Prepared | Gel 10 mg per g, 100 mL | Application | 1 | 2 | EP | |||
Codeine Phosphate | Tablet 30 mg | Oral | 20 | .. | FM | |||
Codeine Phosphate with Paracetamol | Tablet 30 mg-500 mg | Oral | 20 | .. | AL, CO, DK, FM, GK, SW | |||
Colchicine | Tablet 500 micrograms | Oral | 100 | 2 | AS, LN | |||
Colestipol Hydrochloride | Oral powder, sachets 5 g, 120 | Oral | 1 | 5 | PH | |||
Copper Sulfate | Tablets, diagnostic compound, 36 |
| 2 | 3 | BN | |||
Cortisone Acetate | Tablet 5 mg | Oral | 50 | 4 | AS | |||
| Tablet 25 mg | Oral | 60 | 4 | AS | |||
Cyclophosphamide | Tablet 50 mg | Oral | 50 | 2 | PH | |||
| Powder for injection 500 mg (anhydrous) | Injection | 2 | .. | BX | |||
| Powder for injection 1 g (anhydrous) | Injection | 1 | .. | BX | |||
| Powder for injection 2 g (anhydrous) | Injection | 1 | .. | BX | |||
Cyclosporin | Capsule 10 mg | Oral | 120 | 3 | NV | |||
| Capsule 25 mg | Oral | 60 | 3 | HX, MX, NV | |||
| Capsule 50 mg | Oral | 60 | 3 | HX, MX, NV | |||
| Capsule 100 mg | Oral | 60 | 3 | HX, MX, NV | |||
| Oral liquid 100 mg per mL, 50 mL | Oral | 2 | 3 | NV | |||
Cyproheptadine Hydrochloride | Tablet 4 mg (anhydrous) | Oral | 100 | 2 | FR | |||
Cyproterone Acetate | Tablet 50 mg | Oral | 20 | 5 | AF, DP, GX, HX, SC, SY | |||
| Tablet 100 mg | Oral | 50 | 5 | DP, GX, HX, SC, SY | |||
Cytarabine | Injection 100 mg in 5 mL vial | Injection | 10 | 1 | PU | |||
| Injection 500 mg in 5 mL vial | Injection | 2 | 1 | MX | |||
Dalteparin Sodium | Injection 2,500 I.U. (anti-Xa) in 0.2 mL single dose pre-filled syringe | Injection | 10 | 1 | PH | |||
| Injection 5,000 I.U. (anti-Xa) in 0.2 mL single dose pre-filled syringe | Injection | 10 | 1 | PH | |||
| Injection 7,500 I.U. (anti-Xa) in 0.75 mL single dose pre-filled syringe | Injection | 10 | 1 | PH | |||
| Injection 10,000 I.U. (anti-Xa) in 1 mL single dose pre-filled syringe | Injection | 10 | 1 | PH | |||
Danazol | Capsule 100 mg | Oral | 100 | 5 | AF | |||
| Capsule 200 mg | Oral | 100 | 5 | AF | |||
Dantrolene Sodium | Capsule 25 mg | Oral | 100 | 2 | PU | |||
| Capsule 50 mg | Oral | 100 | 2 | PU | |||
Dapsone | Tablet 25 mg | Oral | 100 | 1 | LM | |||
| Tablet 100 mg | Oral | 100 | 1 | LM | |||
Desmopressin Acetate | Intranasal solution 100 micrograms per mL, 2.5 mL dropper bottle | Nasal | 5 | 5 | FP | |||
| Tablet 200 micrograms | Oral | 30 | 5 | FP | |||
| Nasal spray (pump pack) 10 micrograms per actuation, 60 actuations, 6 mL | Nasal | 1 | 5 | FP | |||
Dexamethasone | Tablet 500 micrograms | Oral | 30 | 4 | AS | |||
| Tablet 4 mg | Oral | 30 | 4 | AS | |||
| Eye drops 1 mg per mL, 5 mL | Application to the eye | 1 | 2 | AQ | |||
Dexamethasone Sodium Metasulfobenzoate with Framycetin Sulfate and Gramicidin | Ear drops 500 micrograms (dexamethasone)-5 mg-50 micrograms per mL, 8 mL | Application to the ear | 1 | 2 | AV, QM | |||
Dexamethasone Sodium Phosphate | Injection equivalent to 4 mg dexamethasone phosphate in 1 mL ampoule | Injection | 5 | .. | MX | |||
| Injection equivalent to 8 mg dexamethasone phosphate in 2 mL vial | Injection | 5 | 1 | MX | |||
| Injection equivalent to 120 mg dexamethasone phosphate in 5 mL vial | Injection | 1 | .. | MX | |||
Dexamphetamine Sulfate | Tablet 5 mg | Oral | 100 | 5 | SI | |||
"Dialamine" | Oral powder 200 g | Oral | 10 | 5 | SB | |||
Diazepam | Tablet 2 mg | Oral | 50 | .. | AF, AW, RO, SU | |||
| Tablet 5 mg | Oral | 50 | .. | AF, AW, DP, RO, SU | |||
| Injection 10 mg in 2 mL ampoule | Injection | 5 | .. | MX | |||
Diclofenac Sodium | Tablet 25 mg (enteric coated) | Oral | 100 | 3 | AF, AW, BG, CH, DP, GX, HX, NV, TW | |||
| Tablet 50 mg (enteric coated) | Oral | 50 | 3 | AF, AW, CH, DP, GX, HX, NV, TW | |||
| Eye drops 1 mg per mL, 5 mL | Application to the eye | 1 | .. | NV | |||
| Suppository 100 mg | Rectal | 40 | 3 | NV | |||
Dicloxacillin Sodium | Capsule equivalent to 250 mg dicloxacillin | Oral | 24 | .. | AF, BQ, SI | |||
| Capsule equivalent to 500 mg dicloxacillin | Oral | 24 | .. | AF, BQ, SI | |||
| Powder for injection equivalent to 500 mg dicloxacillin | Injection | 5 | .. | BQ | |||
| Powder for injection equivalent to 1 g dicloxacillin | Injection | 5 | 1 | BQ | |||
"Digestelact" | Oral powder 900 g | Oral | 3 | 1 | SJ | |||
Digoxin | Tablet 62.5 micrograms | Oral | 200 | 1 | FM, SI | |||
| Tablet 250 micrograms | Oral | 100 | 1 | FM, SI | |||
| Paediatric oral solution 50 micrograms per mL, 60 mL | Oral | 2 | 3 | SI | |||
Dihydroergotamine Mesylate | Injection 1 mg in 1 mL ampoule | Injection | 5 | .. | NV | |||
Diltiazem Hydrochloride | Tablet 60 mg | Oral | 90 | 5 | AF, AV, CH, DP, GX, HP, HX, TW | |||
| Capsule 180 mg (controlled delivery) | Oral | 30 | 5 | AV, CH, DP, GX, HP, TW | |||
| Capsule 240 mg (controlled delivery) | Oral | 30 | 5 | AV, CH, DP, GX, HP, TW | |||
| Capsule 360 mg (controlled delivery) | Oral | 30 | 5 | AV, HP | |||
Diphenoxylate Hydrochloride with Atropine Sulfate | Tablet 2.5 mg-25 micrograms | Oral | 20 | .. | KR, PH | |||
Diphtheria and Tetanus Vaccine - Adsorbed | Injection 0.5 mL ampoule | Injection | 3 | .. | CS | |||
Diphtheria and Tetanus Vaccine - Adsorbed (Diluted) | Injection 0.5 mL in pre-filled syringe. For immunisation of adults and children over the age of 8 years | Injection | 3 | .. | CS | |||
Dipivefrine Hydrochloride | Eye drops 1 mg per mL, 10 mL | Application to the eye | 1 | 5 | AG | |||
Dipyridamole | Capsule 200 mg (sustained release) | Oral | 60 | 5 | BY | |||
Dipyridamole with Aspirin | Capsule 200 mg (sustained release)-25 mg | Oral | 60 | 5 | BY | |||
Disodium Etidronate | Tablet 200 mg | Oral | 60 | 5 | PU | |||
Disodium Etidronate and Calcium Carbonate | Pack containing 28 tablets disodium etidronate 200 mg and 76 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium) | Oral | 1 | 1 | PU | |||
Disodium Pamidronate | Concentrated injection 15 mg in 5 mL vial | Injection | 4 | .. | MX | |||
| Injection set containing 4 vials powder for I.V. infusion 15 mg and 4 ampoules solvent 5 mL | Injection | 1 | .. | NV | |||
| Concentrated injection 30 mg in 10 mL vial | Injection | 2 | .. | MX | |||
| Injection set containing 2 vials powder for I.V. infusion 30 mg and 2 ampoules solvent 10 mL | Injection | 1 | .. | NV | |||
| Concentrated injection 60 mg in 10 mL vial | Injection | 1 | .. | MX | |||
Disopyramide | Capsule 100 mg | Oral | 100 | 5 | AV | |||
| Capsule 150 mg | Oral | 100 | 5 | AV | |||
Docetaxel | Injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL | Injection | 2 | .. | AV | |||
| Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL | Injection | 1 | .. | AV | |||
Docusate Sodium with Bisacodyl | Suppositories 100 mg-10 mg, 5 | Rectal | 6 | 5 | FM | |||
Dolasetron Mesylate | Tablet 200 mg | Oral | 2 | .. | AV | |||
| I.V. injection 100 mg in 5 mL ampoule | Injection | 1 | .. | AV | |||
Domperidone | Tablet 10 mg | Oral | 25 | .. | JC | |||
Donepezil Hydrochloride | Tablet 5 mg | Oral | 28 | 5 | PF | |||
| Tablet 10 mg | Oral | 28 | 5 | PF | |||
Dorzolamide Hydrochloride | Eye drops equivalent to 20 mg dorzolamide per mL, 5 mL | Application to the eye | 1 | 5 | MK | |||
Dorzolamide Hydrochloride with Timolol Maleate | Eye drops equivalent to 20 mg dorzolamide-5 mg timolol per mL, 5 mL | Application to the eye | 1 | 5 | MK | |||
Dothiepin Hydrochloride | Capsule 25 mg | Oral | 50 | 2 | AB, AF | |||
| Tablet 75 mg | Oral | 30 | 2 | AB, AF | |||
Doxepin Hydrochloride | Tablet equivalent to 50 mg doxepin | Oral | 50 | 2 | AF | |||
| Capsule equivalent to 10 mg doxepin | Oral | 50 | 2 | AF, PF | |||
| Capsule equivalent to 25 mg doxepin | Oral | 50 | 2 | AF, PF | |||
Doxorubicin Hydrochloride | Solution for I.V. injection or intravesical administration 10 mg in 5 mL single dose vial | Injection or intravesical administration | 4 | .. | IT, MX, PH | |||
| Solution for I.V. injection or intravesical administration 20 mg in 10 mL single dose vial | Injection or intravesical administration | 4 | .. | PH | |||
| Solution for I.V. injection or intravesical administration 50 mg in 25 mL single dose vial | Injection or intravesical administration | 3 | .. | IT, MX, PH | |||
| Solution for I.V. injection or intravesical administration 100 mg in 50 mL single dose vial | Injection or intravesical administration | 1 | .. | IT | |||
| Solution for I.V. injection or intravesical administration 200 mg in 100 mL single dose vial | Injection or intravesical administration | 1 | .. | IT | |||
Doxorubicin Hydrochloride - Pegylated Liposomal | Suspension for I.V. infusion 20 mg in 10 mL vial | Injection | 1 | .. | SH | |||
| Suspension for I.V. infusion 50 mg in 25 mL vial | Injection | 1 | .. | SH | |||
Doxycycline Hydrochloride | Tablet equivalent to 50 mg doxycycline | Oral | 25 | 5 | AF, DP, PF | |||
| Capsule equivalent to 50 mg doxycycline (containing enteric coated pellets) | Oral | 25 | 5 | FA, MX | |||
| Tablet equivalent to 100 mg doxycycline | Oral | 7 | 1 | AF, DP, PF, SI | |||
| Capsule equivalent to 100 mg doxycycline (containing enteric coated pellets) | Oral | 7 | 1 | FA, MX | |||
Doxycycline Monohydrate | Tablet equivalent to 50 mg doxycycline | Oral | 25 | 5 | AW, CH, GX, HX, TW | |||
| Tablet equivalent to 100 mg doxycycline | Oral | 7 | 1 | CH, GX, HX, TW | |||
Drotrecogin Alfa (Activated) | Powder for I.V. infusion 5 mg, vial | Injection | 1 | .. | LY | |||
| Powder for I.V. infusion 20 mg, vial | Injection | 1 | .. | LY | |||
"Duocal" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
Dydrogesterone | Tablet 10 mg | Oral | 28 | 2 | SM | |||
"Easiphen" | Oral liquid 250 mL | Oral | 90 | 5 | SB | |||
Efalizumab | Injection set containing 4 vials powder for injection 125 mg and 4 pre-filled syringes diluent 1.3 mL | Injection | 1 | 3 | SG | |||
Eformoterol Fumarate Dihydrate | Capsule containing powder for oral inhalation 12 micrograms (for use in Foradile Aerolizer) | Inhalation by mouth | 60 | 5 | NV | |||
| Powder for oral inhalation in breath actuated device 6 micrograms per dose, 60 doses | Inhalation by mouth | 1 | 5 | AP | |||
| Powder for oral inhalation in breath actuated device 12 micrograms per dose, 60 doses | Inhalation by mouth | 1 | 5 | AP | |||
"EleCare" | Oral powder 400 g | Oral | 8 | 5 | AB | |||
Enalapril Maleate | Tablet 5 mg | Oral | 30 | 5 | AF, BF, CH, DP, FR, GX, HX, MK, SI, TW | |||
| Tablet 10 mg | Oral | 30 | 5 | AF, BF, CH, DP, FR, GX, HX, MK, SI, TW | |||
| Tablet 20 mg | Oral | 30 | 5 | AF, BF, CH, DP, FR, GX, HX, MK, SI, TW | |||
Enalapril Maleate with Hydrochlorothiazide | Tablet 20 mg-6 mg | Oral | 30 | 5 | MK | |||
"Energivit" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
Enoxaparin Sodium | Injection 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe | Injection | 10 | 1 | AV | |||
| Injection 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe | Injection | 10 | 1 | AV | |||
| Injection 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe | Injection | 10 | 1 | AV | |||
| Injection 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | 10 | 1 | AV | |||
| Injection 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | 10 | 1 | AV | |||
Entacapone | Tablet 200 mg | Oral | 200 | 4 | NV | |||
Epirubicin Hydrochloride | Solution for injection 10 mg in 5 mL | Injection or intravesical administration | 4 | .. | IT, PH | |||
| Solution for injection 20 mg in 10 mL | Injection or intravesical administration | 4 | .. | PH | |||
| Solution for injection 50 mg in 25 mL | Injection or intravesical administration | 3 | .. | IT, PH | |||
| Solution for injection 100 mg in 50 mL | Injection or intravesical administration | 2 | .. | IT | |||
| Solution for injection 200 mg in 100 mL | Injection or intravesical administration | 1 | .. | IT | |||
Eplerenone | Tablet 25 mg | Oral | 30 | 5 | PF | |||
| Tablet 50 mg | Oral | 30 | 5 | PF | |||
Eprosartan Mesylate | Tablet equivalent to 400 mg eprosartan | Oral | 56 | 5 | SM | |||
| Tablet equivalent to 600 mg eprosartan | Oral | 28 | 5 | SM | |||
Eprosartan Mesylate with Hydrochlorothiazide | Tablet equivalent to 600 mg eprosartan with 12.5 mg hydrochlorothiazide | Oral | 28 | 5 | SM | |||
Eptifibatide Acetate | Solution for I.V. injection equivalent to 20 mg eptifibatide in 10 mL vial | Injection | 2 | .. | SH | |||
| Solution for I.V. infusion equivalent to 75 mg eptifibatide in 100 mL vial | Injection | 3 | .. | SH | |||
Erythromycin | Capsule 250 mg (containing enteric coated pellets) | Oral | 25 | 1 | FA, MX | |||
Erythromycin Ethyl Succinate | Tablet equivalent to 400 mg erythromycin | Oral | 25 | 1 | AB, AF | |||
Erythromycin Ethyl Succinate with Water - Purified BP | Powder for oral liquid equivalent to 200 mg erythromycin per 5 mL, 100 mL | Oral | 1 | 1 | AB, AF | |||
| Powder for oral liquid equivalent to 400 mg erythromycin per 5 mL, 100 mL | Oral | 1 | 1 | AB, AF | |||
Erythromycin Lactobionate | Powder for I.V. infusion equivalent to 1 g erythromycin, vial | Injection | 5 | .. | AB | |||
Escitalopram Oxalate | Tablet equivalent to 10 mg escitalopram | Oral | 28 | 5 | LU | |||
| Tablet equivalent to 20 mg escitalopram | Oral | 28 | 5 | LU | |||
| Oral solution equivalent to 10 mg escitalopram per mL, 28 mL | Oral | 1 | 5 | LU | |||
Esomeprazole Magnesium Trihydrate | Tablet (enteric coated), equivalent to 20 mg esomeprazole | Oral | 30 | 1 | AP | |||
| Tablet (enteric coated), equivalent to 40 mg esomeprazole | Oral | 30 | 1 | AP | |||
Esomeprazole Magnesium Trihydrate and Clarithromycin and Amoxycillin Trihydrate | Pack containing 14 tablets (enteric coated) esomeprazole magnesium trihydrate equivalent to 20 mg esomeprazole, 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin trihydrate equivalent to 500 mg amoxycillin | Oral | 1 | .. | AP | |||
Etanercept | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | Injection | 3 | .. | WY | |||
| Injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL | Injection | 1 | 3 | WY | |||
Ethacrynic Acid | Tablet 25 mg | Oral | 200 | 1 | MK | |||
Ethosuximide | Capsule 250 mg | Oral | 200 | 2 | PF | |||
| Oral solution 250 mg per 5 mL, 200 mL | Oral | 1 | 5 | PF | |||
Etonogestrel | Subcutaneous implant 68 mg | Subcutaneous implantation | 1 | .. | OR | |||
Etoposide | Capsule 50 mg | Oral | 20 | .. | BQ | |||
| Capsule 100 mg | Oral | 10 | .. | BQ | |||
| Solution for I.V. infusion 100 mg in 5 mL vial | Injection | 5 | .. | IT, MX | |||
Etoposide Phosphate | Powder for I.V. infusion 113.6 mg, vial | Injection | 5 | .. | BQ | |||
| Powder for I.V. infusion 1.136 g, vial | Injection | 1 | .. | BQ | |||
Everolimus | Tablet 0.25 mg | Oral | 60 | 3 | NV | |||
| Tablet 0.5 mg | Oral | 60 | 3 | NV | |||
| Tablet 0.75 mg | Oral | 120 | 3 | NV | |||
Exemestane | Tablet 25 mg | Oral | 30 | 2 | PH | |||
Ezetimibe | Tablet 10 mg | Oral | 30 | 5 | MK | |||
Ezetimibe with Simvastatin | Tablet 10 mg-40 mg | Oral | 30 | 5 | MK | |||
| Tablet 10 mg-80 mg | Oral | 30 | 5 | MK | |||
Famciclovir | Tablet 125 mg | Oral | 40 | 1 | NV | |||
| Tablet 250 mg | Oral | 21 | .. | NV | |||
| Tablet 500 mg | Oral | 30 | .. | NV | |||
Famotidine | Tablet 20 mg | Oral | 60 | 5 | AF, AW, CH, DP, GX, HX, MK, TW | |||
| Tablet 40 mg | Oral | 30 | 5 | AF, AW, CH, DP, GX, HX, MK, TW | |||
Felodipine | Tablet 2.5 mg (extended release) | Oral | 30 | 5 | AL, AP | |||
| Tablet 5 mg (extended release) | Oral | 30 | 5 | AL, AP | |||
| Tablet 10 mg (extended release) | Oral | 30 | 5 | AL, AP | |||
Fenofibrate | Capsule 67 mg | Oral | 60 | 5 | LF | |||
| Tablet 160 mg | Oral | 30 | 5 | LF | |||
Fentanyl | Transdermal patch 2.1 mg | Transdermal | 5 | .. | JC | |||
| Transdermal patch 2.5 mg | Transdermal | 5 | .. | JC | |||
| Transdermal patch 4.2 mg | Transdermal | 5 | .. | JC | |||
| Transdermal patch 5 mg | Transdermal | 5 | .. | JC | |||
| Transdermal patch 8.4 mg | Transdermal | 5 | .. | JC | |||
| Transdermal patch 7.5 mg | Transdermal | 5 | .. | JC | |||
| Transdermal patch 12.6 mg | Transdermal | 5 | .. | JC | |||
| Transdermal patch 10 mg | Transdermal | 5 | .. | JC | |||
| Transdermal patch 16.8 mg | Transdermal | 5 | .. | JC | |||
Ferrous Sulfate | Oral liquid 30 mg per mL, 250 mL | Oral | 1 | 2 | AE | |||
Flecainide Acetate | Tablet 50 mg | Oral | 60 | 5 | MM | |||
| Tablet 100 mg | Oral | 60 | 5 | AF, MM | |||
Flucloxacillin Magnesium with Water - Purified BP | Powder for oral suspension equivalent to 125 mg flucloxacillin per 5 mL, 100 mL | Oral | 1 | .. | CS, GK | |||
| Powder for oral suspension equivalent to 250 mg flucloxacillin per 5 mL, 100 mL | Oral | 1 | .. | CS, GK | |||
Flucloxacillin Sodium | Capsule equivalent to 250 mg flucloxacillin | Oral | 24 | .. | AF, CS, GK, SI | |||
| Capsule equivalent to 500 mg flucloxacillin | Oral | 24 | .. | AF, CS, GK, SI | |||
| Powder for injection equivalent to 500 mg flucloxacillin | Injection | 5 | .. | CS, DP | |||
| Powder for injection equivalent to 1 g flucloxacillin | Injection | 5 | 1 | AS, CS, DP, MX | |||
Fluconazole | Capsule 50 mg | Oral | 28 | 5 | PF | |||
| Capsule 100 mg | Oral | 28 | 5 | PF | |||
| Capsule 200 mg | Oral | 28 | 5 | PF | |||
| Solution for I.V. infusion 100 mg in 50 mL vial | Injection | 7 | .. | PF | |||
| Solution for I.V. infusion 200 mg in 100 mL vial | Injection | 7 | .. | PF | |||
Fludrocortisone Acetate | Tablet 100 micrograms | Oral | 200 | 1 | BQ | |||
Fluorometholone | Eye drops 1 mg per mL, 5 mL | Application to the eye | 1 | 5 | AG, AQ | |||
Fluorometholone Acetate | Eye drops 1 mg per mL, 5 mL | Application to the eye | 1 | 2 | AQ | |||
Fluorouracil Sodium | Injection equivalent to 500 mg fluorouracil in 10 mL vial | Injection | 10 | .. | MX | |||
Fluoxetine Hydrochloride | Tablet, dispersible, equivalent to 20 mg fluoxetine | Oral | 28 | 5 | AL, LY | |||
| Capsule equivalent to 20 mg fluoxetine | Oral | 28 | 5 | AF, AL, BF, CH, DP, GX, HX, LY, SI, TW | |||
Flupenthixol Decanoate | Oily I.M. injection 20 mg in 1 mL ampoule | Injection | 5 | .. | LU | |||
| Oily I.M. injection 40 mg in 2 mL ampoule | Injection | 5 | .. | LU | |||
| Oily I.M. injection 100 mg in 1 mL ampoule | Injection | 5 | .. | LU | |||
Fluphenazine Decanoate | Injection 12.5 mg in 0.5 mL ampoule | Injection | 5 | .. | BQ | |||
| Injection 25 mg in 1 mL ampoule | Injection | 5 | .. | BQ | |||
| Injection 50 mg in 2 mL ampoule | Injection | 5 | .. | BQ | |||
Flurbiprofen Sodium | Eye drops 300 micrograms per mL, single dose units 0.4 mL, 5 | Application to the eye | 1 | .. | AG | |||
Flutamide | Tablet 250 mg | Oral | 100 | 5 | AF, SH | |||
Fluticasone Propionate | Pressurised inhalation 50 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | GK | |||
| Pressurised inhalation 125 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | GK | |||
| Pressurised inhalation 250 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | 1 | 1 | GK | |||
| Powder for oral inhalation in breath actuated device 100 micrograms per dose, 60 doses | Inhalation by mouth | 1 | 5 | GK | |||
| Powder for oral inhalation in breath actuated device 250 micrograms per dose, 60 doses | Inhalation by mouth | 1 | 5 | GK | |||
| Powder for oral inhalation in breath actuated device 500 micrograms per dose, 60 doses | Inhalation by mouth | 1 | 1 | GK | |||
Fluticasone Propionate with Salmeterol Xinafoate | Pressurised inhalation 50 micrograms fluticasone propionate with salmeterol xinafoate equivalent to 25 micrograms salmeterol per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | GK | |||
| Pressurised inhalation 125 micrograms fluticasone propionate with salmeterol xinafoate equivalent to 25 micrograms salmeterol per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | GK | |||
| Pressurised inhalation 250 micrograms fluticasone propionate with salmeterol xinafoate equivalent to 25 micrograms salmeterol per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | GK | |||
| Powder for oral inhalation in breath actuated device 100 micrograms fluticasone propionate with salmeterol xinafoate equivalent to 50 micrograms salmeterol per dose, 60 doses | Inhalation by mouth | 1 | 5 | GK | |||
| Powder for oral inhalation in breath actuated device 250 micrograms fluticasone propionate with salmeterol xinafoate equivalent to 50 micrograms salmeterol per dose, 60 doses | Inhalation by mouth | 1 | 5 | GK | |||
| Powder for oral inhalation in breath actuated device 500 micrograms fluticasone propionate with salmeterol xinafoate equivalent to 50 micrograms salmeterol per dose, 60 doses | Inhalation by mouth | 1 | 5 | GK | |||
Fluvastatin Sodium | Capsule equivalent to 20 mg fluvastatin | Oral | 28 | 5 | NM, NV | |||
| Capsule equivalent to 40 mg fluvastatin | Oral | 28 | 5 | NM, NV | |||
Fluvoxamine Maleate | Tablet 50 mg | Oral | 30 | 5 | AL, AW, HX, SM | |||
| Tablet 100 mg | Oral | 30 | 5 | AF, AW, HX, SM | |||
Folic Acid | Tablet 500 micrograms | Oral | 200 | .. | AF | |||
| Tablet 5 mg | Oral | 200 | 1 | AF | |||
Follitropin Alfa | Injection set containing 1 vial powder for injection 75 I.U. and 1 pre-filled syringe solvent 1 mL | Injection | 5 | 5 | SG | |||
| Injection set containing 10 vials powder for injection 75 I.U. and 10 pre-filled syringes solvent 1 mL | Injection | 1 | 5 | SG | |||
| Injection 300 I.U. in 0.5 mL multi-dose cartridge | Injection | 3 | 5 | SG | |||
| Injection set containing 1 vial powder for injection 450 I.U. and 1 pre-filled syringe solvent 1 mL | Injection | 3 | 5 | SG | |||
| Injection 450 I.U. in 0.75 mL multi-dose cartridge | Injection | 3 | 5 | SG | |||
| Injection 900 I.U. in 1.5 mL multi-dose cartridge | Injection | 2 | 5 | SG | |||
| Injection set containing 1 vial powder for injection 1,050 I.U. and 1 pre-filled syringe solvent 2 mL | Injection | 1 | 5 | SG | |||
Follitropin Beta | Solution for injection 300 I.U. in 0.36 mL multi-dose cartridge | Injection | 3 | 5 | OR | |||
| Solution for injection 600 I.U. in 0.72 mL multi-dose cartridge | Injection | 2 | 5 | OR | |||
| Solution for injection 900 I.U. in 1.08 mL multi-dose cartridge | Injection | 2 | 5 | OR | |||
Fondaparinux Sodium | Injection 2.5 mg in 0.5 mL single dose pre-filled syringe | Injection | 7 | .. | GK | |||
Fosinopril Sodium | Tablet 10 mg | Oral | 30 | 5 | BQ | |||
| Tablet 20 mg | Oral | 30 | 5 | BQ | |||
Fosinopril Sodium with Hydrochlorothiazide | Tablet 10 mg-12.5 mg | Oral | 30 | 5 | BQ | |||
| Tablet 20 mg-12.5 mg | Oral | 30 | 5 | BQ | |||
Fotemustine | Powder for injection 208 mg with solvent | Injection | 1 | 4 | SE | |||
Framycetin Sulfate | Eye or ear drops 5 mg per mL, 8 mL | Application to the eye or ear | 1 | 2 | AV | |||
Frusemide | Tablet 20 mg | Oral | 100 | 1 | AV, CH, DP, FM, GX, TW | |||
| Tablet 40 mg | Oral | 100 | 1 | AF, AV, CH, DP, FM, GX, HX, TW | |||
| Tablet 500 mg | Oral | 50 | 3 | FM | |||
| Oral solution 10 mg per mL, 30 mL | Oral | 1 | 3 | AV | |||
| Injection 20 mg in 2 mL | Injection | 5 | .. | AV, HX | |||
Gabapentin | Capsule 100 mg | Oral | 100 | 5 | AF, AW, MX, PF | |||
| Capsule 300 mg | Oral | 100 | 5 | AF, AL, AW, DP, GX, HX, MX, PF | |||
| Capsule 400 mg | Oral | 100 | 5 | AF, AL, AW, DP, GX, HX, MX, PF | |||
| Tablet 600 mg | Oral | 100 | 5 | PF | |||
| Tablet 800 mg | Oral | 100 | 5 | AF, AW, PF | |||
Galantamine Hydrobromide | Tablet equivalent to 4 mg galantamine | Oral | 56 | 5 | JC | |||
| Tablet equivalent to 8 mg galantamine | Oral | 56 | 5 | JC | |||
| Tablet equivalent to 12 mg galantamine | Oral | 56 | 5 | JC | |||
| Capsule (prolonged release) equivalent to 8 mg galantamine | Oral | 28 | 5 | JC | |||
| Capsule (prolonged release) equivalent to 16 mg galantamine | Oral | 28 | 5 | JC | |||
| Capsule (prolonged release) equivalent to 24 mg galantamine | Oral | 28 | 5 | JC | |||
Gefitinib | Tablet 250 mg | Oral | 30 | 1 | AP | |||
Gelatin - Succinylated | I.V. infusion 20 g per 500 mL, 500 mL | Injection | 3 | .. | BR | |||
Gemcitabine Hydrochloride | Powder for I.V. infusion equivalent to 200 mg gemcitabine | Injection | 4 | 2 | LY | |||
| Powder for I.V. infusion equivalent to 1 g gemcitabine | Injection | 2 | 2 | LY | |||
Gemfibrozil | Tablet 600 mg | Oral | 60 | 5 | AF, CH, DP, GX, HX, PF, SI, TW | |||
Gentamicin Sulfate | Injection equivalent to 80 mg gentamicin in 2 mL ampoule | Injection | 10 | 1 | MX, PU | |||
| Eye drops equivalent to 3 mg gentamicin per mL, 5 mL | Application to the eye | 1 | 2 | AG | |||
Gestrinone | Capsule 2.5 mg | Oral | 8 | 5 | AV | |||
Glatiramer Acetate | Injection 20 mg in 1 mL single dose pre-filled syringe | Injection | 28 | 5 | AV | |||
Glibenclamide | Tablet 5 mg | Oral | 100 | 5 | AF, AV | |||
Gliclazide | Tablet 30 mg (modified release) | Oral | 100 | 5 | SE | |||
| Tablet 80 mg | Oral | 100 | 5 | AF, AW, CH, GX, HX, SE, TW | |||
Glimepiride | Tablet 1 mg | Oral | 30 | 5 | AV, AW, ML | |||
| Tablet 2 mg | Oral | 30 | 5 | AV, AW, ML | |||
| Tablet 3 mg | Oral | 30 | 5 | AV, AW, ML | |||
| Tablet 4 mg | Oral | 30 | 5 | AV, AW, ML | |||
Glipizide | Tablet 5 mg | Oral | 100 | 5 | AF, PH | |||
Glucagon Hydrochloride | Injection set containing 1 mg (1 I.U.) and 1 mL solvent in disposable syringe | Injection | 1 | 1 | NO | |||
Glucose | I.V. infusion 278 mmol (anhydrous) per L, 1 L | Injection | 5 | 1 | BX | |||
Glucose and Ketone Indicator—Urine | Reagent strips, 50 (Keto-Diabur-Test 5000) |
| 2 | 2 | RD | |||
| Reagent strips, 50 (Keto-Diastix) |
| 2 | 2 | BN | |||
Glucose with Sodium Chloride, Potassium Chloride and Sodium Acid Citrate | Oral rehydration salts 3.56 g-470 mg-300 mg-530 mg per sachet, 10 | Oral | 1 | .. | AS, AV, CH, DP, TW | |||
|
|
|
|
|
| |||
Glucose Indicator—Blood | Electrode strips, 50 (Advantage II) |
| 2 | 5 | RD | |||
| Electrode strips, 50 (Ascensia Elite) |
| 2 | 5 | BN | |||
| Electrode strips, 50 (Freestyle Papillon) |
| 2 | 5 | MS | |||
| Electrode strips, 50 (GlucoCare) |
| 2 | 5 | DR | |||
| Electrode strips, 50 (GlucoCare Super Sensor) |
| 2 | 5 | DR | |||
| Electrode strips, 50 (GlucoMen Sensor) |
| 2 | 5 | GD | |||
| Electrode strips, 50 (Omnitest EZ) |
| 2 | 5 | BR | |||
| Electrode strips, 50 (TrueTrack) |
| 2 | 5 | DR | |||
| Discs containing electrode sensors, 10 sensors per disc, 5 |
| 2 | 5 | BN | |||
| Electrode strips, 100 (Optium glucose) |
| 1 | 5 | MS | |||
| Electrode strips, 100 (Precision Plus) |
| 1 | 5 | MS | |||
| Electrode strips, 100 (SofTact) |
| 1 | 5 | MS | |||
| Electrode strips, 100 (TrueSense) |
| 1 | 5 | MS | |||
| Reagent strips, 50 (Accu-Chek Active) |
| 2 | 5 | RD | |||
| Reagent strips, 50 (Accu-Chek Go) |
| 2 | 5 | RD | |||
| Reagent strips, 51 (Accu-Chek Integra) |
| 2 | 5 | RD | |||
| Reagent strips, 50 (Betachek) |
| 2 | 5 | NA | |||
| Reagent strips, 50 (CareSens) |
| 2 | 5 | LB | |||
| Reagent strips, 50 (Glucoflex-R) |
| 2 | 5 | NA | |||
| Reagent strips, 50 (Glucostix) |
| 2 | 5 | BN | |||
| Reagent strips, 50 (SensoCard) |
| 2 | 5 | PX | |||
Glucose Indicator—Urine | Reagent strips, 50 (Clinistix) |
| 2 | 2 | BN | |||
| Reagent strips, 50 (Diastix) |
| 2 | 2 | BN | |||
Glycerol | Suppositories 700 mg, 12 | Rectal | 3 | 5 | PP | |||
| Suppositories 1.4 g, 12 | Rectal | 3 | 5 | PP | |||
| Suppositories 2.8 g, 12 | Rectal | 3 | 5 | PP | |||
Glyceryl Trinitrate | Tablets 600 micrograms, 100 | Oral | 1 | 5 | FM, SI | |||
| Buccal/sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Buccal/ sublingual | 1 | 5 | AV | |||
| Transdermal patch 18 mg | Transdermal | 30 | 5 | MM | |||
| Transdermal patch 25 mg | Transdermal | 30 | 5 | NV | |||
| Transdermal patch 40 mg | Transdermal | 30 | 5 | SH | |||
| Transdermal patch 36 mg | Transdermal | 30 | 5 | MM | |||
| Transdermal patch 50 mg | Transdermal | 30 | 5 | NV | |||
| Transdermal patch 80 mg | Transdermal | 30 | 5 | SH | |||
| Transdermal patch 54 mg | Transdermal | 30 | 5 | MM | |||
| Transdermal patch 120 mg | Transdermal | 30 | 5 | SH | |||
Goserelin Acetate | Subcutaneous implant equivalent to 3.6 mg goserelin in pre-filled injection syringe | Subcutaneous implantation | 1 | 5 | AP | |||
| Subcutaneous implant (long acting) equivalent to 10.8 mg goserelin in pre-filled injection syringe | Subcutaneous implantation | 1 | 1 | AP | |||
Granisetron Hydrochloride | Tablet equivalent to 2 mg granisetron | Oral | 2 | .. | MX | |||
| Concentrated injection equivalent to 3 mg granisetron in 3 mL ampoule | Injection | 1 | .. | MX | |||
Griseofulvin | Tablet 125 mg | Oral | 100 | 2 | SI | |||
| Tablet 500 mg | Oral | 28 | 2 | SI | |||
Haloperidol | Tablet 500 micrograms | Oral | 100 | 5 | SI | |||
| Tablet 1.5 mg | Oral | 100 | 5 | SI | |||
| Tablet 5 mg | Oral | 50 | 5 | SI | |||
| Oral solution 2 mg per mL, 100 mL | Oral | 1 | 5 | SI | |||
| Injection 5 mg in 1 mL ampoule | Injection | 10 | .. | SI | |||
Haloperidol Decanoate | I.M. injection equivalent to 50 mg haloperidol in 1 mL ampoule | Injection | 5 | .. | JC | |||
| I.M. injection equivalent to 150 mg haloperidol in 3 mL ampoule | Injection | 5 | .. | JC | |||
"HCU express" | Sachets containing oral powder 25 g, 30 | Oral | 4 | 5 | VF | |||
"HCU gel" | Sachets containing oral powder 20 g, 30 | Oral | 4 | 5 | VF | |||
Heparin Sodium | Injection 5,000 units in 0.2 mL ampoule | Injection | 5 | 5 | MX | |||
| Injection 5,000 units in 1 mL ampoule | Injection | 5 | 5 | MX | |||
| Injection (preservative-free) 5,000 I.U. in 5 mL ampoule | Injection | 50 | 5 | PU | |||
| Injection 35,000 units in 35 mL vial | Injection | 12 | 5 | MX | |||
Hexamine Hippurate | Tablet 1 g | Oral | 100 | 5 | MM | |||
Homatropine Hydrobromide | Eye drops 20 mg per mL, 15 mL | Application to the eye | 1 | 2 | AQ | |||
Hydralazine Hydrochloride | Tablet 25 mg | Oral | 200 | 2 | AF | |||
| Tablet 50 mg | Oral | 200 | 2 | AF | |||
Hydrochlorothiazide | Tablet 25 mg | Oral | 100 | 1 | PL | |||
Hydrochlorothiazide with Amiloride Hydrochloride | Tablet 50 mg-5 mg | Oral | 100 | 1 | AF, MK | |||
Hydrochlorothiazide with Triamterene | Tablet 25 mg-50 mg | Oral | 100 | 1 | AF | |||
Hydrocortisone | Tablet 4 mg | Oral | 50 | 4 | AF | |||
| Tablet 20 mg | Oral | 60 | 4 | AF | |||
| Cream 10 mg per g, 50 g | Application | 1 | 1 | EO | |||
Hydrocortisone Acetate | Eye ointment 5 mg per g, 5 g | Application to the eye | 1 | .. | SI | |||
| Eye ointment 10 mg per g, 5 g | Application to the eye | 1 | .. | SI | |||
| Cream 10 mg per g, 30 g | Application | 1 | 1 | FM, SI | |||
| Cream 10 mg per g, 50 g | Application | 1 | 1 | DT, FM, SI | |||
| Ointment 10 mg per g, 30 g | Application | 1 | 1 | FM, SI | |||
| Ointment 10 mg per g, 50 g | Application | 1 | 1 | FM, SI | |||
| Rectal foam 90 mg per applicatorful, 14 applications, aerosol 21.1 g | Rectal | 2 | 3 | GC | |||
Hydrocortisone Sodium Succinate | Injection equivalent to 100 mg hydrocortisone with 2 mL solvent | Injection | 2 | .. | PH | |||
| Injection equivalent to 250 mg hydrocortisone with 2 mL solvent | Injection | 1 | .. | PH | |||
Hydromorphone Hydrochloride | Tablet 2 mg | Oral | 20 | .. | AB | |||
| Tablet 4 mg | Oral | 20 | .. | AB | |||
| Tablet 8 mg | Oral | 20 | .. | AB | |||
| Oral liquid 1 mg per mL, 473 mL | Oral | 1 | .. | AB | |||
| Injection 2 mg in 1 mL ampoule | Injection | 5 | .. | AB | |||
| Injection 10 mg in 1 mL ampoule | Injection | 5 | .. | AB | |||
| Injection 50 mg in 5 mL ampoule | Injection | 5 | .. | AB | |||
| Injection 500 mg in 50 mL vial | Injection | 1 | .. | AB | |||
Hydroxocobalamin | Injection 1 mg in 1 mL ampoule | Injection | 2 | .. | MX | |||
Hydroxychloroquine Sulfate | Tablet 200 mg | Oral | 100 | 1 | SW | |||
Hydroxypropylcellulose | Ophthalmic inserts 5 mg, 60 | Application to the eye | 1 | 5 | SI | |||
Hydroxyurea | Capsule 500 mg | Oral | 100 | .. | BQ | |||
Hypromellose | Eye drops 3 mg per mL, 15 mL | Application to the eye | 1 | 5 | CV, NV | |||
| Eye drops 5 mg per mL, 15 mL | Application to the eye | 1 | 5 | AQ, SI | |||
Hypromellose with Carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the eye | 1 | 5 | CV, NV | |||
Hypromellose 2900 with Dextran 70 | Eye drops 3 mg-1 mg per mL, single dose units 0.4 mL, 28 | Application to the eye | 3 | 5 | AQ | |||
Hypromellose 4500 with Dextran 70 | Eye drops 3 mg-1 mg per mL, 15 mL | Application to the eye | 1 | 5 | AQ, IQ | |||
Ibuprofen | Tablet 200 mg | Oral | 100 | 3 | AF | |||
| Tablet 400 mg | Oral | 100 | 3 | AB | |||
| Tablets 400 mg, 20 | Oral | 1 | .. | AB | |||
Idarubicin Hydrochloride | Capsule 5 mg | Oral | 3 | .. | PH | |||
| Capsule 10 mg | Oral | 3 | .. | PH | |||
| Solution for I.V. injection 5 mg in 5 mL single use vial | Injection | 3 | .. | PH | |||
| Powder for I.V. injection 5 mg in single dose vial | Injection | 3 | .. | PH | |||
| Solution for I.V. injection 10 mg in 10 mL single use vial | Injection | 6 | .. | PH | |||
| Powder for I.V. injection 10 mg in single dose vial | Injection | 6 | .. | PH | |||
Ifosfamide | Powder for I.V. injection 1 g in single dose vial | Injection | 5 | 5 | BX | |||
| Powder for I.V. injection 2 g in single dose vial | Injection | 5 | 5 | BX | |||
Imipramine Hydrochloride | Tablet 10 mg | Oral | 50 | 2 | NV | |||
| Tablet 25 mg | Oral | 50 | 2 | NV, UW | |||
Indapamide Hemihydrate | Tablet 1.5 mg (sustained release) | Oral | 90 | 1 | SE | |||
| Tablet 2.5 mg | Oral | 90 | 1 | AF, CH, DP, GX, HX, SE, SI, TW | |||
Indomethacin | Capsule 25 mg | Oral | 100 | 3 | AF, MK | |||
| Suppository 100 mg | Rectal | 40 | 3 | MK | |||
Influenza Vaccine (Split Virion) - Inactivated | Injection containing antigens representative of the following types: A/New Caledonia/20/99 (H1N1)-like strain 15 micrograms haemagglutinin; | Injection | 1 | .. | AX, CS, GK, SM | |||
Insect Allergen Extract—Honey Bee Venom | Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL | Injection | 1 | .. | TH | |||
|
|
|
|
|
| |||
|
|
|
|
|
| |||
Insect Allergen Extract—Paper Wasp Venom | Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL | Injection | 1 | .. | TH | |||
Insect Allergen Extract—Yellow Jacket Venom | Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL | Injection | 1 | .. | TH | |||
Insulin - Isophane | Injection (bovine) 100 units per mL, 10 mL vial | Injection | 5 | 2 | AS | |||
| Injection (human) 100 units per mL, 10 mL vial | Injection | 5 | 2 | LY, NO | |||
| Injections (human), cartridges, 100 units per mL, 3 mL, 5 | Injection | 5 | 1 | LY, NI, NL, NO | |||
Insulin - Neutral | Injection (bovine) 100 units per mL, 10 mL vial | Injection | 5 | 2 | AS | |||
| Injection (human) 100 units per mL, 10 mL vial | Injection | 5 | 2 | LY, NO | |||
| Injections (human), cartridges, 100 units per mL, 3 mL, 5 | Injection | 5 | 1 | LY, NO | |||
Insulin - Neutral with Insulin - Isophane | Injection (human) 30 units-70 units per mL, 10 mL vial | Injection | 5 | 2 | LY, NO | |||
| Injection (human) 50 units-50 units per mL, 10 mL vial | Injection | 5 | 2 | NO | |||
| Injections (human), cartridges, 20 units-80 units per mL, 3 mL, 5 | Injection | 5 | 1 | NO | |||
| Injections (human), cartridges, 30 units-70 units per mL, 3 mL, 5 | Injection | 5 | 1 | LY, NI, NO | |||
| Injections (human), cartridges, 50 units-50 units per mL, 3 mL, 5 | Injection | 5 | 1 | NO | |||
Insulin Aspart | Injection (human analogue) 100 units per mL, 10 mL vial | Injection | 5 | 2 | NO | |||
| Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | Injection | 5 | 1 | NF, NO | |||
Insulin Aspart with Insulin Aspart Protamine Suspension | Injections (human analogue), cartridges, 30 units-70 units per mL, 3 mL, 5 | Injection | 5 | 1 | NF, NO | |||
Insulin Lispro | Injection (human analogue) 100 units per mL, 10 mL vial | Injection | 5 | 2 | LY | |||
| Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 | Injection | 5 | 1 | LY | |||
Insulin Lispro with Insulin Lispro Protamine Suspension | Injections (human analogue), cartridges, 25 units-75 units per mL, 3 mL, 5 | Injection | 5 | 1 | LY | |||
| Injections (human analogue), cartridges, 50 units-50 units per mL, 3 mL, 5 | Injection | 5 | 1 | LY | |||
Interferon Alfa-2a | Injection 3,000,000 I.U. in 0.5 mL single dose pre-filled syringe | Injection | 15 | 4 | RO | |||
| Injection 4,500,000 I.U. in 0.5 mL single dose pre-filled syringe | Injection | 5 | 4 | RO | |||
| Injection 6,000,000 I.U. in 0.5 mL single dose pre-filled syringe | Injection | 5 | 4 | RO | |||
| Injection 9,000,000 I.U. in 0.5 mL single dose pre-filled syringe | Injection | 5 | 4 | RO | |||
Interferon Alfa-2b | Solution for injection 18,000,000 I.U. in 1.2 mL multi-dose injection pen | Injection | 3 | 4 | SH | |||
| Solution for injection 30,000,000 I.U. in 1.2 mL multi-dose injection pen | Injection | 3 | 5 | SH | |||
Interferon Beta-1a | Injection set comprising 1 vial powder for injection 30 micrograms (6,000,000 I.U.) with diluent | Injection | 4 | 5 | BD | |||
| Injection 30 micrograms (6,000,000 I.U.) in 0.5 mL single dose pre-filled syringe | Injection | 4 | 5 | BD | |||
| Injection 44 micrograms (12,000,000 I.U.) in 0.5 mL single dose pre-filled syringe | Injection | 12 | 5 | SG | |||
Interferon Beta-1b | Injection set comprising 1 vial powder for injection 8,000,000 I.U. (250 micrograms) and solvent | Injection | 15 | 5 | SC | |||
Ipratropium Bromide | Pressurised inhalation 21 micrograms per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | 2 | 5 | BY | |||
| Nebuliser solution 250 micrograms (anhydrous) in 1 mL single dose units, 30 | Inhalation | 2 | 5 | AF, AW, BY, CH, DP, GX, MX, PU, TW | |||
| Nebuliser solution 500 micrograms (anhydrous) in 1 mL single dose units, 30 | Inhalation | 2 | 5 | AF, AW, BY, CH, DP, GX, MX, PU, TW | |||
| Nebuliser solution 250 micrograms (anhydrous) per mL, 20 mL | Inhalation | 2 | 2 | BY | |||
Irbesartan | Tablet 75 mg | Oral | 30 | 5 | BQ, SW | |||
| Tablet 150 mg | Oral | 30 | 5 | BQ, SW | |||
| Tablet 300 mg | Oral | 30 | 5 | BQ, SW | |||
Irbesartan with Hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | 30 | 5 | BQ, SW | |||
Tablet 300 mg-12.5 mg | Oral | 30 | 5 | BQ, SW | ||||
Irinotecan Hydrochloride Trihydrate | I.V. injection 40 mg in 2 mL vial | Injection | 1 | 3 | MX, PU | |||
I.V. injection 100 mg in 5 mL vial | Injection | 2 | 3 | MX, PU | ||||
Iron Polymaltose Complex | Injection 100 mg (iron) in 2 mL ampoule | Injection | 5 | .. | BX, SI | |||
Iron Sucrose | Concentrate for solution for infusion 2.7 g (equivalent to 100 mg iron (III)) in 5 mL ampoule | Injection | 5 | .. | BX | |||
Isoniazid | Tablet 100 mg | Oral | 100 | 2 | FM | |||
Isosorbide Dinitrate | Tablet 10 mg | Oral | 200 | 2 | AF, SI | |||
| Tablet 5 mg (sublingual) | Oral | 200 | 2 | SI | |||
Isosorbide Mononitrate | Tablet 60 mg (sustained release) | Oral | 30 | 5 | AF, AP, CH, DP, GX, HX, PM, TW | |||
| Tablet 120 mg (sustained release) | Oral | 30 | 5 | AP, PM | |||
Isotretinoin | Capsule 10 mg | Oral | 60 | 3 | DP, GX, RO | |||
| Capsule 20 mg | Oral | 60 | 3 | CH, DP, GX, HX, RO, TW | |||
Itraconazole | Capsule 100 mg | Oral | 60 | 5 | JC | |||
Ivermectin | Tablet 3 mg | Oral | 4 | .. | MK | |||
"Karicare De-Lact" | Oral powder 900 g | Oral | 5 | .. | NU | |||
Ketoconazole | Tablet 200 mg | Oral | 10 | .. | JC | |||
"Ketonex-1" | Oral powder 350 g | Oral | 8 | 5 | AB | |||
| Oral powder 400 g | Oral | 8 | 5 | AB | |||
"Ketonex-2" | Oral powder 325 g | Oral | 10 | 5 | AB | |||
| Oral powder 400 g | Oral | 8 | 5 | AB | |||
Ketoprofen | Capsule 200 mg (sustained release) | Oral | 28 | 3 | AV, HP | |||
| Suppository 100 mg | Rectal | 40 | 3 | AV | |||
"Kindergen" | Oral powder 400 g | Oral | 16 | 5 | SB | |||
Labetalol Hydrochloride | Tablet 100 mg | Oral | 100 | 5 | AF, SI | |||
| Tablet 200 mg | Oral | 100 | 5 | AF, SI | |||
Lactulose | Solution BP 3.34 g per 5 mL, 500 mL | Oral | 1 | 5 | AF, AW, DP, GX, HX, SM | |||
Lamotrigine | Tablet 5 mg | Oral | 56 | 5 | AF, AW, GK, HX, ME | |||
| Tablet 25 mg | Oral | 56 | 5 | AF, AW, DP, GK, GX, HX, ME | |||
| Tablet 50 mg | Oral | 56 | 5 | AF, AW, DP, GK, GX, HX, ME | |||
| Tablet 100 mg | Oral | 56 | 5 | AF, AW, DP, GK, GX, HX, ME | |||
| Tablet 200 mg | Oral | 56 | 5 | AF, AW, DP, GK, GX, HX, ME | |||
Lansoprazole | Capsule 30 mg | Oral | 30 | 1 | WY | |||
| Sachet containing granules for oral suspension, 30 mg per sachet | Oral | 28 | 1 | WY | |||
| Capsule 15 mg | Oral | 30 | 5 | WY | |||
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | 1 | 5 | PU | |||
Latanoprost with Timolol Maleate | Eye drops 50 micrograms latanoprost with timolol maleate equivalent to 5 mg timolol per mL, 2.5 mL | Application to the eye | 1 | 5 | PF | |||
Leflunomide | Pack containing 3 tablets leflunomide 100 mg and 30 tablets leflunomide 20 mg | Oral | 1 | .. | AV | |||
| Tablet 10 mg | Oral | 30 | 5 | AV, HP | |||
| Tablet 20 mg | Oral | 30 | 5 | AV, HP | |||
Lercanidipine Hydrochloride | Tablet 10 mg | Oral | 30 | 5 | SM | |||
| Tablet 20 mg | Oral | 30 | 5 | SM | |||
Letrozole | Tablet 2.5 mg | Oral | 30 | 2 | NV | |||
Leuprorelin Acetate | I.M. injection (modified release), powder for injection 7.5 mg with diluent in pre-filled dual-chamber syringe | Injection | 1 | 5 | AB | |||
| I.M. injection (modified release), set containing 1 vial powder for injection 7.5 mg, 1 ampoule diluent 2 mL and 1 syringe with 2 needles | Injection | 1 | 5 | AB | |||
| Suspension for subcutaneous injection (modified release), 7.5 mg injection set | Injection | 1 | 5 | MX | |||
| I.M. injection (modified release), powder for injection 22.5 mg with diluent in pre-filled dual-chamber syringe | Injection | 1 | 1 | AB | |||
| I.M. injection (modified release), set containing 1 vial powder for injection 22.5 mg, 1 ampoule diluent 2 mL and 1 syringe with 2 needles | Injection | 1 | 1 | AB | |||
| Suspension for subcutaneous injection (modified release), 22.5 mg injection set | Injection | 1 | 1 | MX | |||
| I.M. injection (modified release), powder for injection 30 mg with diluent in pre-filled dual-chamber syringe | Injection | 1 | 1 | AB | |||
| I.M. injection (modified release), set containing 1 vial powder for injection 30 mg, 1 ampoule diluent 2 mL and 1 syringe with 2 needles | Injection | 1 | 1 | AB | |||
| Suspension for subcutaneous injection (modified release), 30 mg injection set | Injection | 1 | 1 | MX | |||
| Suspension for subcutaneous injection (modified release), 45 mg injection set | Injection | 1 | .. | MX | |||
Levetiracetam | Tablet 250 mg | Oral | 60 | 5 | UC | |||
| Tablet 500 mg | Oral | 60 | 5 | UC | |||
| Tablet 1 g | Oral | 60 | 5 | UC | |||
Levobunolol Hydrochloride | Eye drops 2.5 mg per mL, 5 mL | Application to the eye | 1 | 5 | AG | |||
Levodopa with Benserazide Hydrochloride | Dispersible tablet 50 mg-12.5 mg (benserazide) | Oral | 100 | 5 | RO | |||
| Dispersible tablet 100 mg-25 mg (benserazide) | Oral | 100 | 5 | RO | |||
| Tablet 100 mg-25 mg (benserazide) | Oral | 100 | 5 | RO | |||
| Tablet 200 mg-50 mg (benserazide) | Oral | 100 | 5 | RO | |||
| Capsule 50 mg-12.5 mg (benserazide) | Oral | 100 | 5 | RO | |||
| Capsule 100 mg-25 mg (benserazide) | Oral | 100 | 5 | RO | |||
| Capsule 100 mg-25 mg (benserazide) (sustained release) | Oral | 100 | 5 | RO | |||
| Capsule 200 mg-50 mg (benserazide) | Oral | 100 | 5 | RO | |||
Levodopa with Carbidopa | Tablet 200 mg-50 mg (anhydrous) (modified release) | Oral | 100 | 5 | MK | |||
| Tablet 100 mg-25 mg (anhydrous) | Oral | 100 | 5 | AF, MK | |||
| Tablet 250 mg-25 mg (anhydrous) | Oral | 100 | 5 | HX, MK | |||
Levodopa with Carbidopa and Entacapone | Tablet 50 mg-12.5 mg-200 mg | Oral | 200 | 4 | NV | |||
| Tablet 100 mg-25 mg-200 mg | Oral | 200 | 4 | NV | |||
| Tablet 150 mg-37.5 mg-200 mg | Oral | 200 | 4 | NV | |||
Levonorgestrel | Tablets 30 micrograms, 28 | Oral | 4 | 2 | SC, WY | |||
| Intrauterine drug delivery system 52 mg | Intrauterine | 1 | .. | SC | |||
Levonorgestrel with Ethinyloestradiol | Pack containing 21 tablets 125 micrograms-50 micrograms and 7 inert tablets | Oral | 4 | 2 | SC | |||
| Tablets 150 micrograms-30 micrograms, 21 | Oral | 4 | 2 | SC | |||
| Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets | Oral | 4 | 2 | SC, SY, WX, WY | |||
| Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets | Oral | 4 | 2 | SC, SY, WX, WY | |||
Lignocaine Hydrochloride | Injection 100 mg in 5 mL | Injection | 5 | .. | PF | |||
| Infusion 500 mg in 5 mL ampoule | Injection | 10 | .. | AP | |||
Lincomycin Hydrochloride | Injection equivalent to 600 mg lincomycin in 2 mL vial | Injection | 5 | .. | PH | |||
Liothyronine Sodium | Tablet 20 micrograms | Oral | 100 | 2 | SI | |||
Lisinopril | Tablet 5 mg | Oral | 30 | 5 | AF, AP, AW, BF, CH, DP, GX, HX, MK, TW | |||
| Tablet 10 mg | Oral | 30 | 5 | AF, AP, AW, BF, CH, DP, GX, HX, MK, TW | |||
| Tablet 20 mg | Oral | 30 | 5 | AF, AP, AW, BF, CH, DP, GX, HX, MK, TW | |||
Lithium Carbonate | Tablet 250 mg | Oral | 200 | 2 | AS | |||
| Tablet 450 mg (slow release) | Oral | 200 | 2 | GK | |||
"Locasol" | Low calcium compound powder 400 g | Oral | 8 | 5 | NU | |||
Lodoxamide Trometamol | Eye drops equivalent to 1 mg lodoxamide per mL, 10 mL | Application to the eye | 1 | 5 | AQ | |||
Loperamide Hydrochloride | Capsule 2 mg | Oral | 12 | .. | AS, JC | |||
"Lophlex" | Sachets containing oral powder 27.8 g, 30 | Oral | 3 | 5 | SB | |||
Macrogol 3350 with Sodium Chloride, Sodium Bicarbonate and Potassium Chloride | Sachets containing powder for oral solution 13.125 g-350.7 mg-178.5 mg-46.6 mg, 30 | Oral | 1 | 5 | NE | |||
"Mapleflex" | Sachets containing oral powder 29 g, 30 | Oral | 4 | 5 | SB | |||
|
|
|
|
|
| |||
Medroxyprogesterone Acetate | Tablet 500 mg | Oral | 30 | 2 | PH | |||
| Tablet 100 mg | Oral | 100 | 2 | PH | |||
| Tablet 200 mg | Oral | 60 | 2 | PH | |||
| Tablet 250 mg | Oral | 60 | 2 | PH | |||
| Tablet 5 mg | Oral | 56 | 2 | KR, PH | |||
| Tablet 10 mg | Oral | 30 | 2 | HX, KR, PH | |||
| Injection 50 mg in 1 mL vial | Injection | 1 | 1 | PH | |||
| Injection 150 mg in 1 mL vial | Injection | 1 | 1 | KR, PH | |||
Mefenamic Acid | Capsule 250 mg | Oral | 50 | 2 | PC, PD | |||
Megestrol Acetate | Tablet 160 mg | Oral | 30 | 2 | BQ | |||
Meloxicam | Tablet 7.5 mg | Oral | 30 | 3 | AW, BY | |||
| Tablet 15 mg | Oral | 30 | 3 | AW, BY | |||
| Capsule 7.5 mg | Oral | 30 | 3 | BY | |||
| Capsule 15 mg | Oral | 30 | 3 | BY | |||
Melphalan | Tablet 2 mg | Oral | 25 | 1 | GK | |||
Mercaptopurine | Tablet 50 mg | Oral | 100 | 2 | GK | |||
Mesalazine | Tablet 250 mg | Oral | 100 | 5 | GK | |||
| Tablet 500 mg (enteric coated) | Oral | 100 | 5 | OA | |||
| Sachet containing granules, 500 mg per sachet | Oral | 100 | 5 | OA | |||
| Sachet containing granules, 1 g per sachet | Oral | 100 | 2 | OA | |||
| Suppositories 1 g, 28 | Rectal | 1 | .. | FP | |||
| Enemas 1 g in 100 mL, 7 | Rectal | 4 | .. | FP | |||
| Enemas 2 g in 60 mL, 7 | Rectal | 4 | .. | OA | |||
| Enemas 4 g in 60 mL, 7 | Rectal | 4 | .. | OA | |||
| Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g | Rectal | 4 | .. | OA | |||
Mesna | Solution for I.V. injection 400 mg in 4 mL ampoule | Injection | 15 | 5 | BX | |||
| Solution for I.V. injection 1 g in 10 mL ampoule | Injection | 15 | 5 | BX | |||
"Metabolic Mineral Mixture" | Oral powder 250 g | Oral | 1 | 5 | SB | |||
Metformin Hydrochloride | Tablet 500 mg | Oral | 100 | 5 | AF, AL, AW, CH, DP, GN, GX, HX, MQ, TW | |||
| Tablet 500 mg (extended release) | Oral | 90 | 5 | AL | |||
| Tablet 850 mg | Oral | 60 | 5 | AF, AL, AW, CH, DP, GN, GX, HX, MQ, TW | |||
| Tablet 1 g | Oral | 90 | 5 | AF, AL, AW | |||
Metformin Hydrochloride with Glibenclamide | Tablet 250 mg-1.25 mg | Oral | 90 | 5 | AL | |||
| Tablet 500 mg-2.5 mg | Oral | 90 | 5 | AL | |||
| Tablet 500 mg-5 mg | Oral | 90 | 5 | AL | |||
Methadone Hydrochloride | Tablet 10 mg | Oral | 20 | .. | GK | |||
| Injection 10 mg in 1 mL ampoule | Injection | 5 | .. | GK | |||
Methotrexate | Tablet 2.5 mg | Oral | 30 | 5 | MX, PH | |||
| Tablet 10 mg | Oral | 50 | 2 | PH | |||
| Injection 5 mg in 2 mL vial | Injection | 5 | .. | MX | |||
| Injection 50 mg in 2 mL vial | Injection | 5 | .. | MX, PU | |||
| Solution concentrate for I.V. infusion 500 mg in 5 mL vial | Injection | 1 | .. | IT | |||
| Solution concentrate for I.V. infusion 500 mg in 20 mL vial | Injection | 1 | .. | MX | |||
| Solution concentrate for I.V. infusion 1000 mg in 10 mL vial | Injection | 1 | .. | IT, MX | |||
| Solution concentrate for I.V. infusion 5000 mg in 50 mL vial | Injection | 1 | .. | IT | |||
Methyldopa | Tablet 250 mg | Oral | 100 | 5 | AF, MK | |||
Methylphenidate Hydrochloride | Tablet 10 mg | Oral | 100 | 5 | AF, NV | |||
Methylprednisolone Aceponate | Cream 1 mg per g, 15 g | Application | 1 | .. | SC | |||
| Ointment 1 mg per g, 15 g | Application | 1 | .. | SC | |||
| Fatty ointment 1 mg per g, 15 g | Application | 1 | .. | SC | |||
| Lotion 1 mg per g, 20 g | Application | 1 | .. | SC | |||
Methylprednisolone Acetate | Injection 40 mg in 1 mL vial | Injection | 5 | .. | KR, PH | |||
Methylprednisolone Sodium Succinate | Powder for injection equivalent to 40 mg methylprednisolone with diluent | Injection | 5 | .. | PF | |||
| Powder for injection equivalent to 1 g methylprednisolone with diluent | Injection | 1 | .. | PF | |||
Methysergide Maleate | Tablet equivalent to 1 mg methysergide | Oral | 100 | 2 | NV | |||
Metoclopramide Hydrochloride | Tablet 10 mg | Oral | 25 | .. | AF, VT | |||
| Oral solution 5 mg per 5 mL, 100 mL | Oral | 1 | .. | VT | |||
| Injection 10 mg in 2 mL ampoule | Injection | 10 | .. | VT | |||
Metoprolol Succinate | Pack containing 15 tablets 23.75 mg (controlled release), 15 tablets 47.5 mg (controlled release) and 15 tablets 95 mg (controlled release) | Oral | 1 | .. | AP | |||
| Tablet 23.75 mg (controlled release) | Oral | 15 | .. | AP | |||
| Tablet 47.5 mg (controlled release) | Oral | 30 | 5 | AP | |||
| Tablet 95 mg (controlled release) | Oral | 30 | 5 | AP | |||
| Tablet 190 mg (controlled release) | Oral | 30 | 5 | AP | |||
Metoprolol Tartrate | Tablet 50 mg | Oral | 100 | 5 | AF, AP, AW, CH, DP, GX, HX, NV, TW | |||
| Tablet 100 mg | Oral | 60 | 5 | AF, AP, AW, CH, DP, GX, HX, NV, TW | |||
Metronidazole | Tablet 200 mg | Oral | 21 | 1 | AF, AV, HP | |||
| Tablet 400 mg | Oral | 5 | 2 | AF | |||
| I.V. infusion 500 mg in 100 mL | Injection | 5 | 1 | BX | |||
| Suppositories 500 mg, 10 | Rectal | 1 | .. | AV | |||
Metronidazole Benzoate | Oral suspension 320 mg per 5 mL, 100 mL | Oral | 1 | .. | AV | |||
Mexiletine Hydrochloride | Capsule 50 mg | Oral | 100 | 5 | BY | |||
| Capsule 200 mg | Oral | 100 | 5 | BY | |||
Mianserin Hydrochloride | Tablet 10 mg | Oral | 50 | 5 | AF, OR | |||
| Tablet 20 mg | Oral | 50 | 5 | AF, OR | |||
"Minaphlex" | Sachets containing oral powder 29 g, 30 | Oral | 4 | 5 | SB | |||
|
|
|
|
|
| |||
|
|
|
|
|
| |||
Minocycline Hydrochloride | Tablet equivalent to 50 mg minocycline | Oral | 60 | 5 | AF, SI | |||
| Capsule equivalent to 100 mg minocycline | Oral | 11 | .. | AF | |||
Minoxidil | Tablet 10 mg | Oral | 100 | 5 | PH | |||
Mirtazapine | Tablet 15 mg (orally disintegrating) | Oral | 30 | 5 | BP | |||
| Tablet 30 mg | Oral | 30 | 5 | AF, AW, BP, OR | |||
| Tablet 30 mg (orally disintegrating) | Oral | 30 | 5 | BP | |||
| Tablet 45 mg | Oral | 30 | 5 | AW, BP | |||
| Tablet 45 mg (orally disintegrating) | Oral | 30 | 5 | BP | |||
Misoprostol | Tablet 200 micrograms | Oral | 120 | 2 | PH | |||
Mitozantrone Hydrochloride | Injection equivalent to 10 mg mitozantrone in 5 mL vial | Injection | 1 | .. | PU | |||
| Injection equivalent to 20 mg mitozantrone in 10 mL vial | Injection | 1 | .. | BX, MX, PU, SI | |||
| Injection equivalent to 25 mg mitozantrone in 12.5 mL vial | Injection | 1 | .. | BX, PU, SI | |||
Moclobemide | Tablet 150 mg | Oral | 60 | 5 | AF, CH, DP, GX, HX, RO, TW | |||
| Tablet 300 mg | Oral | 60 | 5 | AF, CH, DP, GX, HX, RO, SI, TW | |||
Modafinil | Tablet 100 mg | Oral | 120 | 5 | CS | |||
Mometasone Furoate | Cream 1 mg per g, 15 g | Application | 1 | .. | EX, SH | |||
| Ointment 1 mg per g, 15 g | Application | 1 | .. | EX, SH | |||
| Lotion 1 mg per g, 30 mL | Application | 1 | .. | EX, SH | |||
"Monogen" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
Montelukast Sodium | Tablet, chewable, equivalent to 4 mg montelukast | Oral | 28 | 5 | MK | |||
| Tablet, chewable, equivalent to 5 mg montelukast | Oral | 28 | 5 | MK | |||
Morphine Hydrochloride | Oral solution 1 mg per mL, 500 mL | Oral | 1 | .. | VT | |||
| Oral solution 2 mg per mL, 200 mL | Oral | 1 | .. | MF, PF | |||
| Oral solution 5 mg per mL, 200 mL | Oral | 1 | .. | MF, PF | |||
| Oral solution 5 mg per mL, 250 mL | Oral | 1 | .. | VT | |||
| Oral solution 5 mg per mL, 500 mL | Oral | 1 | .. | VT | |||
| Oral solution 10 mg per mL, 200 mL | Oral | 1 | .. | MF, PF | |||
| Oral solution 10 mg per mL, 250 mL | Oral | 1 | .. | VT | |||
Morphine Sulfate | Tablet 10 mg | Oral | 20 | .. | MF | |||
| Tablet 20 mg | Oral | 20 | .. | MF | |||
| Tablet 30 mg | Oral | 20 | .. | FM | |||
| Tablet 5 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 10 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 15 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 30 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 60 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 100 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 200 mg (controlled release) | Oral | 20 | .. | MF | |||
| Capsule 10 mg (containing sustained release pellets) | Oral | 20 | .. | GK | |||
| Capsule 20 mg (containing sustained release pellets) | Oral | 20 | .. | GK | |||
| Capsule 30 mg (controlled release) | Oral | 10 | .. | MF | |||
| Capsule 50 mg (containing sustained release pellets) | Oral | 20 | .. | GK | |||
| Capsule 60 mg (controlled release) | Oral | 10 | .. | MF | |||
| Capsule 90 mg (controlled release) | Oral | 10 | .. | MF | |||
| Capsule 100 mg (containing sustained release pellets) | Oral | 20 | .. | GK | |||
| Capsule 120 mg (controlled release) | Oral | 10 | .. | MF | |||
| Sachet containing controlled release granules for oral suspension, 20 mg per sachet | Oral | 20 | .. | MF | |||
| Sachet containing controlled release granules for oral suspension, 30 mg per sachet | Oral | 20 | .. | MF | |||
| Sachet containing controlled release granules for oral suspension, 60 mg per sachet | Oral | 20 | .. | MF | |||
| Sachet containing controlled release granules for oral suspension, 100 mg per sachet | Oral | 20 | .. | MF | |||
| Sachet containing controlled release granules for oral suspension, 200 mg per sachet | Oral | 20 | .. | MF | |||
| Injection 10 mg in 1 mL ampoule | Injection | 5 | .. | MX | |||
| Injection 15 mg in 1 mL ampoule | Injection | 5 | .. | MX | |||
| Injection 30 mg in 1 mL ampoule | Injection | 5 | .. | MX | |||
Morphine Tartrate | Injection 120 mg in 1.5 mL ampoule | Injection | 5 | .. | MX | |||
Moxifloxacin Hydrochloride | Solution for I.V. infusion equivalent to 400 mg moxifloxacin in 250 mL | Injection | 3 | .. | BN | |||
| Tablet equivalent to 400 mg moxifloxacin | Oral | 5 | 1 | BN | |||
"MSUD AID III" | Oral powder 500 g | Oral | 4 | 5 | SB | |||
"MSUD Analog" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
"MSUD Express" | Sachets containing oral powder 25 g, 30 | Oral | 4 | 5 | VF | |||
"MSUD Maxamaid" | Oral powder 500 g | Oral | 8 | 5 | SB | |||
"MSUD Maxamum" | Oral powder 500 g | Oral | 8 | 5 | SB | |||
"MSUD-gel" | Sachets containing oral powder 20 g, 30 | Oral | 4 | 5 | VF | |||
Mycophenolate Mofetil | Capsule 250 mg | Oral | 300 | 3 | RO | |||
| Tablet 500 mg | Oral | 150 | 3 | RO | |||
Mycophenolate Mofetil with Water - Purified BP | Powder for oral suspension 1 g per 5 mL, 165 mL | Oral | 1 | 3 | RO | |||
Mycophenolate Sodium | Tablet (enteric coated) equivalent to 180 mg mycophenolic acid | Oral | 120 | 3 | NV | |||
| Tablet (enteric coated) equivalent to 360 mg mycophenolic acid | Oral | 120 | 3 | NV | |||
Nafarelin Acetate | Nasal spray (pump pack) equivalent to 200 micrograms nafarelin per dose, 60 doses | Nasal | 1 | 5 | PH | |||
Naloxone Hydrochloride | Injection 400 micrograms in 1 mL disposable injection set | Injection | 1 | .. | CS | |||
| Injection 800 micrograms in 2 mL disposable injection set | Injection | 1 | .. | CS | |||
| Injection 2 mg in 5 mL disposable injection set | Injection | 1 | .. | CS | |||
Naltrexone Hydrochloride | Tablet 50 mg | Oral | 30 | 1 | BQ | |||
Nandrolone Decanoate | Injection 50 mg in 1 mL disposable syringe | Injection | 1 | 7 | OR | |||
Naproxen | Tablet 250 mg | Oral | 100 | 3 | AF, RO | |||
| Tablet 500 mg | Oral | 50 | 3 | AF, RO | |||
| Tablet 750 mg (sustained release) | Oral | 28 | 3 | MD, RO | |||
| Tablet 1 g (sustained release) | Oral | 28 | 3 | MD, RO | |||
| Oral suspension 125 mg per 5 mL, 474 mL | Oral | 1 | 3 | RO | |||
Naproxen Sodium | Tablet 550 mg | Oral | 50 | 3 | MD, RO | |||
Naratriptan Hydrochloride | Tablet equivalent to 2.5 mg naratriptan | Oral | 4 | 5 | GK | |||
Nedocromil Sodium | Pressurised inhalation 2 mg per dose, 112 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | AV | |||
"Neocate" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
"Neocate Advance" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
Neomycin Sulfate | Tablet 500 mg | Oral | 25 | 1 | AF | |||
Neomycin Undecenoate with Bacitracin Zinc | Ear ointment 12 mg (3.5 mg neomycin)-400 units per g, 10 g | Application to the ear | 1 | .. | HA | |||
Nicorandil | Tablets 10 mg, 60 | Oral | 1 | 5 | AV | |||
| Tablets 20 mg, 60 | Oral | 1 | 5 | AV | |||
Nifedipine | Tablet 10 mg | Oral | 60 | 5 | AF, AW, BN | |||
| Tablet 20 mg | Oral | 60 | 5 | AF, AW, BN, CH, DP, GX, HX, TW | |||
| Tablet 20 mg (controlled release) | Oral | 30 | 5 | BN | |||
| Tablet 30 mg (controlled release) | Oral | 30 | 5 | AF, AW, BN | |||
| Tablet 60 mg (controlled release) | Oral | 30 | 5 | AF, AW, BN | |||
Nilutamide | Tablet 150 mg | Oral | 30 | 5 | AV | |||
Nitrazepam | Tablet 5 mg | Oral | 25 | .. | AF, VT | |||
Nitrofurantoin | Capsule 50 mg | Oral | 30 | 1 | PU | |||
| Capsule 100 mg | Oral | 30 | 1 | PU | |||
Nizatidine | Capsule 150 mg | Oral | 60 | 5 | AS, LN | |||
| Capsule 300 mg | Oral | 30 | 5 | AS, LN | |||
Norethisterone | Tablets 350 micrograms, 28 | Oral | 4 | 2 | JC, KR, PH | |||
| Tablet 5 mg | Oral | 30 | 2 | SC | |||
Norethisterone with Ethinyloestradiol | Tablets 500 micrograms-35 micrograms, 21 | Oral | 4 | 2 | PH | |||
| Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets | Oral | 4 | 2 | KR, PH | |||
| Tablets 1 mg-35 micrograms, 21 | Oral | 4 | 2 | PH | |||
| Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets | Oral | 4 | 2 | KR, PH | |||
| Pack containing 12 tablets 500 micrograms-35 micrograms, 9 tablets 1 mg-35 micrograms and 7 inert tablets | Oral | 4 | 2 | KR, PH | |||
Norethisterone with Mestranol | Tablets 1 mg-50 micrograms, 21 | Oral | 4 | 2 | PH | |||
| Pack containing 21 tablets 1 mg-50 micrograms and 7 inert tablets | Oral | 4 | 2 | PH | |||
Norfloxacin | Tablet 400 mg | Oral | 14 | 1 | AF, AW, CH, DP, GX, HX, MK, TW | |||
Nortriptyline Hydrochloride | Tablet equivalent to 10 mg nortriptyline | Oral | 50 | 2 | AS | |||
| Tablet equivalent to 25 mg nortriptyline | Oral | 50 | 2 | AS | |||
Nystatin | Tablet 500,000 units | Oral | 50 | .. | SI | |||
| Capsule 500,000 units | Oral | 50 | .. | SI | |||
| Oral suspension 100,000 units per mL, 24 mL | Oral | 1 | 1 | BQ, SI | |||
Oestradiol | Tablet 2 mg | Oral | 56 | 2 | SM | |||
| Transdermal patches 390 micrograms, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 2 mg, 4 | Transdermal | 1 | 5 | MM, SC | |||
| Transdermal patches 2 mg, 8 (Dermestril 25) | Transdermal | 1 | 5 | MX | |||
| Transdermal patches 2 mg, 8 (Estraderm 25) | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 585 micrograms, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 3.28 mg, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 780 micrograms, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 3.8 mg, 4 | Transdermal | 1 | 5 | MM, SC | |||
| Transdermal patches 4 mg, 8 (Dermestril 50) | Transdermal | 1 | 5 | MX | |||
| Transdermal patches 4 mg, 8 (Estraderm 50) | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 4.33 mg, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 1.17 mg, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 5.7 mg, 4 | Transdermal | 1 | 5 | SC | |||
| Transdermal patches 6.57 mg, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 1.56 mg, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 7.6 mg, 4 | Transdermal | 1 | 5 | MM, SC | |||
| Transdermal patches 8 mg, 8 (Dermestril 100) | Transdermal | 1 | 5 | MX | |||
| Transdermal patches 8 mg, 8 (Estraderm 100) | Transdermal | 1 | 5 | NV | |||
| Transdermal patches 8.66 mg, 8 | Transdermal | 1 | 5 | NV | |||
| Vaginal tablets 25 micrograms, 15 | Vaginal | 1 | 2 | NO | |||
Oestradiol and Oestradiol with Dydrogesterone | Pack containing 14 tablets oestradiol 2 mg and 14 tablets oestradiol 2 mg with dydrogesterone 10 mg | Oral | 1 | 5 | SM | |||
Oestradiol and Oestradiol with Norethisterone Acetate | Pack containing 12 tablets oestradiol 2 mg, 10 tablets oestradiol 2 mg with norethisterone acetate 1 mg and 6 tablets oestradiol 1 mg | Oral | 1 | 5 | NO | |||
| Pack containing 4 transdermal patches oestradiol 4 mg and 4 transdermal patches oestradiol 10 mg with norethisterone acetate 30 mg | Transdermal | 1 | 5 | NV | |||
Oestradiol Hemihydrate | Nasal spray 150 micrograms per actuation, 60 actuations, 4.2 mL | Nasal | 1 | 5 | SE | |||
| Transdermal gel equivalent to 1 mg oestradiol in 1 g sachet, 28 | Transdermal | 1 | 5 | OR | |||
| Transdermal patches equivalent to 750 micrograms oestradiol, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches equivalent to 1.5 mg oestradiol, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches equivalent to 3 mg oestradiol, 8 | Transdermal | 1 | 5 | NV | |||
Oestradiol Hemihydrate and Oestradiol Hemihydrate with Norethisterone Acetate | Pack containing 4 transdermal patches equivalent to 4.33 mg oestradiol and 4 transdermal patches equivalent to 620 micrograms oestradiol with 2.7 mg norethisterone acetate | Transdermal | 1 | 5 | NV | |||
| Pack containing 4 transdermal patches equivalent to 4.33 mg oestradiol and 4 transdermal patches equivalent to 510 micrograms oestradiol with 4.8 mg norethisterone acetate | Transdermal | 1 | 5 | NV | |||
Oestradiol Hemihydrate with Norethisterone Acetate | Tablets equivalent to 1 mg oestradiol with 500 micrograms norethisterone acetate, 28 | Oral | 1 | 5 | NO | |||
| Tablets equivalent to 2 mg oestradiol with 1 mg norethisterone acetate, 28 | Oral | 1 | 5 | NO | |||
| Transdermal patches equivalent to 620 micrograms oestradiol with 2.7 mg norethisterone acetate, 8 | Transdermal | 1 | 5 | NV | |||
| Transdermal patches equivalent to 510 micrograms oestradiol with 4.8 mg norethisterone acetate, 8 | Transdermal | 1 | 5 | NV | |||
Oestradiol Valerate | Tablet 1 mg | Oral | 56 | 2 | SC | |||
| Tablet 2 mg | Oral | 56 | 2 | SC | |||
Oestradiol Valerate and Oestradiol Valerate with Cyproterone Acetate | Pack containing 11 tablets oestradiol valerate 2 mg and 10 tablets oestradiol valerate 2 mg with cyproterone acetate 1 mg | Oral | 1 | 5 | SC | |||
Oestriol | Tablet 1 mg | Oral | 60 | 2 | OR | |||
| Pessaries 500 micrograms, 15 | Vaginal | 1 | 2 | OR | |||
| Vaginal cream 1 mg per g, 15 g | Application | 1 | 1 | OR | |||
Oestrogens—Conjugated | Tablet 300 micrograms | Oral | 56 | 2 | WY | |||
| Tablet 625 micrograms | Oral | 56 | 2 | WY | |||
Oestrogens—Conjugated with Medroxyprogesterone Acetate | Tablets 625 micrograms-2.5 mg, 28 | Oral | 1 | 5 | WY | |||
| Tablets 625 micrograms-5 mg, 28 | Oral | 1 | 5 | WY | |||
Ofloxacin | Eye drops 3 mg per mL, 5 mL | Application to the eye | 2 | .. | AG | |||
Olanzapine | Tablet 2.5 mg | Oral | 30 | 5 | LY | |||
| Tablet 5 mg | Oral | 30 | 5 | LY | |||
| Tablet 7.5 mg | Oral | 30 | 5 | LY | |||
| Tablet 10 mg | Oral | 30 | 5 | LY | |||
| Wafer 5 mg | Oral | 28 | 5 | LY | |||
| Wafer 10 mg | Oral | 28 | 5 | LY | |||
Olsalazine Sodium | Capsule 250 mg | Oral | 100 | 5 | UC | |||
| Tablet 500 mg | Oral | 100 | 5 | UC | |||
Omeprazole | Tablet 20 mg | Oral | 30 | 1 | HX | |||
| Capsule 20 mg | Oral | 30 | 1 | SZ | |||
Omeprazole and Clarithromycin and Amoxycillin Trihydrate | Pack containing 14 capsules omeprazole 20 mg, 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin trihydrate equivalent to 500 mg amoxycillin | Oral | 1 | .. | AB | |||
Omeprazole Magnesium | Tablet equivalent to 20 mg omeprazole | Oral | 30 | 1 | AL, AP, PM | |||
| Tablet equivalent to 10 mg omeprazole | Oral | 30 | 5 | AP | |||
Ondansetron | Wafer 4 mg | Oral | 4 | .. | GK, HX, RE | |||
| Wafer 8 mg | Oral | 4 | .. | GK, HX, RE | |||
Ondansetron Hydrochloride Dihydrate | Tablet equivalent to 4 mg ondansetron | Oral | 4 | .. | GK, HX, RE | |||
| Tablet equivalent to 8 mg ondansetron | Oral | 4 | .. | GK, HX, RE | |||
| Syrup equivalent to 4 mg ondansetron per 5 mL, 50 mL | Oral | 1 | 1 | GK | |||
| I.V. injection equivalent to 4 mg ondansetron in 2 mL ampoule | Injection | 1 | .. | GK, HX, RE | |||
| I.V. injection equivalent to 8 mg ondansetron in 4 mL ampoule | Injection | 1 | .. | GK, HX, RE | |||
Oxaliplatin | Solution concentrate for I.V. infusion 50 mg in 10 mL vial | Injection | 1 | 2 | SW | |||
| Solution concentrate for I.V. infusion 100 mg in 20 mL vial | Injection | 1 | 2 | SW | |||
Oxandrolone | Tablet 2.5 mg | Oral | 100 | 1 | CS | |||
Oxazepam | Tablet 15 mg | Oral | 25 | .. | AF, SI | |||
| Tablet 30 mg | Oral | 25 | .. | AF, FM, SI | |||
Oxcarbazepine | Tablet 150 mg | Oral | 100 | 5 | NV | |||
| Tablet 300 mg | Oral | 100 | 5 | NV | |||
| Tablet 600 mg | Oral | 100 | 5 | NV | |||
| Oral suspension 60 mg per mL, 250 mL | Oral | 2 | 5 | NV | |||
Oxprenolol Hydrochloride | Tablet 20 mg | Oral | 100 | 5 | AF | |||
| Tablet 40 mg | Oral | 100 | 5 | AF | |||
Oxybutynin Hydrochloride | Tablet 5 mg | Oral | 100 | 5 | AV | |||
Oxycodone Hydrochloride | Tablet 5 mg | Oral | 20 | .. | SI | |||
| Capsule 5 mg | Oral | 20 | .. | MF | |||
| Capsule 10 mg | Oral | 20 | .. | MF | |||
| Capsule 20 mg | Oral | 20 | .. | MF | |||
| Oral solution 5 mg per 5 mL, 250 mL | Oral | 1 | .. | MF | |||
| Tablet 5 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 10 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 20 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 40 mg (controlled release) | Oral | 20 | .. | MF | |||
| Tablet 80 mg (controlled release) | Oral | 20 | .. | MF | |||
Oxycodone Pectinate | Suppository equivalent to 30 mg oxycodone | Rectal | 12 | .. | PL | |||
Paclitaxel | Solution concentrate for I.V. infusion 30 mg in 5 mL vial | Injection | 5 | .. | BQ, IT, MX | |||
| Solution concentrate for I.V. infusion 100 mg in 16.7 mL vial | Injection | 2 | .. | BQ, IT, MX | |||
| Solution concentrate for I.V. infusion 150 mg in 25 mL vial | Injection | 2 | .. | BQ, IT, MX | |||
| Solution concentrate for I.V. infusion 300 mg in 50 mL vial | Injection | 1 | .. | BQ, IT, MX | |||
Pancreatic Extract | Capsule (containing enteric coated minimicrospheres) providing not less than 5,000 BP units of lipase activity | Oral | 500 | 10 | SM | |||
| Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity | Oral | 500 | 10 | SM | |||
| Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity | Oral | 200 | 10 | SM | |||
Pancrelipase | Capsule (containing enteric coated microspheres) providing not less than 10,000 BP units of lipase activity | Oral | 500 | 10 | OR | |||
| Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity | Oral | 200 | 10 | TM | |||
Pantoprazole Sodium Sesquihydrate | Tablet (enteric coated), equivalent to 40 mg pantoprazole | Oral | 30 | 2 | PH | |||
| Tablet (enteric coated), equivalent to 20 mg pantoprazole | Oral | 30 | 5 | PH | |||
Paracetamol | Tablet 500 mg | Oral | 100 | 1 | AW, CH, DG, FM, HX, JT, PC, SW, TW | |||
| Tablet 665 mg (modified release) | Oral | 192 | 5 | GC, ME | |||
| Oral liquid 120 mg per 5 mL, 100 mL | Oral | 1 | 2 | SW | |||
| Oral liquid 240 mg per 5 mL, 200 mL | Oral | 1 | 2 | SW | |||
Paraffin - Soft White with Paraffin - Liquid | Eye ointment, compound, 3.5 g | Application to the eye | 2 | 5 | AQ, IQ | |||
| Pack containing 2 tubes eye ointment, compound, 3.5 g | Application to the eye | 1 | 5 | AG, IQ, PE | |||
Paroxetine Hydrochloride | Tablet equivalent to 20 mg paroxetine | Oral | 30 | 5 | AF, CH, GK, GX, HX, TW | |||
Pemetrexed Disodium Heptahydrate | Powder for I.V. infusion equivalent to 500 mg pemetrexed, vial | Injection | 2 | 2 | LY | |||
Penicillamine | Tablet 125 mg | Oral | 100 | 1 | AL | |||
| Tablet 250 mg | Oral | 100 | 1 | AL | |||
"Pepti-Junior" | Oral powder 450 g | Oral | 8 | 5 | NU | |||
Pergolide Mesylate | Tablet equivalent to 50 micrograms pergolide | Oral | 100 | .. | AS | |||
| Tablet equivalent to 250 micrograms pergolide | Oral | 100 | 5 | AS | |||
| Tablet equivalent to 1 mg pergolide | Oral | 100 | 5 | AS | |||
Perhexiline Maleate | Tablet 100 mg | Oral | 100 | 5 | SI | |||
Pericyazine | Tablet 2.5 mg | Oral | 100 | 5 | AV | |||
| Tablet 10 mg | Oral | 100 | 5 | AV | |||
|
|
|
|
|
| |||
Perindopril Erbumine | Tablet 2 mg | Oral | 30 | 5 | SE | |||
| Tablet 4 mg | Oral | 30 | 5 | SE | |||
| Tablet 8 mg | Oral | 30 | 5 | SE | |||
Perindopril Erbumine with Indapamide Hemihydrate | Tablet 4 mg-1.25 mg | Oral | 30 | 5 | SE | |||
Permethrin | Cream 50 mg per g, 30 g | Application | 1 | 1 | PC | |||
Pethidine Hydrochloride | Injection 100 mg in 2 mL ampoule | Injection | 5 | .. | MX | |||
Phenelzine Sulfate | Tablet equivalent to 15 mg phenelzine | Oral | 100 | 1 | LM | |||
"Phenex-1" | Oral powder 350 g | Oral | 8 | 5 | AB | |||
| Oral powder 400 g | Oral | 8 | 5 | AB | |||
"Phenex-2" | Oral powder 325 g | Oral | 10 | 5 | AB | |||
| Oral powder 400 g | Oral | 8 | 5 | AB | |||
Phenobarbitone | Tablet 30 mg | Oral | 200 | 4 | SI | |||
Phenobarbitone Sodium | Injection 200 mg in 1 mL ampoule | Injection | 5 | .. | FM | |||
Phenoxybenzamine Hydrochloride | Capsule 10 mg | Oral | 100 | 5 | LM | |||
Phenoxymethylpenicillin Benzathine | Oral suspension equivalent to 125 mg phenoxymethylpenicillin per 5 mL, 100 mL | Oral | 2 | .. | FM, SI | |||
| Oral suspension equivalent to 250 mg phenoxymethylpenicillin per 5 mL, 100 mL | Oral | 2 | .. | FM, SI | |||
Phenoxymethylpenicillin Potassium | Tablet equivalent to 250 mg phenoxymethylpenicillin | Oral | 50 | .. | SI | |||
| Tablet equivalent to 500 mg phenoxymethylpenicillin | Oral | 50 | .. | SI | |||
| Capsule equivalent to 250 mg phenoxymethylpenicillin | Oral | 50 | .. | CS, DP, FM, HX | |||
| Capsule equivalent to 500 mg phenoxymethylpenicillin | Oral | 50 | .. | CS, DP, FM, HX | |||
Phenytoin | Tablet 50 mg | Oral | 200 | 2 | PF | |||
| Oral suspension 30 mg per 5 mL, 500 mL | Oral | 1 | 3 | PF | |||
Phenytoin Sodium | Capsule 30 mg | Oral | 200 | 2 | PF | |||
| Capsule 100 mg | Oral | 200 | 2 | PF | |||
"Phlexy-10" | Capsules 500 mg, 200 | Oral | 16 | 5 | SB | |||
| Tablets 1 g, 75 | Oral | 24 | 5 | SB | |||
| Bars 42 g, 20 | Oral | 10 | 5 | SB | |||
"Phlexy-10 Drink Mix" | Sachets containing oral powder 20 g, 30 | Oral | 7 | 5 | SB | |||
Pilocarpine Hydrochloride | Eye drops 5 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG, PE | |||
| Eye drops 10 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG, AQ, PE | |||
| Eye drops 20 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG, AQ, PE | |||
| Eye drops 30 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG, PE | |||
| Eye drops 40 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG, AQ, PE | |||
| Eye drops 60 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG, PE | |||
Pimecrolimus | Cream 10 mg per g, 15 g | Application | 1 | 1 | NV | |||
Pindolol | Tablet 5 mg | Oral | 100 | 5 | AF, NV | |||
| Tablet 15 mg | Oral | 50 | 5 | AF, NV | |||
Pioglitazone Hydrochloride | Tablet equivalent to 15 mg pioglitazone | Oral | 28 | 5 | LY | |||
| Tablet equivalent to 30 mg pioglitazone | Oral | 28 | 5 | LY | |||
| Tablet equivalent to 45 mg pioglitazone | Oral | 28 | 5 | LY | |||
Piperazine Oestrone Sulfate | Tablet 730 micrograms | Oral | 56 | 2 | KR, PH | |||
| Tablet 1.46 mg | Oral | 56 | 2 | KR, PH | |||
Piroxicam | Dispersible tablet 10 mg | Oral | 50 | 3 | AF, GX, HX, PF | |||
| Dispersible tablet 20 mg | Oral | 25 | 3 | AF, CH, GX, HX, PF, TW | |||
| Capsule 10 mg | Oral | 50 | 3 | AF, CH, GX, PF, TW | |||
| Capsule 20 mg | Oral | 25 | 3 | AF, CH, GX, PF, TW | |||
Pizotifen Malate | Tablet equivalent to 500 micrograms pizotifen | Oral | 100 | 2 | NV | |||
"PK AID II" | Oral powder 250 g | Oral | 8 | 5 | SB | |||
"PK Max" | Sachets containing oral powder 19 g, 30 | Oral | 4 | 5 | SB | |||
"PKU Express Liquid" | Oral liquid 130 mL, 30 | Oral | 4 | 5 | VF | |||
"PKU-gel" | Sachets containing oral powder 20 g, 30 | Oral | 4 | 5 | VF | |||
"PKU-Express" | Sachets containing oral powder 25 g, 30 | Oral | 4 | 5 | VF | |||
Pneumococcal Vaccine - Polyvalent | Injection 0.5 mL vial (23 valent) | Injection | 1 | .. | CS | |||
Polyethylene Glycol 400 with Propylene Glycol | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the eye | 1 | 5 | AQ | |||
Polygeline | I.V. infusion 17.5 g per 500 mL with electrolytes, 500 mL | Injection | 3 | .. | AE | |||
Polymyxin B Sulfate with Bacitracin Zinc and Neomycin Sulfate | Eye ointment 5,000 units-400 units-5 mg per g, 4 g | Application to the eye | 1 | .. | PC | |||
Polyvinyl Alcohol | Eye drops 14 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG, PE | |||
| Eye drops 14 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) | Application to the eye | 1 | 5 | AE | |||
| Eye drops 30 mg per mL, 15 mL | Application to the eye | 1 | 5 | AG, PE | |||
| Eye drops 30 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) | Application to the eye | 1 | 5 | AE | |||
Potassium Chloride | Tablet 600 mg (sustained release) | Oral | 200 | 1 | AS, NV, SZ | |||
Potassium Chloride with Potassium Bicarbonate | Tablet, effervescent, 14 mmol K+ and 8 mmol Cl- | Oral | 60 | 1 | AS, LN | |||
Pravastatin Sodium | Tablet 10 mg | Oral | 30 | 5 | AW, BQ | |||
| Tablet 20 mg | Oral | 30 | 5 | AW, BQ | |||
| Tablet 40 mg | Oral | 30 | 5 | AW, BQ | |||
| Tablet 80 mg | Oral | 30 | 5 | AW, BQ | |||
Prazosin Hydrochloride | Tablet equivalent to 1 mg prazosin | Oral | 100 | 5 | AF, CH, GX, HX, PF, TW | |||
| Tablet equivalent to 2 mg prazosin | Oral | 100 | 5 | AF, CH, GX, HX, PF, TW | |||
| Tablet equivalent to 5 mg prazosin | Oral | 100 | 5 | AF, CH, GX, HX, PF, TW | |||
Prednisolone | Tablet 1 mg | Oral | 100 | 4 | AS, LN | |||
| Tablet 5 mg | Oral | 60 | 4 | AS, FM | |||
| Tablet 25 mg | Oral | 30 | 4 | AS, FM | |||
Prednisolone Acetate with Phenylephrine Hydrochloride | Eye drops 10 mg-1.2 mg per mL, 10 mL | Application to the eye | 1 | 2 | AG | |||
Prednisolone Sodium Phosphate | Oral solution equivalent to 5 mg prednisolone per mL, 30 mL | Oral | 1 | 5 | AS, LN | |||
| Enema, retention, equivalent to 20 mg prednisolone in 100 mL | Rectal | 28 | 3 | SI | |||
| Suppositories equivalent to 5 mg prednisolone, 10 | Rectal | 3 | 3 | SI | |||
Prednisone | Tablet 1 mg | Oral | 100 | 4 | AS, LN | |||
| Tablet 5 mg | Oral | 60 | 4 | AS, FM | |||
| Tablet 25 mg | Oral | 30 | 4 | AS, FM | |||
Primidone | Tablet 250 mg | Oral | 200 | 2 | LM | |||
"Pro-Phree" | Oral powder 400 g | Oral | 8 | 5 | AB | |||
Probenecid | Tablet 500 mg | Oral | 100 | 5 | PL | |||
Procaine Penicillin | Injection 1.5 g in disposable syringe | Injection | 5 | .. | SI | |||
Prochlorperazine | Suppositories 3 mg, equivalent to 5 mg prochlorperazine maleate, 5 | Rectal | 1 | 2 | AV | |||
| Suppositories 15 mg, equivalent to 25 mg prochlorperazine maleate, 5 | Rectal | 1 | 2 | AV | |||
Prochlorperazine Maleate | Tablet 5 mg | Oral | 25 | .. | AV, HP | |||
Prochlorperazine Mesylate | Injection 12.5 mg in 1 mL ampoule | Injection | 10 | .. | AV | |||
Promethazine Hydrochloride | Injection 50 mg in 2 mL ampoule | Injection | 10 | .. | MX | |||
Propantheline Bromide | Tablet 15 mg | Oral | 200 | 5 | SI | |||
Propranolol Hydrochloride | Tablet 10 mg | Oral | 100 | 5 | AF, AP | |||
| Tablet 40 mg | Oral | 100 | 5 | AF, AP | |||
| Tablet 160 mg | Oral | 50 | 5 | AF | |||
Propylthiouracil | Tablet 50 mg | Oral | 200 | 2 | PL | |||
Pyrantel Embonate | Tablet equivalent to 125 mg pyrantel | Oral | 6 | .. | AF | |||
| Tablet equivalent to 250 mg pyrantel | Oral | 6 | .. | AF | |||
Pyridostigmine Bromide | Tablet 10 mg | Oral | 100 | 5 | VT | |||
| Tablet 60 mg | Oral | 150 | 5 | VT | |||
| Tablet 180 mg (modified release) | Oral | 100 | 5 | VT | |||
Pyrimethamine | Tablet 25 mg | Oral | 50 | .. | GK | |||
Quetiapine Fumarate | Tablet equivalent to 25 mg quetiapine | Oral | 60 | 5 | AP | |||
| Tablet equivalent to 100 mg quetiapine | Oral | 90 | 5 | AP | |||
| Tablet equivalent to 200 mg quetiapine | Oral | 60 | 5 | AP | |||
| Tablet equivalent to 300 mg quetiapine | Oral | 60 | 5 | AP | |||
Quinagolide Hydrochloride | Pack containing 3 tablets equivalent to 25 micrograms quinagolide and 3 tablets equivalent to 50 micrograms quinagolide | Oral | 1 | .. | FP | |||
| Tablet equivalent to 75 micrograms quinagolide | Oral | 30 | 5 | FP | |||
Quinapril Hydrochloride | Tablet equivalent to 5 mg quinapril | Oral | 30 | 5 | PF, SI | |||
| Tablet equivalent to 10 mg quinapril | Oral | 30 | 5 | PF, SI | |||
| Tablet equivalent to 20 mg quinapril | Oral | 30 | 5 | PF, SI | |||
Quinapril Hydrochloride with Hydrochlorothiazide | Tablet equivalent to 10 mg quinapril with 12.5 mg hydrochlorothiazide | Oral | 30 | 5 | PF | |||
| Tablet equivalent to 20 mg quinapril with 12.5 mg hydrochlorothiazide | Oral | 30 | 5 | PF | |||
Quinidine Bisulfate | Tablet 250 mg (sustained release) | Oral | 100 | 5 | AP | |||
Quinine Bisulfate | Tablet 300 mg | Oral | 50 | 2 | AS | |||
Quinine Sulfate | Tablet 300 mg | Oral | 50 | 2 | AS, LN | |||
Rabeprazole Sodium | Tablet 20 mg (enteric coated) | Oral | 30 | 2 | JC | |||
| Tablet 10 mg (enteric coated) | Oral | 28 | 5 | JC | |||
Raloxifene Hydrochloride | Tablet 60 mg | Oral | 28 | 5 | LY | |||
Raltitrexed | Powder for I.V. infusion 2 mg in single use vial | Injection | 3 | 2 | AP | |||
Ramipril | Tablet 1.25 mg | Oral | 30 | 5 | AV, ML | |||
| Tablet 2.5 mg | Oral | 30 | 5 | AV, ML | |||
| Tablet 5 mg | Oral | 30 | 5 | AV, ML | |||
| Capsule 10 mg | Oral | 30 | 5 | AV | |||
| Pack containing 7 tablets 2.5 mg, 21 tablets 5 mg and 10 capsules 10 mg | Oral | 1 | .. | AV | |||
Ranitidine Hydrochloride | Tablet equivalent to 150 mg ranitidine | Oral | 60 | 5 | AF, CH, DP, GK, GX, HX, SI, TW | |||
| Tablet, effervescent, equivalent to 150 mg ranitidine | Oral | 60 | 5 | GK | |||
| Tablet equivalent to 300 mg ranitidine | Oral | 30 | 5 | AF, CH, DP, GK, GX, HX, SI, TW | |||
| Syrup equivalent to 150 mg ranitidine per 10 mL, 300 mL | Oral | 2 | 5 | GK | |||
"RCF" | Oral liquid 384 mL | Oral | 120 | 5 | AB | |||
Reboxetine Mesilate | Tablet equivalent to 4 mg reboxetine | Oral | 60 | 5 | PH | |||
Reteplase | Pack containing 2 vials powder for injection 10 units, 2 single use pre-filled syringes with solvent, 2 reconstitution spikes and 2 needles | Injection | 1 | .. | RO | |||
Rifampicin | Capsule 150 mg | Oral | 10 | .. | AF | |||
| Capsule 300 mg | Oral | 10 | .. | AF | |||
| Syrup 100 mg per 5 mL, 60 mL | Oral | 1 | .. | AV | |||
Riluzole | Tablet 50 mg | Oral | 56 | 5 | AV | |||
Risedronate Sodium | Tablet 5 mg | Oral | 28 | 5 | AV | |||
| Tablet 35 mg | Oral | 4 | 5 | AV | |||
| Tablet 30 mg | Oral | 28 | 1 | AV | |||
Risedronate Sodium and Calcium Carbonate | Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg calcium) | Oral | 1 | 5 | AV | |||
Risperidone | Tablet 0.5 mg | Oral | 60 | 2 | JC | |||
| Tablet 0.5 mg (orally disintegrating) | Oral | 56 | 2 | JC | |||
| Tablet 1 mg | Oral | 60 | 2 | JC | |||
| Tablet 1 mg (orally disintegrating) | Oral | 56 | 2 | JC | |||
| Tablet 2 mg | Oral | 60 | 5 | JC | |||
| Tablet 2 mg (orally disintegrating) | Oral | 56 | 5 | JC | |||
| Tablet 3 mg | Oral | 60 | 5 | JC | |||
| Tablet 4 mg | Oral | 60 | 5 | JC | |||
| Oral solution 1 mg per mL, 30 mL | Oral | 1 | 2 | JC | |||
| Oral solution 1 mg per mL, 100 mL | Oral | 1 | 5 | JC | |||
| I.M. injection (modified release), set containing 1 vial powder for injection 25 mg and 1 pre-filled syringe diluent 2 mL | Injection | 2 | 5 | JC | |||
| I.M. injection (modified release), set containing 1 vial powder for injection 37.5 mg and 1 pre-filled syringe diluent 2 mL | Injection | 2 | 5 | JC | |||
| I.M. injection (modified release), set containing 1 vial powder for injection 50 mg and 1 pre-filled syringe diluent 2 mL | Injection | 2 | 5 | JC | |||
Rituximab | Solution for I.V. infusion 100 mg in 10 mL vial | Injection | 2 | 3 | RO | |||
| Solution for I.V. infusion 500 mg in 50 mL vial | Injection | 1 | 3 | RO | |||
Rivastigmine Hydrogen Tartrate | Capsule equivalent to 1.5 mg rivastigmine | Oral | 56 | 5 | NV | |||
| Capsule equivalent to 3 mg rivastigmine | Oral | 56 | 5 | NV | |||
| Capsule equivalent to 4.5 mg rivastigmine | Oral | 56 | 5 | NV | |||
| Capsule equivalent to 6 mg rivastigmine | Oral | 56 | 5 | NV | |||
| Oral solution equivalent to 2 mg rivastigmine per mL, 120 mL | Oral | 1 | 5 | NV | |||
Rosiglitazone Maleate | Tablet equivalent to 4 mg rosiglitazone | Oral | 28 | 5 | GK | |||
| Tablet equivalent to 8 mg rosiglitazone | Oral | 28 | 5 | GK | |||
Roxithromycin | Tablet for oral suspension 50 mg | Oral | 10 | 1 | AV | |||
| Tablet 150 mg | Oral | 10 | 1 | AF, AV, AW, HP | |||
| Tablet 300 mg | Oral | 5 | 1 | AF, AV, AW, HP | |||
"S-26 LF" | Infant formula powder 900 g | Oral | 5 | .. | WY | |||
Salbutamol Sulfate | Oral solution equivalent to 2 mg salbutamol per 5 mL, 150 mL | Oral | 2 | 5 | GK | |||
| Capsule containing powder for oral inhalation equivalent to 200 micrograms salbutamol (for use in Ventolin Rotahaler) | Inhalation by mouth | 200 | 5 | GK | |||
| Pressurised inhalation equivalent to 100 micrograms salbutamol per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | 2 | 5 | AL, AW, GK, MM | |||
| Pressurised inhalation in breath actuated device equivalent to 100 micrograms salbutamol per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | 2 | 5 | MM | |||
| Nebuliser solution equivalent to 2.5 mg salbutamol in 2.5 mL single dose units, 30 | Inhalation | 2 | 5 | AF, AW, CH, GK, GX, PU, TW | |||
| Nebuliser solution equivalent to 5 mg salbutamol in 2.5 mL single dose units, 30 | Inhalation | 2 | 5 | AF, AW, CH, GK, GX, TW | |||
| Nebuliser solution equivalent to 5 mg salbutamol per mL, 30 mL | Inhalation | 2 | 2 | PU | |||
Salcatonin | Injection 50 I.U. in 1 mL ampoule | Injection | 30 | 5 | NV | |||
| Injection 100 I.U. in 1 mL ampoule | Injection | 15 | 5 | NV | |||
Salmeterol Xinafoate | Pressurised inhalation equivalent to 25 micrograms salmeterol per dose, 120 doses | Inhalation by mouth | 1 | 5 | GK | |||
| Powder for oral inhalation in breath actuated device equivalent to 50 micrograms salmeterol per dose, 60 doses | Inhalation by mouth | 1 | 5 | GK | |||
Selegiline Hydrochloride | Tablet 5 mg | Oral | 100 | 5 | AF, DP | |||
Sertraline Hydrochloride | Tablet equivalent to 50 mg sertraline | Oral | 30 | 5 | AF, AW, CH, DP, GX, HX, PF, TW | |||
| Tablet equivalent to 100 mg sertraline | Oral | 30 | 5 | AF, AW, CH, DP, GX, HX, PF, TW | |||
Silver Sulfadiazine with Chlorhexidine Gluconate | Cream 10 mg-2 mg per g, 50 g | Application | 1 | .. | SN | |||
Cream 10 mg-2 mg per g, 100 g | Application | 1 | .. | SN | ||||
Simvastatin | Tablet 5 mg | Oral | 30 | 5 | AF, BF, FR, HX, MK, RE | |||
| Tablet 10 mg | Oral | 30 | 5 | AF, AW, BF, CH, DP, FR, GN, GX, HX, MK, RE, TW | |||
| Tablet 20 mg | Oral | 30 | 5 | AF, AW, BF, CH, DP, FR, GN, GX, HX, MK, RE, TW | |||
| Tablet 40 mg | Oral | 30 | 5 | AF, AW, BF, CH, DP, FR, GN, GX, HX, MK, RE, TW | |||
| Tablet 80 mg | Oral | 30 | 5 | AF, AW, BF, CH, DP, FR, GN, GX, HX, MK, RE, TW | |||
Sirolimus | Tablet 1 mg | Oral | 100 | 3 | WY | |||
| Tablet 2 mg | Oral | 100 | 3 | WY | |||
| Oral solution 1 mg per mL, 60 mL | Oral | 1 | 3 | WY | |||
Sodium Acid Phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral | 100 | 5 | NV | |||
Sodium Alginate with Calcium Carbonate and Sodium Bicarbonate | Oral liquid 1 g-320 mg-534 mg in 20 mL, 500 mL | Oral | 2 | 5 | RC | |||
Sodium Aurothiomalate | Injection 10 mg ampoule | Injection | 10 | .. | AV | |||
| Injection 20 mg ampoule | Injection | 10 | 1 | AV | |||
| Injection 50 mg ampoule | Injection | 10 | 1 | AV | |||
Sodium Chloride | I.V. infusion 154 mmol per L, 1 L | Injection | 5 | 1 | BX | |||
| I.V. infusion 513 mmol per L, 1 L | Injection | 2 | 1 | BX | |||
Sodium Chloride with Glucose | I.V. infusion 31 mmol-222 mmol (anhydrous) per L, 1 L | Injection | 5 | 1 | BX | |||
| I.V. infusion 19 mmol-104 mmol (anhydrous) per 500 mL, 500 mL | Injection | 5 | 1 | BX | |||
| I.V. infusion 39 mmol-69 mmol (anhydrous) per 500 mL, 500 mL | Injection | 5 | 1 | BX | |||
Sodium Chloride with Potassium Chloride and Calcium Chloride | I.V. infusion containing approximately 148 mmol Na+, 4 mmol K+, 2 mmol Ca2+ and 156 mmol Cl- per L, 1 L | Injection | 4 | 1 | BX | |||
Sodium Chloride with Sodium Acetate, Sodium Gluconate, Potassium Chloride and Magnesium Chloride | Electrolyte replacement solution 5.26 g-3.68 g-5.02 g- 370 mg-300 mg per L, 1 L | Injection | 2 | 1 | BX | |||
Sodium Clodronate Tetrahydrate | Capsule equivalent to 400 mg sodium clodronate | Oral | 100 | 2 | SC | |||
| Tablet equivalent to 800 mg sodium clodronate | Oral | 60 | 2 | SC | |||
Sodium Cromoglycate | Capsule containing powder for oral inhalation 20 mg (for use in Intal Spinhaler or Intal Halermatic) | Inhalation by mouth | 100 | 5 | DP | |||
| Solution for inhalation 20 mg in 2 mL ampoule | Inhalation | 120 | 3 | AV | |||
| Pressurised inhalation 1 mg per dose, 200 doses | Inhalation by mouth | 1 | 5 | AV | |||
| Pressurised inhalation 1 mg per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | AV | |||
| Pressurised inhalation 5 mg per dose, 112 doses (CFC-free formulation) | Inhalation by mouth | 1 | 5 | AV | |||
| Eye drops 20 mg per mL, 10 mL | Application to the eye | 1 | 5 | AV | |||
Sodium Fusidate | Tablet 250 mg | Oral | 36 | 1 | CS | |||
Sodium Lactate with Sodium Chloride, Potassium Chloride and Calcium Chloride | I.V. infusion containing approximately 131 mmol Na+, 5 mmol K+, 2 mmol Ca2+, 29 mmol HCO3- (as lactate) and 111 mmol Cl- per L, 1 L | Injection | 5 | 1 | BX | |||
Sodium Valproate | Tablet, crushable, 100 mg | Oral | 200 | 2 | SW | |||
| Tablet 200 mg (enteric coated) | Oral | 200 | 2 | AF, SW | |||
| Tablet 500 mg (enteric coated) | Oral | 200 | 2 | AF, SW | |||
| Oral liquid 200 mg per 5 mL, 300 mL | Oral | 2 | 2 | SW | |||
| Oral solution 200 mg per 5 mL, 300 mL | Oral | 2 | 2 | SW | |||
Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate | Enemas 3.125 g-450 mg-45 mg in 5 mL, 12 | Rectal | 2 | 2 | PH | |||
Sotalol Hydrochloride | Tablet 80 mg | Oral | 60 | 5 | AW, BQ, GX, HX | |||
| Tablet 160 mg | Oral | 60 | 5 | AF, AW, BQ, CH, DP, GX, HX, TW | |||
Spironolactone | Tablet 25 mg | Oral | 100 | 5 | AF, PH | |||
| Tablet 100 mg | Oral | 100 | 5 | AF, PH | |||
Sterculia with Frangula Bark | Granules 620 mg-80 mg per g, 500 g | Oral | 1 | 1 | NE | |||
Sucralfate | Tablet equivalent to 1 g anhydrous sucralfate | Oral | 120 | 2 | AF, AS | |||
Sulfacetamide Sodium | Eye drops 100 mg per mL, 15 mL | Application to the eye | 1 | 2 | AG | |||
Sulfasalazine | Tablet 500 mg | Oral | 200 | 5 | PH | |||
| Tablet 500 mg (enteric coated) | Oral | 200 | 5 | KR, PH | |||
Sulindac | Tablet 100 mg | Oral | 100 | 3 | AF | |||
| Tablet 200 mg | Oral | 50 | 3 | AF | |||
Sulthiame | Tablet 50 mg | Oral | 200 | 2 | PL | |||
| Tablet 200 mg | Oral | 200 | 2 | PL | |||
Sumatriptan | Nasal spray 20 mg in 0.1 mL single dose unit | Nasal | 2 | 5 | GK | |||
Sumatriptan Succinate | Tablet equivalent to 50 mg sumatriptan | Oral | 4 | 5 | AW, GK | |||
| Tablet (fast disintegrating) equivalent to 50 mg sumatriptan | Oral | 4 | 5 | GK | |||
Tacrolimus | Capsule 500 micrograms | Oral | 100 | 3 | JC | |||
| Capsule 1 mg | Oral | 100 | 3 | JC | |||
| Capsule 5 mg | Oral | 50 | 3 | JC | |||
Tamoxifen Citrate | Tablet equivalent to 10 mg tamoxifen | Oral | 60 | 5 | AF, AP, DP | |||
| Tablet equivalent to 20 mg tamoxifen | Oral | 60 | 5 | AF, AP, CH, DP, GX, HX, SI, TW | |||
Telmisartan | Tablet 40 mg | Oral | 28 | 5 | BY | |||
| Tablet 80 mg | Oral | 28 | 5 | BY | |||
Telmisartan with Hydrochlorothiazide | Tablet 40 mg-12.5 mg | Oral | 28 | 5 | BY | |||
| Tablet 80 mg-12.5 mg | Oral | 28 | 5 | BY | |||
Temazepam | Tablet 10 mg | Oral | 25 | .. | AF, FM, SI | |||
Temozolomide | Capsule 5 mg | Oral | 15 | 2 | SH | |||
| Capsule 20 mg | Oral | 15 | 2 | SH | |||
| Capsule 100 mg | Oral | 15 | 2 | SH | |||
| Capsule 250 mg | Oral | 5 | 5 | SH | |||
Tenecteplase | Powder for injection 40 mg vial with solvent | Injection | 1 | .. | BY | |||
| Powder for injection 50 mg vial with solvent | Injection | 1 | .. | BY | |||
Terbinafine Hydrochloride | Tablet equivalent to 250 mg terbinafine | Oral | 42 | 1 | AF, AW, DP, GX, HX, NV | |||
Terbutaline Sulfate | Injection 500 micrograms in 1 mL ampoule | Injection | 5 | .. | AP | |||
| Powder for oral inhalation in breath actuated device 500 micrograms per dose, 200 doses | Inhalation by mouth | 1 | 5 | AP | |||
| Nebuliser solution 5 mg in 2 mL single dose units, 30 | Inhalation | 2 | 5 | AP | |||
Testosterone | Subcutaneous implant 100 mg | Subcutaneous implantation | 6 | .. | OR | |||
| Subcutaneous implant 200 mg | Subcutaneous implantation | 3 | .. | OR | |||
| Transdermal gel 50 mg in 5 g sachet, 30 | Transdermal | 1 | 5 | SC | |||
| Transdermal patches 12.2 mg, 60 | Transdermal | 1 | 5 | MX | |||
| Transdermal patches 24.3 mg, 30 | Transdermal | 1 | 5 | MX | |||
Testosterone Enanthate | Injection 250 mg in 1 mL | Injection | 3 | 3 | SC | |||
Testosterone Propionate with Testosterone Phenylpropionate and Testosterone Isocaproate | Injection 20 mg-40 mg-40 mg in 1 mL ampoule | Injection | 3 | 3 | OR | |||
Testosterone Propionate with Testosterone Phenylpropionate, Testosterone Isocaproate and Testosterone Decanoate | Injection 30 mg-60 mg-60 mg-100 mg in 1 mL ampoule | Injection | 3 | 3 | OR | |||
Testosterone Undecanoate | Capsule 40 mg | Oral | 60 | 5 | OR | |||
Tetrabenazine | Tablet 25 mg | Oral | 112 | 5 | OA | |||
Tetracosactrin | Compound depot injection 1 mg in 1 mL ampoule | Injection | 5 | 5 | NV | |||
Theophylline | Tablet 200 mg (sustained release) | Oral | 100 | 5 | MM | |||
| Tablet 250 mg (sustained release) | Oral | 100 | 5 | MM | |||
| Tablet 300 mg (sustained release) | Oral | 100 | 5 | MM | |||
| Oral solution 133.3 mg per 25 mL, 500 mL | Oral | 1 | 5 | MM | |||
Thioguanine | Tablet 40 mg | Oral | 25 | 1 | GK | |||
Thioridazine Hydrochloride | Tablet 10 mg | Oral | 100 | 5 | AF | |||
| Tablet 25 mg | Oral | 100 | 5 | AF | |||
| Tablet 50 mg | Oral | 100 | 5 | AF | |||
| Tablet 100 mg | Oral | 100 | 5 | AF | |||
Thiotepa | Powder for injection 15 mg | Injection or intravesical administration | 2 | 1 | SI | |||
Thyroxine Sodium | Tablet equivalent to 50 micrograms anhydrous thyroxine sodium | Oral | 200 | 1 | FM, SI | |||
| Tablet equivalent to 100 micrograms anhydrous thyroxine sodium | Oral | 200 | 1 | FM, SI | |||
| Tablet equivalent to 200 micrograms anhydrous thyroxine sodium | Oral | 200 | 1 | FM, SI | |||
Tiagabine Hydrochloride | Tablet equivalent to 5 mg tiagabine | Oral | 100 | 5 | MX | |||
| Tablet equivalent to 10 mg tiagabine | Oral | 100 | 5 | MX | |||
| Tablet equivalent to 15 mg tiagabine | Oral | 100 | 5 | MX | |||
Tiaprofenic Acid | Tablet 300 mg | Oral | 60 | 3 | AV | |||
Ticarcillin Sodium with Potassium Clavulanate | Powder for injection equivalent to 3 g ticarcillin-100 mg clavulanic acid | Injection | 10 | .. | GK | |||
Ticlopidine Hydrochloride | Tablet 250 mg | Oral | 60 | 5 | AF, HX, RO | |||
Tiludronate Disodium | Tablet equivalent to 200 mg tiludronic acid | Oral | 56 | 2 | MX | |||
Timolol Maleate | Eye gel equivalent to 1 mg timolol per g, 5 g | Application to the eye | 1 | 5 | NV | |||
| Eye drops equivalent to 2.5 mg timolol per mL, 5 mL | Application to the eye | 1 | 5 | FR, SI | |||
| Eye drops equivalent to 5 mg timolol per mL, 5 mL | Application to the eye | 1 | 5 | FR, SI | |||
| Eye drops (gellan gum solution) equivalent to 2.5 mg timolol per mL, 2.5 mL | Application to the eye | 1 | 5 | MK | |||
| Eye drops (gellan gum solution) equivalent to 5 mg timolol per mL, 2.5 mL | Application to the eye | 1 | 5 | MK | |||
Tinidazole | Tablet 500 mg | Oral | 4 | .. | GP, PF | |||
Tiotropium Bromide Monohydrate | Capsule containing powder for oral inhalation equivalent to 18 micrograms tiotropium (for use in HandiHaler) | Inhalation by mouth | 30 | 5 | BY | |||
Tirofiban Hydrochloride | Solution concentrate for I.V. infusion equivalent to 12.5 mg tirofiban in 50 mL vial | Injection | 1 | 2 | MK | |||
Tobramycin | Eye drops 3 mg per mL, 5 mL | Application to the eye | 1 | 2 | AQ | |||
| Eye ointment 3 mg per g, 3.5 g | Application to the eye | 1 | .. | AQ | |||
Tobramycin Sulfate | Injection equivalent to 80 mg tobramycin in 2 mL (with preservative) | Injection | 10 | 1 | AS, MX | |||
| Injection equivalent to 80 mg tobramycin in 2 mL (without preservative) | Injection | 10 | 1 | PU | |||
Topiramate | Tablet 25 mg | Oral | 60 | 5 | JC | |||
| Tablet 50 mg | Oral | 60 | 5 | JC | |||
| Tablet 100 mg | Oral | 60 | 5 | JC | |||
| Tablet 200 mg | Oral | 60 | 5 | JC | |||
| Capsule 15 mg | Oral | 60 | 5 | JC | |||
| Capsule 25 mg | Oral | 60 | 5 | JC | |||
| Capsule 50 mg | Oral | 60 | 5 | JC | |||
Topotecan Hydrochloride | Powder for I.V. infusion equivalent to 4 mg topotecan, vial | Injection | 5 | 1 | GK | |||
Toremifene Citrate | Tablet equivalent to 60 mg toremifene | Oral | 30 | 5 | SH | |||
Tramadol Hydrochloride | Capsule 50 mg | Oral | 20 | .. | AF, AW, CH, CS, GX, TW | |||
| Tablet 100 mg (sustained release) | Oral | 20 | .. | AW, CS, HX | |||
| Tablet 150 mg (sustained release) | Oral | 20 | .. | AW, CS, HX | |||
| Tablet 200 mg (sustained release) | Oral | 20 | .. | AW, CS, HX | |||
|
|
|
|
|
| |||
| Oral drops 100 mg per mL, 10 mL | Oral | 1 | .. | CS | |||
| Injection 100 mg in 2 mL ampoule | Injection | 5 | .. | CS, HX | |||
Trandolapril | Capsule 500 micrograms | Oral | 28 | 5 | AB, KN | |||
| Capsule 1 mg | Oral | 28 | 5 | AB, KN | |||
| Capsule 2 mg | Oral | 28 | 5 | AB, KN | |||
| Capsule 4 mg | Oral | 28 | 5 | AB | |||
Tranexamic Acid | Tablet 500 mg | Oral | 100 | 2 | PH | |||
Tranylcypromine Sulfate | Tablet equivalent to 10 mg tranylcypromine | Oral | 50 | 2 | LM | |||
Travoprost | Eye drops 40 micrograms per mL, 2.5 mL | Application to the eye | 1 | 5 | AQ | |||
Triamcinolone Acetonide | Injection 10 mg in 1 mL ampoule | Injection | 5 | .. | BQ | |||
| Cream 200 micrograms per g, 100 g | Application | 2 | .. | FM, SI | |||
| Ointment 200 micrograms per g, 100 g | Application | 2 | .. | FM, SI | |||
Triamcinolone Acetonide with Neomycin Sulfate, Gramicidin and Nystatin | Ear drops 1 mg-2.5 mg (neomycin)-250 micrograms-100,000 units per g, 7.5 mL | Application to the ear | 1 | 2 | BC, BQ | |||
| Ear ointment 1 mg-2.5 mg (neomycin)-250 micrograms-100,000 units per g, 5 g | Application to the ear | 1 | 2 | BC, BQ | |||
Trifluoperazine Hydrochloride | Tablet equivalent to 1 mg trifluoperazine | Oral | 100 | 5 | LM | |||
| Tablet equivalent to 2 mg trifluoperazine | Oral | 100 | 5 | LM | |||
| Tablet equivalent to 5 mg trifluoperazine | Oral | 100 | 5 | LM | |||
Triglycerides Oil - Medium Chain | 500 mL | Oral | 2 | 5 | SB | |||
Trimethoprim | Tablet 300 mg | Oral | 7 | 1 | AF, SI | |||
Trimethoprim with Sulfamethoxazole | Tablet 80 mg-400 mg | Oral | 10 | 1 | AF, SI | |||
| Tablet 160 mg-800 mg | Oral | 10 | 1 | AF, CH, GX, RO, SI, TW | |||
| Paediatric oral suspension 40 mg-200 mg per 5 mL, 100 mL | Oral | 1 | 1 | AF, RO, SI | |||
Tropisetron Hydrochloride | Capsule equivalent to 5 mg tropisetron | Oral | 2 | .. | NV | |||
| I.V. injection equivalent to 5 mg tropisetron in 5 mL ampoule | Injection | 1 | .. | NV | |||
"TYR gel" | Sachets containing oral powder 20 g, 30 | Oral | 4 | 5 | VF | |||
"TYR Express" | Sachets containing oral powder 25 g, 30 | Oral | 4 | 5 | VF | |||
Ursodeoxycholic Acid | Capsule 250 mg | Oral | 100 | 2 | OA | |||
Valaciclovir Hydrochloride | Tablet equivalent to 500 mg valaciclovir | Oral | 20 | .. | GK | |||
Vancomycin Hydrochloride | Capsule equivalent to 125 mg (125,000 I.U.) vancomycin activity | Oral | 40 | .. | LY | |||
| Capsule equivalent to 250 mg (250,000 I.U.) vancomycin activity | Oral | 40 | .. | LY | |||
| Powder for injection equivalent to 500 mg (500,000 I.U.) vancomycin activity | Injection | 2 | .. | AS, MX | |||
Venlafaxine Hydrochloride | Capsule (modified release) equivalent to 37.5 mg venlafaxine | Oral | 28 | .. | WY | |||
| Capsule (modified release) equivalent to 75 mg venlafaxine | Oral | 28 | 5 | WY | |||
| Capsule (modified release) equivalent to 150 mg venlafaxine | Oral | 28 | 5 | WY | |||
Verapamil Hydrochloride | Tablet 40 mg | Oral | 100 | 5 | AB, AF | |||
| Tablet 80 mg | Oral | 100 | 5 | AB, AF | |||
| Tablet 120 mg | Oral | 100 | 5 | AB | |||
| Tablet 160 mg | Oral | 60 | 5 | AB | |||
| Tablet 180 mg (sustained release) | Oral | 30 | 5 | AB, KN | |||
| Tablet 240 mg (sustained release) | Oral | 30 | 5 | AB, AF, KN | |||
| Capsule 160 mg (sustained release) | Oral | 30 | 5 | SI | |||
| Capsule 240 mg (sustained release) | Oral | 30 | 5 | SI | |||
| Injection 5 mg in 2 mL ampoule | Injection | 5 | .. | AB | |||
Vigabatrin | Tablet 500 mg | Oral | 100 | 5 | AV | |||
| Oral powder, sachet 500 mg | Oral | 60 | 5 | AV | |||
Vinblastine Sulfate | Powder for injection 10 mg | Injection | 5 | .. | AS | |||
| Solution for I.V. injection 10 mg in 10 mL vial | Injection | 5 | .. | MX | |||
Vincristine Sulfate | I.V. injection 1 mg in 1 mL vial | Injection | 10 | .. | MX, PU | |||
Vinorelbine Tartrate | Solution for I.V. infusion equivalent to 10 mg vinorelbine in 1 mL vial | Injection | 16 | 2 | FB, MX | |||
| Solution for I.V. infusion equivalent to 50 mg vinorelbine in 5 mL vial | Injection | 4 | 2 | FB, MX | |||
Warfarin Sodium | Tablet 1 mg | Oral | 50 | 2 | FM, SI | |||
| Tablet 2 mg | Oral | 50 | 2 | SI | |||
| Tablet 3 mg | Oral | 50 | 2 | FM | |||
| Tablet 5 mg | Oral | 50 | 2 | FM, SI | |||
"XMET Analog" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
"XMET Maxamaid" | Oral powder 500 g | Oral | 8 | 5 | SB | |||
"XMET Maxamum" | Oral powder 500 g | Oral | 8 | 5 | SB | |||
"XMTVI Analog" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
"XMTVI Asadon" | Oral powder 200 g | Oral | 5 | 5 | SB | |||
"XMTVI Maxamaid" | Oral powder 500 g | Oral | 8 | 5 | SB | |||
"XMTVI Maxamum" | Oral powder 500 g | Oral | 8 | 5 | SB | |||
"XP Analog" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
"XP Analog LCP" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
"XP Maxamaid" | Oral powder 500 g | Oral | 8 | 5 | SB | |||
"XP Maxamum" | Sachets containing oral powder 50 g, 30 | Oral | 3 | 5 | SB | |||
| Oral powder 500 g | Oral | 8 | 5 | SB | |||
"XPhen, Tyr Analog" | Oral powder 400 g | Oral | 8 | 5 | SB | |||
"XPhen, Tyr Maxamaid" | Oral powder 500 g | Oral | 8 | 5 | SB | |||
"XPhen, Tyr Maxamum" | Oral powder 500 g | Oral | 8 | 5 | SB | |||
"XPTM Tyrosidon" | Oral powder 500 g | Oral | 4 | 5 | SB | |||
Zolmitriptan | Tablet 2.5 mg | Oral | 4 | 5 | AP | |||
Zuclopenthixol Decanoate | Oily I.M. injection 200 mg in 1 mL ampoule | Injection | 5 | .. | LU | |||
| ||||||||
Aciclovir | Tablet 200 mg | In compliance with authority procedures set out in subparagraph 11 (d): Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis | Oral | 90 | 5 | AF, CH, DP, GK, GX, HX, TW | |
|
|
|
| ||||
| Tablet 800 mg | In compliance with authority procedures set out in subparagraph 11 (d): Patients with advanced human immunodeficiency virus disease (CD4 cell counts of less than 150 million per L) | Oral | 120 | 5 | AF, DP, GK, HX | |
|
|
|
| ||||
Adalimumab | Injection 40 mg in 0.8 mL pre-filled syringe | In compliance with authority procedures set out in subsubparagraph 11 (d)(i) : | Injection | 2 | 5 | AB | |
|
| Commencement of adalimumab treatment in a bDMARD treatment cycle with an initial supply subsidised under the Pharmaceutical Benefits Scheme (PBS) for continuing treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who were receiving treatment with adalimumab prior to 1 November 2004, who failed to qualify for PBS-subsidised therapy after 1 May 2004 due to an inability to receive concomitant methotrexate, and who have demonstrated a response to adalimumab treatment as specified in the criteria for continuing PBS-subsidised treatment with adalimumab detailed below; and where bDMARD means a drug included in the following list of drugs: adalimumab, anakinra, etanercept or infliximab; and
|
|
|
|
| |
|
| where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: the authority application includes sufficient information to determine the patient's eligibility for treatment and the date of assessment of the patient; the course of treatment is limited to a maximum of 24 weeks of treatment at a dose that does not exceed 40 mg per fortnight |
|
|
|
| |
|
| Commencement of adalimumab treatment in a bDMARD treatment cycle with an initial supply subsidised under the Pharmaceutical Benefits Scheme (PBS) for continuing treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who were receiving treatment with adalimumab prior to 1 March 2005, who failed to qualify for PBS-subsidised therapy after 1 May 2004 due to testing negative for rheumatoid factor, and who have demonstrated a response to adalimumab treatment as specified in the criteria for continuing PBS-subsidised treatment with adalimumab detailed below; and where bDMARD means a drug included in the following list of drugs:
|
|
|
|
| |
|
| where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: the authority application includes sufficient information to determine the patient's eligibility for treatment and the date of assessment of the patient; the course of treatment is limited to a maximum of 24 weeks of treatment at a dose that does not exceed 40 mg per fortnight |
|
|
|
| |
|
| Continuing treatment within an ongoing biological disease modifying anti-rheumatic drug (bDMARD) treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis, and: (a) who have demonstrated an adequate response to treatment with adalimumab; and (b) whose most recent course of bDMARD treatment subsidised under the Pharmaceutical Benefits Scheme (PBS) in this bDMARD treatment cycle was with adalimumab; and where bDMARD means a drug included in the following list of drugs: adalimumab, anakinra, etanercept or infliximab; and
|
|
|
|
| |
|
| where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: patients who commenced PBS-subsidised bDMARD treatment prior to 1 December 2004 are deemed to have commenced their first bDMARD treatment cycle with that therapy and any PBS-subsidised treatment received prior to 1 December 2004 is deemed to be treatment received as part of the patient's first bDMARD treatment cycle; an adequate response to treatment is defined as an erythrocyte sedimentation rate no greater than 25 mm per hour or a C-reactive protein level no greater than 15 mg per L or either marker reduced by at least 20% from baseline, and either a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints, or a reduction in the number of the following major joints which are active, from at least 4, by at least 50%: — elbow, wrist, knee or ankle (assessed as active if swollen and tender); or — shoulder or hip (assessed as active if there is pain in passive movement and restriction of passive movement, and where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth); the same indices of disease severity used to establish baseline at the commencement of treatment are used to determine response;
|
|
|
|
| |
|
| the authority application includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form, and a measurement of response to the most recent prior course of therapy with adalimumab, where response is assessed, and this assessment is provided to the Medicare Australia CEO, no later than 4 weeks from the cessation of that treatment course; if the most recent course of adalimumab therapy was an initial 16 week course, the application for continuing treatment is accompanied by an assessment of response to a minimum of 12 weeks of treatment with that course; a course of treatment is limited to a maximum of 24 weeks of treatment at a dose that does not exceed 40 mg per fortnight In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuing treatment within an ongoing bDMARD treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who have previously been issued with an authority prescription for continuing treatment with this drug for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total, at a dose that does not exceed 40 mg per fortnight; and where 'bDMARD' and 'bDMARD treatment cycle' have the meaning given above |
|
|
|
| |
Adrenaline | I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 2 | .. | CS | |
Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years who has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician, where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times, and where the name of the specialist consulted is included in the authority application |
|
|
|
| |||
|
| Continuing supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years, where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times, and where the patient has previously been issued with an authority prescription for this drug |
|
|
|
| |
| I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 2 | .. | CS | |
| Initial supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years who has been assessed to be at significant risk of anaphylaxis by, or in consultation with, a clinical immunologist, allergist, paediatrician or respiratory physician, where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times, and where the name of the specialist consulted is included in the authority application |
|
|
|
| ||
|
| Continuing supply for anticipated emergency treatment of acute allergic reactions with anaphylaxis in a patient aged less than 17 years, where a quantity of 2 adrenaline auto-injectors is necessary to ensure 1 is on hand at all times, and where the patient has previously been issued with an authority prescription for this drug |
|
|
|
| |
Amlodipine Besylate | Tablet equivalent to 5 mg amlodipine | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 30 | 5 | PF | |
| Adverse effects occurring with all of the base-priced drugs |
|
|
|
| ||
|
| Drug interactions occurring with all of the base-priced drugs |
|
|
|
| |
|
| Drug interactions expected to occur with all of the base-priced drugs |
|
|
|
| |
|
| Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance |
|
|
|
| |
| Tablet equivalent to 10 mg amlodipine | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 30 | 5 | PF | |
| Adverse effects occurring with all of the base-priced drugs |
|
|
|
| ||
|
| Drug interactions occurring with all of the base-priced drugs |
|
|
|
| |
|
| Drug interactions expected to occur with all of the base-priced drugs |
|
|
|
| |
|
| Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
Anakinra | Injection 100 mg in 0.67 mL single use pre-filled syringe | In compliance with authority procedures set out in subsubparagraph 11 (d)(i): | Injection | 28 | 5 | AN | |
| Commencement of anakinra treatment in a bDMARD treatment cycle with an initial supply subsidised under the Pharmaceutical Benefits Scheme (PBS) for continuing treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who were receiving treatment with anakinra prior to 1 July 2004 and who have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with anakinra detailed below; and where bDMARD means a drug included in the following list of drugs: adalimumab, anakinra, etanercept or infliximab; and where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: the patient receives concomitant treatment with methotrexate at a dose of at least 7.5 mg weekly; the authority application includes sufficient information to determine the patient's eligibility for treatment and the date of assessment of the patient; the course of treatment is limited to a maximum of 24 weeks of treatment |
|
|
|
| ||
|
| Commencement of anakinra treatment in a bDMARD treatment cycle with an initial supply subsidised under the Pharmaceutical Benefits Scheme (PBS) for continuing treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who were receiving treatment with anakinra prior to 1 March 2005, who failed to qualify for PBS-subsidised therapy after 1 December 2004 due to testing negative for rheumatoid factor, and who have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with anakinra detailed below; and where bDMARD means a drug included in the following list of drugs: where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: the patient receives concomitant treatment with methotrexate at a dose of at least 7.5 mg weekly; the authority application includes sufficient information to determine the patient's eligibility for treatment and the date of assessment of the patient; the course of treatment is limited to a maximum of 24 weeks of treatment |
|
|
|
| |
|
| Continuing treatment within an ongoing biological disease modifying anti-rheumatic drug (bDMARD) treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis, and: (a) who have demonstrated an adequate response to treatment with anakinra; and (b) whose most recent course of bDMARD treatment subsidised under the Pharmaceutical Benefits Scheme (PBS) in this bDMARD treatment cycle was with anakinra; and where bDMARD means a drug included in the following list of drugs: where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: the patient receives concomitant treatment with methotrexate at a dose of at least 7.5 mg weekly; patients who commenced PBS-subsidised bDMARD treatment prior to 1 December 2004 are deemed to have commenced their first bDMARD treatment cycle with that therapy and any PBS-subsidised treatment received prior to 1 December 2004 is deemed to be treatment received as part of the patient's first bDMARD treatment cycle; |
|
|
|
| |
|
| if this treatment cycle is the patient's first bDMARD treatment cycle and the patient has failed to demonstrate a response to PBS-subsidised treatment with adalimumab, etanercept and infliximab commenced prior to 1 December 2004, the patient is eligible to continue PBS-subsidised therapy with anakinra in this first treatment cycle, despite having previously failed to respond to 3 bDMARDs; an adequate response to treatment is defined as an erythrocyte sedimentation rate no greater than 25 mm per hour or a C-reactive protein level no greater than 15 mg per L or either marker reduced by at least 20% from baseline, and either a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints, or a reduction in the number of the following major joints which are active, from at least 4, by at least 50%: — elbow, wrist, knee or ankle (assessed as active if swollen and tender); or — shoulder or hip (assessed as active if there is pain in passive movement and restriction of passive movement, and where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth); the same indices of disease severity used to establish baseline at the commencement of treatment are used to determine response; the authority application includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form, and a measurement of response to the most recent prior course of therapy with anakinra, where response is assessed, and this assessment is provided to the Medicare Australia CEO, no later than 4 weeks from the cessation of that treatment course; if the most recent course of anakinra therapy was an initial 16 week course, the application for continuing treatment is accompanied by an assessment of response to a minimum of 12 weeks of treatment with that course; a course of treatment is limited to a maximum of 24 weeks of treatment |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuing treatment within an ongoing bDMARD treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who are receiving concomitant treatment with methotrexate at a dose of at least 7.5 mg weekly and who have previously been issued with an authority prescription for continuing treatment with this drug for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total; and where 'bDMARD' and 'bDMARD treatment cycle' have the meaning given above |
|
|
|
| |
Azithromycin Dihydrate | Tablet equivalent to 500 mg azithromycin | Trachoma | Oral | 2 | 2 | PF | |
Benzathine Penicillin | Injection 900 mg in 2 mL cartridge-needle unit (for use with Tubex Injector) | Syphilis | Injection | 2 | .. | AS | |
| Powder for injection 900 mg | Syphilis | Injection | 2 | .. | AS | |
Bromocriptine Mesylate | Tablet equivalent to 2.5 mg bromocriptine | Acromegaly | Oral | 60 | 5 | AF, HX, NV | |
| Parkinson's disease |
|
|
| |||
|
| Pathological hyperprolactinaemia where surgery is not indicated |
|
|
|
| |
|
| Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution |
|
|
|
| |
|
| Pathological hyperprolactinaemia where radiotherapy is not indicated |
|
|
|
| |
|
| Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution |
|
|
|
| |
Buprenorphine | Transdermal patch 5 mg | In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia | Transdermal | 4 | .. | MF | |
|
|
|
|
| |||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Transdermal patch 10 mg | In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia | Transdermal | 4 | .. | MF | |
|
|
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Transdermal patch 20 mg | In compliance with authority procedures set out in subparagraph 11 (d): Chronic severe disabling pain associated with proven malignant neoplasia | Transdermal | 4 | .. | MF | |
|
|
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
Bupropion Hydrochloride | Tablet 150 mg (sustained release) | In compliance with authority procedures set out in subparagraph 11 (d): Completion of treatment as short-term adjunctive therapy for nicotine dependence to facilitate the goal of achieving abstinence in patients who have indicated that they are ready to cease smoking and who have entered a comprehensive support and counselling program, and where the patient has previously been issued with an authority prescription for commencement of treatment with this drug | Oral | 90 | .. | GK, HX, RE | |
|
|
|
|
|
| ||
Cabergoline | Tablet 500 micrograms | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 8 | 5 | PH | |
|
| Pathological hyperprolactinaemia where surgery is not indicated |
|
|
|
| |
|
| Pathological hyperprolactinaemia where surgery has already been used with incomplete resolution |
|
|
|
| |
|
| Pathological hyperprolactinaemia where radiotherapy is not indicated |
|
|
|
| |
|
| Pathological hyperprolactinaemia where radiotherapy has already been used with incomplete resolution |
|
|
|
| |
Ceftriaxone Sodium | Powder for injection equivalent to 250 mg ceftriaxone | Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent | Injection | 5 | .. | RO | |
| Septicaemia, suspected |
|
|
|
| ||
| Septicaemia, proven |
|
|
|
| ||
Chorionic Gonadotrophin | Injection set containing 3 ampoules powder for injection 500 units and 3 ampoules solvent 1 mL | Cryptorchism not due to organic obstruction in boys over 12 months of age | Injection | 2 | 1 | OR | |
Cimetidine Hydrochloride | Tablet, effervescent, equivalent to 800 mg cimetidine | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 30 | 5 | GK | |
| Adverse effects occurring with all of the base-priced drugs Drug interactions occurring with all of the base-priced drugs Drug interactions expected to occur with all of the base-priced drugs Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance |
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
Ciprofloxacin Hydrochloride | Tablet equivalent to 250 mg ciprofloxacin | In compliance with authority procedures set out in subparagraph 11 (d): Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients Bacterial gastroenteritis in severely immunocompromised patients | Oral | 14 | .. | AL, AW, BG, BN, GX, HX | |
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
| Treatment of infections proven to be due to Pseudomonas aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobials |
|
|
|
| |
|
| Treatment of joint and bone infections, epididymo-orchitis, prostatitis or perichondritis of the pinna, suspected or proven to be caused by gram-negative bacteria or gram-positive bacteria resistant to all other appropriate antimicrobials |
|
|
|
| |
Codeine Phosphate with Paracetamol | Tablet 30 mg-500 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | .. | AL, CO, DK, FM, GK, SW | |
| Treatment (for up to 6 months) of severe disabling pain not responding to non-narcotic analgesics, at a dose not exceeding 8 tablets per day |
|
|
| |||
Cyproterone Acetate | Tablet 50 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | 5 | AF, DP, GX, HX, SC, SY | |
| Advanced carcinoma of the prostate | ||||||
|
| To reduce drive in sexual deviations in males | |||||
Dalteparin Sodium | Injection 2,500 I.U. (anti-Xa) in 0.2 mL single dose pre-filled syringe | Haemodialysis | Injection | 20 | 3 | PH | |
| Injection 5,000 I.U. (anti-Xa) in 0.2 mL single dose pre-filled syringe | Haemodialysis | Injection | 20 | 3 | PH | |
| Injection 7,500 I.U. (anti-Xa) in 0.75 mL single dose pre-filled syringe | Haemodialysis | Injection | 20 | 3 | PH | |
Desmopressin Acetate | Tablet 200 micrograms | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 90 | 5 | FP | |
|
| Cranial diabetes insipidus |
|
|
|
| |
| Nasal spray (pump pack) 10 micrograms per actuation, 60 actuations, 6 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Nasal | 2 | 5 | FP | |
| Cranial diabetes insipidus |
|
|
|
| ||
Diazepam | Tablet 2 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | .. | AF, AW, RO, SU | |
|
| Disabling spasticity |
|
|
| ||
|
| Malignant neoplasia (late stage) |
|
|
| ||
|
| For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
|
| For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
| Tablet 5 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | .. | AF, AW, DP, RO, SU | |
|
| Disabling spasticity |
|
|
| ||
|
| Malignant neoplasia (late stage) |
|
|
| ||
|
| For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
|
| For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
"Digestelact" | Oral powder 900 g | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 3 | 10 | SJ | |
|
| Proven chronic lactose intolerance in children aged 1 year and over who are significantly malnourished, where the date of birth of the patient is included in the authority application, and where lactose intolerance has been proven either by the relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food, or by the presence of not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet |
|
|
|
| |
|
|
|
|
|
|
| |
Doxycycline Hydrochloride | Tablet equivalent to 100 mg doxycycline | Pelvic inflammatory disease | Oral | 28 | .. | AF, DP, PF, SI | |
| Capsule equivalent to 100 mg doxycycline (containing enteric coated pellets) | Pelvic inflammatory disease | Oral | 28 | .. | FA, MX | |
| Tablet equivalent to 100 mg doxycycline | Urethritis | Oral | 21 | .. | AF, DP, PF, SI | |
| Capsule equivalent to 100 mg doxycycline (containing enteric coated pellets) | Urethritis | Oral | 21 | .. | FA, MX | |
Doxycycline Monohydrate | Tablet equivalent to 100 mg doxycycline | Pelvic inflammatory disease | Oral | 28 | .. | CH, GX, HX, TW | |
| Tablet equivalent to 100 mg doxycycline | Urethritis | Oral | 21 | .. | CH, GX, HX, TW | |
Efalizumab | Injection set containing 4 vials powder for injection 125 mg and 4 pre-filled syringes diluent 1.3 mL | In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (i.e. not in conjunction with acitretin, methotrexate or cyclosporin) by a dermatologist for adults 18 years and over who: (a) have a documented history of severe chronic plaque psoriasis and were receiving treatment with efalizumab prior to 10 November 2005; and (b) had a Psoriasis Area and Severity Index (PASI) score of greater than 15 prior to commencing treatment with efalizumab; and (c) have signed a patient acknowledgement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and (d) have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with efalizumab; and | Injection | 1 | 5 | SG | |
|
|
|
|
|
|
| |
|
| where the following conditions apply: the application for authorisation includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form which includes the following: (i) a copy of the completed Psoriasis Area and Severity Index (PASI) calculation sheet and whole body area diagrams including the date of the assessment of the patient's condition at baseline (prior to initiation of efalizumab therapy) and the most recent PASI assessment; and (ii) details of previous phototherapy and systemic drug therapy (dosage (where applicable), date of commencement and duration of therapy); and (iii) a copy of the signed patient acknowledgement form; the most recent PASI assessment is no more than 1 month old at the time of application; the course of treatment is limited to a maximum of 24 weeks of treatment; patients are eligible for PBS-subsidised treatment under the above criteria once only |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Initial PBS-subsidised treatment as systemic monotherapy by a dermatologist for adults 18 years and over who have a history of severe chronic plaque psoriasis, who were receiving non-PBS-subsidised treatment with efalizumab prior to 10 November 2005, and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for initial PBS-subsidised treatment with this drug for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total
|
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Continuing PBS-subsidised treatment as systemic monotherapy (i.e. not in conjunction with acitretin, methotrexate or cyclosporin) by a dermatologist for adults 18 years and over who: (a) have a documented history of severe chronic plaque psoriasis; and (b) have demonstrated an adequate response to PBS-subsidised treatment with efalizumab; and where the following conditions apply: an adequate response to treatment is defined as a Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more after at least 12 weeks of efalizumab treatment, when compared with the pre-efalizumab treatment value; the application for authorisation includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form which includes a copy of the completed Psoriasis Area and Severity Index (PASI) calculation sheet and whole body area diagrams along with the date of the assessment of the patient's condition; |
|
|
|
| |
|
| the PASI assessment is no more than 1 month old at the time of application; if the application is the first application for continuing treatment with efalizumab following an initial 16 week treatment course, it is accompanied by an assessment of response to a minimum of 12 weeks of initial treatment; where the most recent course of PBS-subsidised efalizumab treatment was approved under this continuing treatment restriction, the patient's response is assessed, and the assessment is submitted to the Medicare Australia CEO, no later that 4 weeks from the date that course was completed or treatment was ceased; where an assessment of response is not submitted to the Medicare Australia CEO within these timeframes, the patient is deemed to have failed to respond, or to have failed to sustain a response, to treatment with efalizumab; |
|
|
|
| |
|
| a course of continuing treatment is limited to a maximum of 24 weeks of treatment; patients are eligible to receive continuing efalizumab treatment in courses of up to 24 weeks providing they continue to sustain the response to treatment; patients who have previously ceased efalizumab treatment due to failure to demonstrate an adequate response to treatment are not eligible to recommence treatment until a period of 12 months has elapsed since cessation of the previous treatment; authority applications for re-treatment with efalizumab after a break in PBS-subsidised treatment with the drug include the reason for and date of cessation of the previous treatment course |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuing PBS-subsidised treatment as systemic monotherapy by a dermatologist for adults 18 years and over who have a history of severe chronic plaque psoriasis and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for continuing treatment with this drug for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Initial PBS-subsidised supply for continuing treatment as systemic monotherapy (i.e. not in conjunction with acitretin, methotrexate or cyclosporin) by a dermatologist for adults 18 years and over: (a) who have a documented history of severe chronic plaque psoriasis of the face or palm of a hand or sole of a foot and were receiving treatment with efalizumab prior to 10 November 2005; and |
|
|
|
| |
|
| (b) whose disease, prior to treatment with efalizumab, was classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where either at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling were rated as severe or very severe, or the skin area affected was 30% or more of the face, palm of a hand or sole of a foot; and (c) who have signed a patient acknowledgement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment; and (d) who have demonstrated a response as specified in the criterion included in the restriction for continuing PBS-subsidised treatment with efalizumab; and |
|
|
|
| |
|
| where the following conditions apply: the application for authorisation includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form which includes the following: (i) a copy of the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition at baseline (prior to initiation of efalizumab therapy) and the most recent PASI assessment; and (ii) details of previous phototherapy and systemic drug therapy (dosage (where applicable), date of commencement and duration of therapy); and (iii) a copy of the signed patient acknowledgement form; the PASI assessment is performed on the same affected area as assessed prior to initiation of efalizumab treatment; the course of treatment is limited to a maximum of 24 weeks of treatment; |
|
|
|
| |
|
| the most recent PASI assessment is no more than 1 month old at the time of application; patients are eligible for PBS-subsidised treatment under the above criteria once only |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Initial PBS-subsidised treatment as systemic monotherapy by a dermatologist for adults 18 years and over who have a history of severe chronic plaque psoriasis of the face or palm of a hand or sole of a foot, who were receiving non-PBS-subsidised treatment with efalizumab prior to 10 November 2005, and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for initial PBS-subsidised treatment with this drug for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Continuing PBS-subsidised treatment as systemic monotherapy (i.e. not in conjunction with acitretin, methotrexate or cyclosporin) by a dermatologist for adults 18 years and over who: (a) have a documented history of severe chronic plaque psoriasis of the face or palm of a hand or sole of a foot; and (b) have demonstrated an adequate response to PBS-subsidised treatment with efalizumab; and where the following conditions apply: an adequate response to efalizumab treatment is defined as the plaque or plaques assessed prior to efalizumab treatment showing: (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better after at least 12 weeks of efalizumab treatment, as compared to the pre-efalizumab treatment values; or (ii) a reduction by 75% or more in the skin area affected after at least 12 weeks of efalizumab treatment, as compared to the pre-efalizumab treatment value; |
|
|
|
| |
|
| the PASI assessment for continuing treatment is performed on the same affected area assessed prior to initiation of efalizumab treatment; the application for authorisation includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form which includes a copy of the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams along with the date of the assessment of the patient's condition; the PASI assessment is no more than 1 month old at the time of application; |
|
|
|
| |
|
| if the application is the first application for continuing treatment with efalizumab following an initial 16 week treatment course, it is accompanied by an assessment of response to a minimum of 12 weeks of initial treatment; where the most recent course of PBS-subsidised efalizumab treatment was approved under these continuing treatment criteria, the patient's response is assessed, and the assessment is submitted to the Medicare Australia CEO, no later than 4 weeks from the date that course was completed or treatment was ceased; where an assessment of response is not submitted to the Medicare Australia CEO within these timeframes, the patient is deemed to have failed to respond, or to have failed to sustain a response, to treatment with efalizumab; a course of continuing treatment is limited to a maximum of 24 weeks of treatment; |
|
|
|
| |
|
| patients are eligible to receive continuing efalizumab treatment in courses of up to 24 weeks providing they continue to sustain the response to treatment; patients who have previously ceased efalizumab treatment due to failure to demonstrate an adequate response to treatment are not eligible to recommence treatment until a period of 12 months has elapsed since cessation of the previous treatment; |
|
|
|
| |
|
| authority applications for re-treatment with efalizumab after a break in PBS-subsidised treatment with the drug include the reason for and date of cessation of the previous treatment course In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuing PBS-subsidised treatment as systemic monotherapy by a dermatologist for adults 18 years and over who have a history of severe chronic plaque psoriasis of the face or palm of a hand or sole of a foot and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for continuing treatment with this drug for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total |
|
|
|
| |
"EleCare" | Oral powder 400 g | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 8 | 5 | AB | |
|
| Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in children up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician, and where the date of birth of the patient is included in the authority application |
|
|
|
| |
|
| Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in children aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months, and where the date of birth of the patient is included in the authority application |
|
|
|
| |
|
| Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed |
|
|
|
| |
|
| Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition |
|
|
|
| |
Enoxaparin Sodium | Injection 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe | Haemodialysis | Injection | 20 | 3 | AV | |
| Injection 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe | Haemodialysis | Injection | 20 | 3 | AV | |
| Injection 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe | Haemodialysis | Injection | 20 | 3 | AV | |
Escitalopram Oxalate | Tablet equivalent to 10 mg escitalopram | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 28 | 5 | LU | |
| Major depressive disorders, where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| ||
|
| Major depressive disorders, where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Major depressive disorders, where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Major depressive disorders, where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Major depressive disorders, where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Tablet equivalent to 20 mg escitalopram | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 28 | 5 | LU | |
| Major depressive disorders, where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| ||
|
| Major depressive disorders, where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Major depressive disorders, where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Major depressive disorders, where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Major depressive disorders, where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Oral solution equivalent to 10 mg escitalopram per mL, 28 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 1 | 5 | LU | |
| Major depressive disorders, where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| ||
|
| Major depressive disorders, where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Major depressive disorders, where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Major depressive disorders, where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Major depressive disorders, where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
Esomeprazole Magnesium Trihydrate | Tablet (enteric coated), equivalent to 20 mg esomeprazole | Maintenance of healed gastro-oesophageal reflux disease | Oral | 30 | 5 | AP | |
Etanercept | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Continuing treatment within an ongoing treatment cycle, by a rheumatologist, of adults with active ankylosing spondylitis who have received 6 weeks or more of treatment with etanercept subsidised under the Pharmaceutical Benefits Scheme (PBS) as 'new' patients, who have demonstrated a response to treatment with etanercept, and whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept; and | Injection | 2 | 5 | WY | |
|
| where a treatment cycle is a period of treatment which commences when an eligible patient (one who has not received PBS-subsidised treatment with etanercept or with infliximab for ankylosing spondylitis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with either etanercept or infliximab, and which continues until the patient has tried and either failed, or ceased to respond to, PBS-subsidised courses of treatment with one or other drug up to 3 times (but with the same drug no more than twice), at which point the patient is no longer eligible for treatment with etanercept or infliximab for ankylosing spondylitis and the period of treatment ceases; and |
|
|
|
| |
|
| where a 'new' patient is one who was not 'grandfathered' onto PBS-subsidised treatment with either etanercept or infliximab; and where to be 'grandfathered' onto PBS-subsidised treatment with infliximab or with etanercept means to be commenced on PBS-subsidised treatment under the eligiblity criteria specified for the initiation of PBS-subsidised treatment in patients who commenced non-PBS-subsidised treatment with infliximab prior to 1 March 2004 (where the patient is 'grandfathered' onto infliximab) or with etanercept prior to 1 July 2004 (where the patient is 'grandfathered' onto etanercept); and |
|
|
|
| |
|
| where the following conditions apply: patients who commenced PBS-subsidised treatment with etanercept or infliximab prior to 1 August 2005 are deemed to have commenced their first treatment cycle with that therapy and any PBS-subsidised treatment with either drug received prior to 1 August 2005 is deemed to be treatment received as part of the patient's first treatment cycle; response is defined as an improvement from baseline of at least 2 in the patient's Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and 1 of the following: (a) an erythrocyte sedimentation rate (ESR) measurement no greater than 25 mm per hour; or |
|
|
|
| |
|
| (b) a C-reactive protein (CRP) measurement no greater than 10 mg per L; or (c) an ESR or CRP measurement reduced by at least 20% from baseline; all measurements provided are no more than 1 month old at the time of application; the same acute phase reactant used to establish baseline at the commencement of an initial treatment course is measured for all subsequent continuing treatment applications for the patient; patients will be deemed to have failed to respond to treatment with a course of PBS-subsidised therapy, despite demonstrating a response as defined above, unless: |
|
|
|
| |
|
| (i) the response assessment is provided to the Medicare Australia CEO no later than 4 weeks from the date that course of treatment ceased; and (ii) if the course of therapy is a 6 week initial course, the assessment of response is made no earlier than 4 weeks from the commencement of that course; |
|
|
|
| |
|
| the application for authorisation includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form which includes a copy of the completed BASDAI Assessment Form, including certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment; a course of continuing treatment within an ongoing treatment cycle is limited to a maximum of 24 weeks of treatment |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or11 (d)(ii): Continuing treatment within an ongoing treatment cycle, by a rheumatologist, of adults with active ankylosing spondylitis who, qualifying under the criteria specified above, have previously been issued with an authority prescription for continuing treatment with etanercept as 'new' patients for a period of less than 24 weeks (other than a prescription for the first 4 weeks of continuing treatment immediately following an initial treatment course), and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(ii): Continuing treatment, for up to 4 weeks, within an ongoing treatment cycle, by a rheumatologist, of adults with active ankylosing spondylitis who have received 6 weeks of initial PBS-subsidised treatment with etanercept as 'new' patients immediately prior to this course of therapy and who, at the time of application, meet the criteria for continuing treatment with etanercept as specified above, and where a completed copy of the appropriate PBS Authority Application - Supporting Information Form (which includes a copy of the completed BASDAI Assessment Form) is submitted to the Medicare Australia CEO by facsimile |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Commencement of a treatment cycle with an initial PBS-subsidised course of etanercept for continuing treatment, by a rheumatologist, of adults with active ankylosing spondylitis who have radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis, who were receiving treatment with etanercept prior to 1 July 2004; and |
|
|
|
| |
|
| (a) who are receiving treatment with etanercept at the time of application; and (b) who have not received prior PBS-subsidised treatment with infliximab; and (c) who have documented confirmation of human leucocyte antigen B27 (HLA-B27) positive status; and (d) whose Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score is less than or equal to 5 on a 0-10 scale; and (e) who have: (i) an erythrocyte sedimentation rate (ESR) measurement no greater than 25 mm per hour; or (ii) a C-reactive protein (CRP) measurement no greater than 10 mg per L; or (iii) an ESR or CRP measurement reduced by at least 20% from pre-treatment baseline; and |
|
|
|
| |
|
| (f) who have signed a patient acknowledgment form declaring that they understand and acknowledge that PBS-subsidised treatment with etanercept and with infliximab for ankylosing spondylitis will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated; and |
|
|
|
| |
|
| where a treatment cycle is a period of treatment which commences when an eligible patient (one who has not received PBS-subsidised treatment with etanercept or with infliximab for ankylosing spondylitis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with either etanercept or infliximab, and which continues until the patient has tried and either failed, or ceased to respond to, PBS-subsidised courses of treatment with one or other drug up to 3 times (but with the same drug no more than twice), at which point the patient is no longer eligible for treatment with etanercept or infliximab for ankylosing spondylitis and the period of treatment ceases; and |
|
|
|
| |
|
| where the following conditions apply: the BASDAI assessment and the ESR and CRP measurements are no more than 1 month old at the time of application; the application for authorisation includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form which includes the following: (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and (ii) a copy of the pathology report from an Approved Pathology Authority confirming the presence of HLA-B27; and (iii) a copy of the completed BASDAI Assessment Form; and (iv) a copy of the signed patient acknowledgment form; the course of treatment is limited to a maximum of 24 weeks of treatment; patients are eligible for PBS-subsidised treatment under the above criteria once only |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuation of a course of initial PBS-subsidised treatment commencing a treatment cycle, by a rheumatologist, of adults with active ankylosing spondylitis who were receiving non-PBS-subsidised treatment with etanercept prior to 1 July 2004 and at the time of the initial application for PBS-subsidised therapy and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for initial PBS-subsidised treatment with etanercept for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Continuing PBS-subsidised treatment within an ongoing treatment cycle, by a rheumatologist, of adults with active ankylosing spondylitis who were 'grandfathered' onto PBS-subsidised treatment with etanercept or infliximab, who have received 6 weeks or more of PBS-subsidised treatment with etanercept, who have demonstrated a response to treatment with etanercept, and whose most recent course of PBS-subsidised therapy in this treatment cycle was with etanercept; and |
|
|
|
| |
|
| where a treatment cycle is a period of treatment which commences when an eligible patient (one who has not received PBS-subsidised treatment with etanercept or with infliximab for ankylosing spondylitis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with either etanercept or infliximab, and which continues until the patient has tried and either failed, or ceased to respond to, PBS-subsidised courses of treatment with one or other drug up to 3 times (but with the same drug no more than twice), at which point the patient is no longer eligible for treatment with etanercept or infliximab for ankylosing spondylitis and the period of treatment ceases; and |
|
|
|
| |
|
| where to be 'grandfathered' onto PBS-subsidised treatment with infliximab or with etanercept means to be commenced on PBS-subsidised treatment under the eligiblity criteria specified for the initiation of PBS-subsidised treatment in patients who commenced non-PBS-subsidised treatment with infliximab prior to 1 March 2004 (where the patient is 'grandfathered' onto infliximab) or with etanercept prior to 1 July 2004 (where the patient is 'grandfathered' onto etanercept); and |
|
|
|
| |
|
| where the following conditions apply: patients who commenced PBS-subsidised treatment with etanercept or infliximab prior to 1 August 2005 are deemed to have commenced their first treatment cycle with that therapy and any PBS-subsidised treatment with either drug received prior to 1 August 2005 is deemed to be treatment received as part of the patient's first treatment cycle; response to treatment is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score no more than 20% greater than the score included in the initial application for PBS-subsidised treatment, and: (a) an erythrocyte sedimentation rate (ESR) measurement no greater than 25 mm per hour; or (b) a C-reactive protein (CRP) measurement no greater than 10 mg per L; or (c) an ESR or CRP measurement reduced by at least 20% from pre-treatment baseline; all measurements provided are no more than 1 month old at the time of application; |
|
|
|
| |
|
| the same acute phase reactant used to establish baseline at the commencement of an initial treatment course is measured for all subsequent continuing treatment applications for the patient; patients will be deemed to have failed to respond to treatment with a course of PBS-subsidised therapy, despite demonstrating a response as defined above, unless: (i) the response assessment is provided to the Medicare Australia CEO no later than 4 weeks from the date that course of treatment ceased; and (ii) if the course of therapy is a 6 week initial course, the assessment of response is made no earlier than 4 weeks from the commencement of that course; |
|
|
|
| |
|
| the application for authorisation includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form which includes a copy of the completed BASDAI Assessment Form including certification by the prescriber and the patient that the patient did not have access to their baseline BASDAI at the time of their continuing treatment assessment; |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuing treatment within an ongoing treatment cycle, by a rheumatologist, of adults with active ankylosing spondylitis who were 'grandfathered' onto PBS-subsidised treatment with etanercept or infliximab and who, qualifying under the criteria specified above, have previously been issued with an authority prescription for continuing PBS-subsidised treatment with etanercept for a period of less than 24 weeks (other than a prescription for the first 4 weeks of continuing treatment immediately following an initial treatment course), and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(ii): Continuing treatment, for up to 4 weeks, within an ongoing treatment cycle, by a rheumatologist, of adults with active ankylosing spondylitis who have received 6 weeks or more of initial PBS-subsidised treatment with etanercept as 'grandfathered' patients immediately prior to this course of therapy and who, at the time of application, meet the criteria for continuing treatment with etanercept as specified above, and where a completed copy of the appropriate PBS Authority Application - Supporting Information Form (which includes a copy of the completed BASDAI Assessment Form) is submitted to the Medicare Australia CEO by facsimile |
|
|
|
| |
| Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Initial treatment in a biological disease modifying anti-rheumatic drug (bDMARD) treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis, and: (a) (i) who have not previously received treatment with a bDMARD for this condition subsidised under the Pharmaceutical Benefits Scheme (PBS); or (ii) who, where the patient has previously received PBS-subsidised bDMARD treatment, have received no PBS-subsidised treatment with a bDMARD for this condition for a period of 5 years or more starting from the date the last course of PBS-subsidised bDMARD therapy was approved; and | Injection | 2 | 3 | WY | |
|
| (b) who have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly, have failed to achieve an adequate response to methotrexate (at a dose of at least 7.5 mg weekly) in combination with 2 other non-biological disease modifying anti-rheumatic drugs (DMARDs) for a minimum of 3 months, and have failed to achieve an adequate response following a minimum of 3 months' treatment with leflunomide alone or with leflunomide in combination with methotrexate or with cyclosporin alone, unless: (i) treatment with any of the above-mentioned drugs is contraindicated according to the relevant Therapeutic Goods Administration-approved Product Information, or intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use, in which case the patient is exempted from demonstrating an inadequate response to that particular agent (or agents) only; or |
|
|
|
| |
|
|
|
|
|
|
| |
|
| (ii) the patient has had a break in PBS-subsidised bDMARD treatment of at least 5 years, in which case the patient is required to demonstrate failure to achieve an adequate response to treatment with at least 1 non-biological DMARD, at an adequate dose, for a minimum of 3 months; and (c) who have signed a patient acknowledgement form declaring that they understand and acknowledge that, within a single bDMARD treatment cycle, PBS-subsidised treatment with any bDMARD will cease if they do not demonstrate the response to treatment required to support continuation of PBS-subsidised treatment at any assessment where a response must be demonstrated; and where bDMARD means a drug included in the following list of drugs: adalimumab, anakinra, etanercept or infliximab; and |
|
|
|
| |
|
| where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: failure to achieve an adequate response to the treatment regimens specified at (b) above is demonstrated by an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L, and either a total active joint count of at least 20 active (swollen and tender) joints, or at least 4 active joints from the following list of major joints: |
|
|
|
| |
|
| — elbow, wrist, knee or ankle (assessed as active if swollen and tender); or — shoulder or hip (assessed as active if there is pain in passive movement and restriction of passive movement, and where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth); if the requirement to demonstrate an elevated ESR or CRP cannot be met, the authority application includes the reasons why this criterion cannot be satisfied; where the patient is exempted from demonstrating an inadequate response to a treatment regimen specified at (b) above on the basis of contraindication or intolerance, the authority application includes details of the contraindication or intolerance, including the degree of toxicity; the authority application includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form which includes details of the patient's ESR and CRP measurements, and an assessment of the patient's active joint count, conducted no earlier than 1 month prior to the date of application, and a copy of the signed patient acknowledgment form; a course of treatment is limited to a maximum of 16 weeks of treatment In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuation of initial treatment in a bDMARD treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who have previously been issued with an authority prescription for initial treatment with this drug for a period of less than 16 weeks, and where approval of the application would enable the patient to complete a course of 16 weeks of treatment in total; and where 'bDMARD' and 'bDMARD treatment cycle' have the meaning given above
|
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Initial treatment or recommencement of treatment within an ongoing bDMARD treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who have received prior PBS-subsidised treatment with a bDMARD for this condition in this bDMARD treatment cycle and who are eligible to receive further bDMARD therapy within this treatment cycle; and where bDMARD means a drug included in the following list of drugs: adalimumab, anakinra, etanercept or infliximab; and |
|
|
|
| |
|
| where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: |
|
|
|
| |
|
| patients who commenced PBS-subsidised bDMARD treatment prior to 1 December 2004 are deemed to have commenced their first bDMARD treatment cycle with that therapy and any PBS-subsidised treatment received prior to 1 December 2004 is deemed to be treatment received as part of the patient's first bDMARD treatment cycle; patients are eligible to commence therapy with etanercept within this bDMARD treatment cycle provided they have not already tried, and either failed or ceased to respond to, PBS-subsidised treatment with 3 bDMARDs within this treatment cycle, and provided they also meet the conditions applying to recommencement of etanercept therapy specified below, if applicable; |
|
|
|
| |
|
| patients who have previously commenced, and subsequently ceased, PBS-subsidised treatment with etanercept within this bDMARD treatment cycle are eligible to recommence therapy with this drug within this same cycle if: |
|
|
|
| |
|
| an adequate response to treatment is defined as an erythrocyte sedimentation rate no greater than 25 mm per hour or a C-reactive protein level no greater than 15 mg per L or either marker reduced by at least 20% from baseline, and either a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints, or a reduction in the number of the following major joints which are active, from at least 4, by at least 50%: — elbow, wrist, knee or ankle (assessed as active if swollen and tender); or — shoulder or hip (assessed as active if there is pain in passive movement and restriction of passive movement, and where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth);
|
|
|
|
| |
|
| the authority application includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form and, where this is required, evidence of the patient's response to their most recent course of etanercept therapy; a course of treatment is limited to a maximum of 16 weeks of treatment |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuation of initial treatment, or of a course which recommences treatment, within an ongoing bDMARD treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who have previously been issued with an authority prescription for initial treatment or recommencement of treatment with this drug for a period of less than 16 weeks, and where approval of the application would enable the patient to complete a course of 16 weeks of treatment in total; and where 'bDMARD' and 'bDMARD treatment cycle' have the meaning given above |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Initial treatment, for up to 4 months, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, and who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if their response to treatment as assessed against the predetermined response criteria does not support continuation of PBS-subsidised treatment; and |
|
|
|
| |
|
|
|
|
|
|
| |
|
| where the patient has failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly, has failed to achieve an adequate response to methotrexate in combination with 2 other disease modifying anti-rheumatic drugs for a minimum of 3 months, and has subsequently failed to achieve an adequate response following a minimum of 3 months' treatment with leflunomide alone or leflunomide in combination with methotrexate or cyclosporin alone, unless treatment with any of the above-mentioned drugs is contraindicated according to the relevant Therapeutic Goods Administration-approved Product Information, or intolerance of a severity necessitating permanent treatment withdrawal develops during the relevant period of use, in which case the patient is exempted from demonstrating an inadequate response to the above treatment regimens; and |
|
|
|
| |
|
| where the following conditions apply: failure to achieve an adequate response is demonstrated by an elevated erythrocyte sedimentation rate greater than 25 mm per hour or a C-reactive protein level greater than 15 mg per L, and either an active joint count of at least 20 active (swollen and tender) joints or at least 4 active joints from the following list: if the requirement to demonstrate an elevated erythrocyte sedimentation rate or C-reactive protein level cannot be met, the authority application includes the reasons why this criterion cannot be satisfied; the authority application includes sufficient information to determine the patient's eligibility according to the above criteria and the date of joint assessment; |
|
|
|
| |
|
| where the patient is exempted from demonstrating an inadequate response to the treatment regimens specified above, the authority application includes details of the contraindication or intolerance, including the degree of toxicity |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Initial treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, who have previously been issued with an authority prescription for initial treatment with this drug for a period of less than 4 months, and where approval of the application would enable the patient to complete a period of initial treatment of not more than 4 months of uninterrupted therapy |
|
|
|
| |
| Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | In compliance with authority procedures set out in subsubparagraph 11 (d)(i): | Injection | 2 | 5 | WY | |
| Commencement of etanercept treatment in a bDMARD treatment cycle with an initial supply subsidised under the Pharmaceutical Benefits Scheme (PBS) for continuing treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who were receiving treatment with etanercept prior to 1 March 2005, who failed to qualify for PBS-subsidised therapy after 1 August 2003 due to testing negative for rheumatoid factor, and who have demonstrated a response to etanercept treatment as specified in the criteria for continuing PBS-subsidised treatment with etanercept detailed below; and where bDMARD means a drug included in the following list of drugs: |
|
|
|
| ||
|
| where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: the authority application includes sufficient information to determine the patient's eligibility for treatment and the date of assessment of the patient; the course of treatment is limited to a maximum of 24 weeks of treatment |
|
|
|
| |
|
| Continuing treatment within an ongoing biological disease modifying anti-rheumatic drug (bDMARD) treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis, and: (a) who have demonstrated an adequate response to treatment with etanercept; and (b) whose most recent course of bDMARD treatment subsidised under the Pharmaceutical Benefits Scheme (PBS) in this bDMARD treatment cycle was with etanercept; and where bDMARD means a drug included in the following list of drugs: |
|
|
|
| |
|
| where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: patients who commenced PBS-subsidised bDMARD treatment prior to 1 December 2004 are deemed to have commenced their first bDMARD treatment cycle with that therapy and any PBS-subsidised treatment received prior to 1 December 2004 is deemed to be treatment received as part of the patient's first bDMARD treatment cycle; |
|
|
|
| |
|
| an adequate response to treatment is defined as an erythrocyte sedimentation rate no greater than 25 mm per hour or a C-reactive protein level no greater than 15 mg per L or either marker reduced by at least 20% from baseline, and either a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints, or a reduction in the number of the following major joints which are active, from at least 4, by at least 50%: — elbow, wrist, knee or ankle (assessed as active if swollen and tender); or — shoulder or hip (assessed as active if there is pain in passive movement and restriction of passive movement, and where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth); the same indices of disease severity used to establish baseline at the commencement of treatment are used to determine response; |
|
|
|
| |
|
| the authority application includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form, and a measurement of response to the most recent prior course of therapy with etanercept, where response is assessed, and this assessment is provided to the Medicare Australia CEO, no later than 4 weeks from the cessation of that treatment course; if the most recent course of etanercept therapy was an initial 16 week course, the application for continuing treatment is accompanied by an assessment of response to a minimum of 12 weeks of treatment with that course; a course of treatment is limited to a maximum of 24 weeks of treatment In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuing treatment within an ongoing bDMARD treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who have previously been issued with an authority prescription for continuing treatment with this drug for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total; and where 'bDMARD' and 'bDMARD treatment cycle' have the meaning given above |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Initial PBS-subsidised supply for continuing treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, who were receiving treatment with etanercept prior to 1 December 2002, who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if their response to treatment as assessed against predetermined response criteria does not support continuation of PBS-subsidised treatment, and who have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept; and where the authority application includes sufficient information to determine the patient's eligibility for treatment and the date of assessment of the patient |
|
|
|
| |
|
| Continuing PBS-subsidised treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, who, at the time of application, demonstrate an adequate response to treatment with etanercept as manifested by an erythrocyte sedimentation rate no greater than 25 mm per hour or a C-reactive protein level no greater than 15 mg per L or either marker reduced by at least 20% from baseline, and an active joint count of fewer than 10 active (swollen and tender) joints or a reduction in the active (swollen and tender) joint count by at least 50% from baseline or a reduction in the number of the following active joints, from at least 4, by at least 50%: |
|
|
|
| |
|
| — shoulder, cervical spine or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth); and where the following conditions apply: the authority application includes sufficient information to determine the patient's response to treatment with etanercept according to the above criteria and the date of assessment of the patient; patients who have previously ceased treatment with etanercept due to failure to demonstrate an adequate response to treatment are not eligible to recommence treatment until a period of 12 months has elapsed since cessation of the previous treatment; authority applications for re-treatment with etanercept following a break in PBS-subsidised treatment with the drug include the reason for and date of cessation of the previous treatment course |
|
|
|
| |
| Injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL | In compliance with authority procedures set out in subsubparagraph 11 (d)(i): | Injection | 1 | 5 | WY | |
| Commencement of etanercept treatment in a bDMARD treatment cycle with an initial supply subsidised under the Pharmaceutical Benefits Scheme (PBS) for continuing treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who were receiving treatment with etanercept prior to 1 March 2005, who failed to qualify for PBS-subsidised therapy after 1 August 2003 due to testing negative for rheumatoid factor, and who have demonstrated a response to etanercept treatment as specified in the criteria for continuing PBS-subsidised treatment with etanercept detailed below; and where bDMARD means a drug included in the following list of drugs: |
|
|
|
| ||
|
| where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: the authority application includes sufficient information to determine the patient's eligibility for treatment and the date of assessment of the patient; the course of treatment is limited to a maximum of 24 weeks of treatment |
|
|
|
| |
|
| Continuing treatment within an ongoing biological disease modifying anti-rheumatic drug (bDMARD) treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis, and: where bDMARD means a drug included in the following list of drugs: |
|
|
|
| |
|
| where a bDMARD treatment cycle is a period of treatment with successive bDMARDs which commences when an eligible patient (one who has not received PBS-subsidised treatment with a bDMARD for rheumatoid arthritis in at least the previous 5 years) receives an initial course of PBS-subsidised therapy with 1 bDMARD, and which continues until the patient has tried, and either failed or ceased to respond to, PBS-subsidised treatment with a maximum of 3 bDMARDs, at which point the patient is no longer eligible for treatment and the period of treatment ceases; and where the following conditions apply: an adequate response to treatment is defined as an erythrocyte sedimentation rate no greater than 25 mm per hour or a C-reactive protein level no greater than 15 mg per L or either marker reduced by at least 20% from baseline, and either a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints, or a reduction in the number of the following major joints which are active, from at least 4, by at least 50%: — elbow, wrist, knee or ankle (assessed as active if swollen and tender); or — shoulder or hip (assessed as active if there is pain in passive movement and restriction of passive movement, and where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth); the same indices of disease severity used to establish baseline at the commencement of treatment are used to determine response; |
|
|
|
| |
|
| the authority application includes a completed copy of the appropriate PBS Authority Application - Supporting Information Form, and a measurement of response to the most recent prior course of therapy with etanercept, where response is assessed, and this assessment is provided to the Medicare Australia CEO, no later than 4 weeks from the cessation of that treatment course; if the most recent course of etanercept therapy was an initial 16 week course, the application for continuing treatment is accompanied by an assessment of response to a minimum of 12 weeks of treatment with that course; a course of treatment is limited to a maximum of 24 weeks of treatment In compliance with authority procedures set out in subsubparagraph 11 (d)(i) or 11 (d)(ii): Continuing treatment within an ongoing bDMARD treatment cycle, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of adults with severe active rheumatoid arthritis who have previously been issued with an authority prescription for continuing treatment with this drug for a period of less than 24 weeks, and where approval of the application would enable the patient to complete a course of 24 weeks of treatment in total; and where 'bDMARD' and 'bDMARD treatment cycle' have the meaning given above |
|
|
|
| |
|
| In compliance with authority procedures set out in subsubparagraph 11 (d)(i): Initial PBS-subsidised supply for continuing treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, who were receiving treatment with etanercept prior to 1 December 2002, who have signed a patient agreement form indicating that they understand and acknowledge that PBS-subsidised treatment will cease if their response to treatment as assessed against predetermined response criteria does not support continuation of PBS-subsidised treatment, and who have demonstrated a response as specified in the criteria for continuing PBS-subsidised treatment with etanercept; and where the authority application includes sufficient information to determine the patient's eligibility for treatment and the date of assessment of the patient |
|
|
|
| |
|
| Continuing PBS-subsidised treatment, by a rheumatologist or by a clinical immunologist with expertise in the management of rheumatoid arthritis, of patients aged 18 years or older with a documented history of severe active polyarticular course juvenile chronic arthritis with onset prior to the age of 18 years, who, at the time of application, demonstrate an adequate response to treatment with etanercept as manifested by an erythrocyte sedimentation rate no greater than 25 mm per hour or a C-reactive protein level no greater than 15 mg per L or either marker reduced by at least 20% from baseline, and an active joint count of fewer than 10 active (swollen and tender) joints or a reduction in the active (swollen and tender) joint count by at least 50% from baseline or a reduction in the number of the following active joints, from at least 4, by at least 50%: |
|
|
|
| |
|
| — shoulder, cervical spine or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth); and where the following conditions apply: the authority application includes sufficient information to determine the patient's response to treatment with etanercept according to the above criteria and the date of assessment of the patient; patients who have previously ceased treatment with etanercept due to failure to demonstrate an adequate response to treatment are not eligible to recommence treatment until a period of 12 months has elapsed since cessation of the previous treatment; authority applications for re-treatment with etanercept following a break in PBS-subsidised treatment with the drug include the reason for and date of cessation of the previous treatment course |
|
|
|
| |
Famciclovir | Tablet 250 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 56 | 5 | NV | |
|
| Suppressive therapy of moderate to severe recurrent genital herpes, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis |
|
|
|
| |
| Tablet 500 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 56 | 5 | NV | |
|
| Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes in immunocompromised patients, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis |
|
|
|
| |
Granisetron Hydrochloride | Tablet equivalent to 2 mg granisetron | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 5 | 1 | MX | |
| Management of nausea and vomiting associated with radiotherapy being used to treat malignancy |
|
|
|
| ||
| Concentrated injection equivalent to 3 mg granisetron in 3 mL ampoule | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 1 | .. | MX | |
| Management of nausea and vomiting associated with radiotherapy being used to treat malignancy |
|
|
|
| ||
Hydrocortisone Sodium Succinate | Injection equivalent to 100 mg hydrocortisone with 2 mL solvent | For use in a hospital | Injection | 6 | .. | PH | |
| Injection equivalent to 250 mg hydrocortisone with 2 mL solvent | For use in a hospital | Injection | 6 | .. | PH | |
Hydromorphone Hydrochloride | Tablet 2 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | AB | |
|
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| |
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 4 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | AB | |
|
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| |
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 8 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | AB | |
|
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| |
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Oral liquid 1 mg per mL, 473 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | AB | |
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
Interferon Alfa-2a | Injection 3,000,000 I.U. in 0.5 mL single dose pre-filled syringe | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 15 | 5 | RO | |
| Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy |
|
|
|
| ||
| Injection 4,500,000 I.U. in 0.5 mL single dose pre-filled syringe | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 5 | 5 | RO | |
| Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy |
|
|
|
| ||
| Injection 6,000,000 I.U. in 0.5 mL single dose pre-filled syringe | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 5 | 5 | RO | |
| Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy |
|
|
|
| ||
| Injection 9,000,000 I.U. in 0.5 mL single dose pre-filled syringe | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 5 | 5 | RO | |
| Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy |
|
|
|
| ||
Interferon Alfa-2b | Solution for injection 18,000,000 I.U. in 1.2 mL multi-dose injection pen | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 3 | 5 | SH | |
| Maintenance treatment of multiple myeloma once remission has been achieved with chemotherapy |
|
|
|
| ||
|
| Low grade non-Hodgkin's lymphoma with clinical features suggestive of a poor prognosis, in combination with anthracycline-based chemotherapy |
|
|
|
| |
"Karicare De-Lact" | Oral powder 900 g | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 5 | 5 | NU | |
|
| Proven chronic lactose intolerance in patients up to the age of 12 months, where the date of birth of the patient is included in the authority application, and where lactose intolerance has been proven either by the relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food, or by the presence of not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet |
|
|
|
| |
Ketoconazole | Tablet 200 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 30 | 5 | JC | |
|
| Oral candidiasis in severely immunocompromised persons where topical therapy has failed |
|
|
|
| |
|
| Systemic or deep mycoses where other forms of therapy have failed |
|
|
|
| |
Lansoprazole | Capsule 30 mg | Gastro-oesophageal reflux disease | Oral | 30 | 5 | WY | |
|
| Scleroderma oesophagus |
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
| Sachet containing granules for oral suspension, 30 mg per sachet | Gastro-oesophageal reflux disease | Oral | 28 | 5 | WY | |
| Scleroderma oesophagus |
|
|
|
| ||
| Sachet containing granules for oral suspension, 30 mg per sachet | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 28 | 1 | WY | |
| Initial treatment of peptic ulcer, in patients unable to take a solid dose form of a proton pump inhibitor |
|
|
|
| ||
| Sachet containing granules for oral suspension, 30 mg per sachet | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 28 | 5 | WY | |
| Gastro-oesophageal reflux disease, in patients unable to take a solid dose form of a proton pump inhibitor |
|
|
|
| ||
|
| Scleroderma oesophagus, in patients unable to take a solid dose form of a proton pump inhibitor |
|
|
|
| |
Lercanidipine Hydrochloride | Tablet 10 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 30 | 5 | SM | |
|
| Adverse effects occurring with all of the base-priced drugs |
|
|
|
| |
|
| Drug interactions occurring with all of the base-priced drugs |
|
|
|
| |
|
| Drug interactions expected to occur with all of the base-priced drugs |
|
|
|
| |
|
| Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance |
|
|
|
| |
| Tablet 20 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 30 | 5 | SM | |
|
| Adverse effects occurring with all of the base-priced drugs |
|
|
|
| |
|
| Drug interactions occurring with all of the base-priced drugs |
|
|
|
| |
|
| Drug interactions expected to occur with all of the base-priced drugs |
|
|
|
| |
|
| Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance |
|
|
|
| |
Levetiracetam | Tablet 250 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | UC | |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Tablet 500 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | UC | |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Tablet 1 g | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | UC | |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
Medroxyprogesterone Acetate | Tablet 10 mg | Endometriosis | Oral | 100 | 2 | KR, PH | |
Methadone Hydrochloride | Tablet 10 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | GK | |
|
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| |
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Injection 10 mg in 1 mL ampoule | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 10 | .. | GK | |
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
|
|
|
|
|
|
| |
Metronidazole | Tablet 400 mg | Treatment of anaerobic infections | Oral | 21 | 1 | AF, AV, HP | |
Morphine Hydrochloride | Oral solution 1 mg per mL, 500mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | VT | |
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Oral solution 2 mg per mL, 200 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | MF, PF | |
Severe disabling pain associated with proven malignant neoplasia | |||||||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Oral solution 5 mg per mL, 200 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | MF, PF | |
Severe disabling pain associated with proven malignant neoplasia | |||||||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Oral solution 5 mg per mL, 250 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | VT | |
Severe disabling pain associated with proven malignant neoplasia | |||||||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Oral solution 5 mg per mL, 500 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | VT | |
Severe disabling pain associated with proven malignant neoplasia | |||||||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Oral solution 10 mg per mL, 200 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | MF, PF | |
Severe disabling pain associated with proven malignant neoplasia | |||||||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Oral solution 10 mg per mL, 250 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | VT | |
Severe disabling pain associated with proven malignant neoplasia | |||||||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
Morphine Sulfate | Tablet 30 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | FM | |
|
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| |
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 5 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 10 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 15 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 30 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
|
|
|
|
|
|
| |
| Tablet 60 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 100 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 10 mg (containing sustained release pellets) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | GK | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 20 mg (containing sustained release pellets) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | GK | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 30 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 20 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
|
|
|
|
|
|
| |
| Capsule 50 mg (containing sustained release pellets) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | GK | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 60 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 20 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 90 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 20 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 100 mg (containing sustained release pellets) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | GK | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 120 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 20 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
|
|
|
|
|
|
| |
| Sachet containing controlled release granules for oral suspension, 20 mg per sachet | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| ||
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Sachet containing controlled release granules for oral suspension, 30 mg per sachet | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| ||
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Sachet containing controlled release granules for oral suspension, 60 mg per sachet | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| ||
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Sachet containing controlled release granules for oral suspension, 100 mg per sachet | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| ||
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
"Neocate" | Oral powder 400 g | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 8 | 5 | SB | |
|
| Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in children up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician, and where the date of birth of the patient is included in the authority application |
|
|
|
| |
|
| Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in children aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months, and where the date of birth of the patient is included in the authority application |
|
|
|
| |
|
| Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed |
|
|
|
| |
|
| Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition |
|
|
|
| |
"Neocate Advance" | Oral powder 400 g | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 8 | 5 | SB | |
|
| Continuing treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in children up to the age of 2 years, where the child has been assessed by a suitably qualified allergist or paediatrician, and where the date of birth of the patient is included in the authority application |
|
|
|
| |
|
| Treatment for combined intolerance (not infant colic) to cows' milk protein, soy protein and protein hydrolysate formulae in children aged 2 years and over, where the child is assessed by a suitably qualified allergist or paediatrician at intervals not greater than 6 months, and where the date of birth of the patient is included in the authority application |
|
|
|
| |
|
| Severe intestinal malabsorption including short bowel syndrome where protein hydrolysate formulae have failed |
|
|
|
| |
|
| Severe intestinal malabsorption including short bowel syndrome where the patient has been receiving parenteral nutrition |
|
|
|
| |
Nifedipine | Tablet 20 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 30 | 5 | BN | |
| Adverse effects occurring with all of the base-priced drugs |
|
|
|
| ||
|
| Drug interactions occurring with all of the base-priced drugs |
|
|
|
| |
|
| Drug interactions expected to occur with all of the base-priced drugs |
|
|
|
| |
|
| Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance |
|
|
|
| |
Nitrazepam | Tablet 5 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 5 | AF, VT | |
|
| Myoclonic epilepsy |
|
|
|
| |
|
| Malignant neoplasia (late stage) |
|
|
|
| |
|
| For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
|
| For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
Omeprazole | Tablet 20 mg | Gastro-oesophageal reflux disease | Oral | 30 | 5 | HX | |
|
| Scleroderma oesophagus |
|
|
|
| |
|
| Zollinger-Ellison syndrome |
|
|
|
| |
| Capsule 20 mg | Gastro-oesophageal reflux disease | Oral | 30 | 5 | SZ | |
|
| Scleroderma oesophagus |
|
|
|
| |
|
| Zollinger-Ellison syndrome |
|
|
|
| |
Omeprazole Magnesium | Tablet equivalent to 20 mg omeprazole | Gastro-oesophageal reflux disease | Oral | 30 | 5 | AL, AP, PM | |
| Scleroderma oesophagus |
|
|
| |||
| Zollinger-Ellison syndrome |
|
|
| |||
Ondansetron | Wafer 4 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 10 | 1 | GK, HX, RE | |
|
| Management of nausea and vomiting associated with radiotherapy being used to treat malignancy |
|
|
| ||
| Wafer 8 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 10 | 1 | GK, HX, RE | |
|
| Management of nausea and vomiting associated with radiotherapy being used to treat malignancy |
|
|
| ||
Ondansetron Hydrochloride Dihydrate | Tablet equivalent to 4 mg ondansetron | In compliance with authority procedures set out in subparagraph 11 (d): Management of nausea and vomiting associated with radiotherapy being used to treat malignancy | Oral | 10 | 1 | GK, HX, RE | |
|
|
|
| ||||
| Tablet equivalent to 8 mg ondansetron | In compliance with authority procedures set out in subparagraph 11 (d): Management of nausea and vomiting associated with radiotherapy being used to treat malignancy | Oral | 10 | 1 | GK, HX, RE | |
|
|
|
|
|
| ||
| I.V. injection equivalent to 4 mg ondansetron in 2 mL ampoule | In compliance with authority procedures set out in subparagraph 11 (d): Management of nausea and vomiting associated with radiotherapy being used to treat malignancy | Injection | 1 | .. | GK, HX, RE | |
|
|
|
| ||||
| I.V. injection equivalent to 8 mg ondansetron in 4 mL ampoule | In compliance with authority procedures set out in subparagraph 11 (d): Management of nausea and vomiting associated with radiotherapy being used to treat malignancy | Injection | 1 | .. | GK, HX, RE | |
|
|
|
|
| |||
Oxazepam | Tablet 15 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 5 | AF, SI | |
|
| Malignant neoplasia (late stage) |
|
|
|
| |
|
| For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
|
| For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
| Tablet 30 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 5 | AF, FM, SI | |
|
| Malignant neoplasia (late stage) |
|
|
|
| |
|
| For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
|
| For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
Oxycodone Hydrochloride | Tablet 5 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | SI | |
|
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| |
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 5 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
|
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| |
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 10 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
|
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| |
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Capsule 20 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
|
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| |
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Oral solution 5 mg per 5 mL, 250 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | MF | |
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 5 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 10 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 20 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 40 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
| Tablet 80 mg (controlled release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | MF | |
| Chronic severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
Oxycodone Pectinate | Suppository equivalent to 30 mg oxycodone | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 24 | .. | PL | |
| Severe disabling pain associated with proven malignant neoplasia |
|
|
|
| ||
|
| Chronic severe disabling pain not responding to non-narcotic analgesics where the total duration of narcotic analgesic treatment is less than 12 months |
|
|
|
| |
|
| Initial treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics in a patient who has been receiving narcotic analgesic treatment for this condition, where the patient's pain management has been reviewed through consultation by the patient with another medical practitioner no earlier than 3 months prior to the date of the authority application and the clinical need for continuing narcotic analgesic treatment has been confirmed, and where the full name of the medical practitioner consulted and the date of consultation are included in the authority application |
|
|
|
| |
|
| Continuing treatment of chronic severe disabling pain not responding to non-narcotic analgesics where the patient has previously been issued with an authority prescription under the Pharmaceutical Benefits Scheme for treatment beyond 12 months of chronic severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| |
Pantoprazole Sodium Sesquihydrate | Tablet (enteric coated), equivalent to 40 mg pantoprazole | Gastro-oesophageal reflux disease Scleroderma oesophagus Zollinger-Ellison syndrome | Oral | 30 | 5 | PH | |
|
|
|
|
| |||
|
|
|
|
| |||
Paracetamol | Tablet 500 mg | Chronic arthropathies | Oral | 300 | 4 | AW, CH, DG, FM, HX, JT, PC, SW, TW | |
Pemetrexed Disodium Heptahydrate | Powder for I.V. infusion equivalent to 500 mg pemetrexed, vial | In compliance with authority procedures set out in subparagraph 11 (d): Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with paclitaxel or docetaxel is contraindicated | Injection | 2 | 2 | LY | |
|
|
|
|
| |||
|
| Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where intolerance to treatment with either docetaxel or paclitaxel has developed |
|
|
|
| |
|
| Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where treatment with either docetaxel or paclitaxel has been unsuccessful |
|
|
|
| |
|
| Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy, where transfer to docetaxel or paclitaxel is likely to result in adverse clinical consequences |
|
|
|
| |
Phenoxymethylpenicillin Potassium | Tablet equivalent to 250 mg phenoxymethylpenicillin | Prophylaxis of recurrent streptococcal infections (including rheumatic fever) | Oral | 50 | 5 | SI | |
| Capsule equivalent to 250 mg phenoxymethylpenicillin | Prophylaxis of recurrent streptococcal infections (including rheumatic fever) | Oral | 50 | 5 | CS, DP, FM, HX | |
Rabeprazole Sodium | Tablet 20 mg (enteric coated) | Gastro-oesophageal reflux disease | Oral | 30 | 5 | JC | |
|
| Scleroderma oesophagus |
|
|
|
| |
Ramipril | Capsule 10 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 30 | 5 | AV | |
|
| Adverse effects occurring with all of the base-priced drugs |
|
|
|
| |
|
| Drug interactions occurring with all of the base-priced drugs |
|
|
|
| |
|
| Drug interactions expected to occur with all of the base-priced drugs |
|
|
|
| |
|
| Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance |
|
|
|
| |
Ranitidine Hydrochloride | Tablet, effervescent, equivalent to 150 mg ranitidine | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | GK | |
| Adverse effects occurring with all of the base-priced drugs Drug interactions occurring with all of the base-priced drugs Drug interactions expected to occur with all of the base-priced drugs Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance |
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
| Syrup equivalent to 150 mg ranitidine per 10 mL, 300 mL | In compliance with authority procedures set out in subparagraph 11 (d): Adverse effects occurring with all of the base-priced drugs Drug interactions occurring with all of the base-priced drugs Drug interactions expected to occur with all of the base-priced drugs Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance | Oral | 2 | 5 | GK | |
|
|
|
|
| |||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
Rifampicin | Capsule 150 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | .. | AF | |
|
| Leprosy in adults |
|
|
|
| |
| Capsule 300 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | .. | AF | |
|
| Leprosy in adults |
|
|
|
| |
Risperidone | Tablet 0.5 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | JC | |
|
| Schizophrenia |
|
|
|
| |
| Tablet 0.5 mg (orally disintegrating) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 56 | 5 | JC | |
| Schizophrenia |
|
|
|
| ||
| Tablet 1 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | JC | |
|
| Schizophrenia |
|
|
|
| |
|
| Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder |
|
|
|
| |
| Tablet 1 mg (orally disintegrating) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 56 | 5 | JC | |
| Schizophrenia |
|
|
|
| ||
| Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder |
|
|
|
| ||
Rituximab | Solution for I.V. infusion 100 mg in 10 mL vial | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 2 | 7 | RO | |
|
| Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy |
|
|
|
| |
| Solution for I.V. infusion 500 mg in 50 mL vial | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 1 | 7 | RO | |
|
| Treatment of previously untreated, CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy |
|
|
|
| |
"S-26 LF" | Infant formula powder 900 g | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 5 | 5 | WY | |
| Proven chronic lactose intolerance in patients up to the age of 12 months, where the date of birth of the patient is included in the authority application, and where lactose intolerance has been proven either by the relief of symptoms on supervised withdrawal of lactose from the diet for 3 or 4 days and subsequent re-emergence of symptoms on rechallenge with lactose containing formulae or milk or food, or by the presence of not less than 0.5% reducing substance in stool exudate tested with copper sulfate diagnostic compound tablet |
|
|
|
| ||
Sertraline Hydrochloride | Tablet equivalent to 50 mg sertraline | Obsessive-compulsive disorder Panic disorder where other treatments have failed or are inappropriate | Oral | 30 | 5 | AF, AW, PF | |
|
|
|
| ||||
| Tablet equivalent to 100 mg sertraline | Obsessive-compulsive disorder Panic disorder where other treatments have failed or are inappropriate | Oral | 30 | 5 | AF, AW, PF | |
|
|
|
| ||||
Temazepam | Tablet 10 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 5 | AF, FM, SI | |
|
| Malignant neoplasia (late stage) |
|
|
|
| |
|
| For use by patients who are receiving long-term nursing care on account of age, infirmity or other condition in hospitals, nursing homes or residential facilities and who have been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
|
| For use by a patient who is receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult and who has been demonstrated, within the past 6 months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal |
|
|
|
| |
Temozolomide | Capsule 5 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 5 | 5 | SH | |
|
| Recurrence of anaplastic astrocytoma following standard therapy |
|
|
|
| |
|
| Recurrence of glioblastoma multiforme following standard therapy |
|
|
|
| |
|
| Glioblastoma multiforme following radiotherapy |
|
|
|
| |
| Capsule 20 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 5 | 5 | SH | |
|
| Recurrence of anaplastic astrocytoma following standard therapy |
|
|
|
| |
|
| Recurrence of glioblastoma multiforme following standard therapy |
|
|
|
| |
|
| Glioblastoma multiforme following radiotherapy |
|
|
|
| |
| Capsule 100 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 5 | 5 | SH | |
|
| Recurrence of anaplastic astrocytoma following standard therapy |
|
|
|
| |
|
| Recurrence of glioblastoma multiforme following standard therapy |
|
|
|
| |
|
| Glioblastoma multiforme following radiotherapy |
|
|
|
| |
Topiramate | Tablet 25 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | JC | |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Tablet 50 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | JC | |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Tablet 100 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | JC | |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Tablet 200 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | JC | |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Capsule 15 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | JC | |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Capsule 25 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | JC | |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
| Capsule 50 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 60 | 5 | JC | |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where adverse events have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions have occurred with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where drug interactions are expected to occur with other suitable drugs available under the Pharmaceutical Benefits Scheme |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme would cause patient confusion resulting in problems with compliance |
|
|
|
| |
|
| Treatment of partial epileptic seizures, primary generalised tonic-clonic epileptic seizures and seizures of the Lennox-Gastaut syndrome, which are not controlled satisfactorily by other anti-epileptic drugs, and where transfer to another suitable drug available under the Pharmaceutical Benefits Scheme is likely to result in adverse clinical consequences |
|
|
|
| |
Tramadol Hydrochloride | Capsule 50 mg | For dosage titration in chronic pain where aspirin or paracetamol alone is inappropriate or has failed | Oral | 20 | 2 | AF, AW, CH, CS, GX, TW | |
| Tablet 100 mg (sustained release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | AW, CS, HX | |
| Severe disabling pain not responding to non-narcotic analgesics |
|
|
| |||
| Tablet 150 mg (sustained release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | AW, CS, HX | |
| Severe disabling pain not responding to non-narcotic analgesics |
|
|
| |||
| Tablet 200 mg (sustained release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 40 | .. | AW, CS, HX | |
| Severe disabling pain not responding to non-narcotic analgesics |
|
|
| |||
| Oral drops 100 mg per mL, 10 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | .. | CS | |
| Severe disabling pain not responding to non-narcotic analgesics |
|
|
|
| ||
Valaciclovir Hydrochloride | Tablet equivalent to 500 mg valaciclovir | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 30 | 5 | GK | |
| Episodic treatment or suppressive therapy of moderate to severe recurrent genital herpes, where the diagnosis is confirmed microbiologically (by viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction) but where commencement of treatment need not await confirmation of diagnosis |
|
|
|
| ||
|
|
|
|
|
|
| |
| Tablet equivalent to 500 mg valaciclovir | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 42 | .. | GK | |
| Treatment of patients with herpes zoster within 72 hours of the onset of the rash |
|
|
|
| ||
| Herpes zoster ophthalmicus |
|
|
|
| ||
Vancomycin Hydrochloride | Powder for injection equivalent to 500 mg (500,000 I.U.) vancomycin activity | Endophthalmitis | Injection | 5 | .. | AS, MX | |
| Use initiated in a hospital for infections where vancomycin hydrochloride is an appropriate antibiotic |
|
|
|
| ||
| |||||||
Bisacodyl | Tablet 5 mg | Oral | 200 | .. | AE, AS |
| Suppositories 10 mg, 10 | Rectal | 3 | .. | BY, PP |
| Suppositories 10 mg, 12 | Rectal | 3 | .. | FL, PP |
| Enemas 10 mg in 5 mL, 25 | Rectal | 1 | .. | AS |
Carmellose Sodium | Mouth spray 10 mg per mL, 25 mL | Oral application | 1 | .. | HA |
| Mouth spray 10 mg per mL, 100 mL | Oral application | 1 | .. | HA |
Clonazepam | Tablet 500 micrograms | Oral | 100 | .. | AF, RO |
| Tablet 2 mg | Oral | 100 | .. | AF, RO |
| Oral liquid 2.5 mg per mL, 10 mL | Oral | 2 | .. | RO |
Diazepam | Tablet 2 mg | Oral | 50 | .. | AF, AW, RO, SU |
| Tablet 5 mg | Oral | 50 | .. | AF, AW, DP, RO, SU |
Diclofenac Sodium | Tablet 25 mg (enteric coated) | Oral | 100 | .. | AF, AW, BG, CH, DP, GX, HX, NV, TW |
| Tablet 50 mg (enteric coated) | Oral | 50 | .. | AF, AW, CH, DP, GX, HX, NV, TW |
| Suppository 100 mg | Rectal | 40 | .. | NV |
Docusate Sodium with Bisacodyl | Suppositories 100 mg-10 mg, 5 | Rectal | 6 | .. | FM |
Glycerol | Suppositories 700 mg, 12 | Rectal | 3 | .. | PP |
| Suppositories 1.4 g, 12 | Rectal | 3 | .. | PP |
| Suppositories 2.8 g, 12 | Rectal | 3 | .. | PP |
Hyoscine Butylbromide | Injection 20 mg in 1 mL ampoule | Injection | 5 | .. | BY |
Ibuprofen | Tablet 200 mg | Oral | 100 | .. | AF |
| Tablet 400 mg | Oral | 100 | .. | AB |
Indomethacin | Capsule 25 mg | Oral | 100 | .. | AF, MK |
| Suppository 100 mg | Rectal | 40 | .. | MK |
Naproxen | Tablet 250 mg | Oral | 100 | .. | AF, RO |
| Tablet 500 mg | Oral | 50 | .. | AF, RO |
| Tablet 750 mg (sustained release) | Oral | 28 | .. | MD, RO |
| Tablet 1 g (sustained release) | Oral | 28 | .. | MD, RO |
Naproxen Sodium | Tablet 550 mg | Oral | 50 | .. | MD, RO |
Nitrazepam | Tablet 5 mg | Oral | 50 | .. | AF, VT |
Oxazepam | Tablet 15 mg | Oral | 50 | .. | AF, SI |
| Tablet 30 mg | Oral | 50 | .. | AF, FM, SI |
Paracetamol | Tablet 665 mg (modified release) | Oral | 96 | .. | GC, ME |
| Suppositories 500 mg, 24 | Rectal | 1 | .. | GC |
Promethazine Hydrochloride | Tablet 10 mg | Oral | 50 | .. | AV |
| Tablet 25 mg | Oral | 50 | .. | AV |
| Oral liquid 5 mg per 5 mL, 100 mL | Oral | 1 | .. | AV |
Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate | Enemas 3.125 g-450 mg-45 mg in 5 mL, 12 | Rectal | 2 | .. | PH |
Sterculia with Frangula Bark | Granules 620 mg-80 mg per g, 500 g | Oral | 1 | .. | NE |
Sulindac | Tablet 100 mg | Oral | 100 | .. | AF |
| Tablet 200 mg | Oral | 50 | .. | AF |
Temazepam | Tablet 10 mg | Oral | 50 | .. | AF, FM, SI |
| |||||
Bisacodyl | Tablet 5 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 200 | 3 | AE, AS | |
|
| Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Suppositories 10 mg, 10 | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 3 | 3 | BY, PP | |
|
| Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Suppositories 10 mg, 12 | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 3 | 3 | FL, PP | |
|
| Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Enemas 10 mg in 5 mL, 25 | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 1 | 3 | AS | |
|
| Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Carmellose Sodium | Mouth spray 10 mg per mL, 25 mL | In compliance with authority procedures set out in subparagraph 11 (d): Initial supply, for up to 4 months, for palliative care patients where dry mouth is a symptom, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life | Oral application | 1 | 3 | HA | |
|
|
|
|
| |||
|
| Continuing supply for palliative care patients where dry mouth is a symptom, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Mouth spray 10 mg per mL, 100 mL | In compliance with authority procedures set out in subparagraph 11 (d): Initial supply, for up to 4 months, for palliative care patients where dry mouth is a symptom, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life Continuing supply for palliative care patients where dry mouth is a symptom, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life | Oral application | 1 | 3 | HA | |
|
|
|
|
|
| ||
|
|
|
|
|
| ||
Clonazepam | Tablet 500 micrograms | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | 3 | AF, RO | |
|
| Initial supply, for up to 4 months, for palliative care patients for the prevention of epilepsy, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients for the prevention of epilepsy, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 2 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | 3 | AF, RO | |
|
| Initial supply, for up to 4 months, for palliative care patients for the prevention of epilepsy, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients for the prevention of epilepsy, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Oral liquid 2.5 mg per mL, 10 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 2 | 3 | RO | |
| Initial supply, for up to 4 months, for palliative care patients for the prevention of epilepsy, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| ||
|
| Continuing supply for palliative care patients for the prevention of epilepsy, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Diazepam | Tablet 2 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AF, AW, RO, SU | |
| Initial supply, for up to 4 months, for palliative care patients where anxiety is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
| |||
|
| Continuing supply for palliative care patients where anxiety is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 5 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AF, AW, DP, RO, SU | |
|
| Initial supply, for up to 4 months, for palliative care patients where anxiety is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
| ||
|
| Continuing supply for palliative care patients where anxiety is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Diclofenac Sodium | Tablet 25 mg (enteric coated) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | 3 | AF, AW, BG, CH, DP, GX, HX, NV, TW | |
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
| |||
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 50 mg (enteric coated) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AF, AW, CH, DP, GX, HX, NV, TW | |
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
| |||
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Suppository 100 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 40 | 3 | NV | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Docusate Sodium with Bisacodyl | Suppositories 100 mg-10 mg, 5 | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 6 | 3 | FM | |
| Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| ||
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Glycerol | Suppositories 700 mg, 12 | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 3 | 3 | PP | |
|
| Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Suppositories 1.4 g, 12 | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 3 | 3 | PP | |
|
| Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Suppositories 2.8 g, 12 | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 3 | 3 | PP | |
|
| Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
Hyoscine Butylbromide | Injection 20 mg in 1 mL ampoule | In compliance with authority procedures set out in subparagraph 11 (d): | Injection | 5 | 3 | BY | |
| Initial supply, for up to 4 months, for palliative care patients where colicky pain is a symptom, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| ||
|
| Continuing supply for palliative care patients where colicky pain is a symptom, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Ibuprofen | Tablet 200 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | 3 | AF | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 400 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | 3 | AB | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
Indomethacin | Capsule 25 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | 3 | AF, MK | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Suppository 100 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 40 | 3 | MK | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Naproxen | Tablet 250 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | 3 | AF, RO | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 500 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AF, RO | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 750 mg (sustained release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 28 | 3 | MD, RO | |
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| ||
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 1 g (sustained release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 28 | 3 | MD, RO | |
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| ||
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Naproxen Sodium | Tablet 550 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | MD, RO | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Nitrazepam | Tablet 5 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AF, VT | |
|
| Initial supply, for up to 4 months, for palliative care patients where insomnia is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where insomnia is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Oxazepam | Tablet 15 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AF, SI | |
|
| Initial supply, for up to 4 months, for palliative care patients where anxiety is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where anxiety is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 30 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AF, FM, SI | |
|
| Initial supply, for up to 4 months, for palliative care patients where anxiety is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where anxiety is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Paracetamol | Tablet 665 mg (modified release) | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 96 | 3 | GC, ME | |
| Initial supply, for up to 4 months, for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| ||
|
| Continuing supply for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Suppositories 500 mg, 24 | In compliance with authority procedures set out in subparagraph 11 (d): | Rectal | 1 | 3 | GC | |
|
| Initial supply, for up to 4 months, for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients for analgesia or fever where alternative therapy cannot be tolerated, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
|
|
|
|
|
| |
Promethazine Hydrochloride | Tablet 10 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AV | |
|
| Initial supply, for up to 4 months, for palliative care patients where nausea or vomiting is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where nausea or vomiting is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 25 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AV | |
|
| Initial supply, for up to 4 months, for palliative care patients where nausea or vomiting is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where nausea or vomiting is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Oral liquid 5 mg per 5 mL, 100 mL | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 1 | 3 | AV | |
| Initial supply, for up to 4 months, for palliative care patients where nausea or vomiting is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| ||
|
| Continuing supply for palliative care patients where nausea or vomiting is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate | Enemas 3.125 g-450 mg-45 mg in 5 mL, 12 | In compliance with authority procedures set out in subparagraph 11 (d): Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life | Rectal | 2 | 3 | PH | |
|
|
|
|
| |||
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Sterculia with Frangula Bark | Granules 620 mg-80 mg per g, 500 g | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 1 | 3 | NE | |
| Initial supply, for up to 4 months, for palliative care patients where constipation is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| ||
|
| Continuing supply for palliative care patients where constipation is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Sulindac | Tablet 100 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 100 | 3 | AF | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| Tablet 200 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AF | |
|
| Initial supply, for up to 4 months, for palliative care patients where severe pain is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where severe pain is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
Temazepam | Tablet 10 mg | In compliance with authority procedures set out in subparagraph 11 (d): | Oral | 50 | 3 | AF, FM, SI | |
|
| Initial supply, for up to 4 months, for palliative care patients where insomnia is a problem, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
|
| Continuing supply for palliative care patients where insomnia is a problem, where consultation with a palliative care specialist or service has occurred, and where a palliative care patient is a patient with an active, progressive, far-advanced disease and for whom the prognosis is limited and the focus of care is the quality of life |
|
|
|
| |
| |||||||
Adrenaline Acid Tartrate | Injection equivalent to adrenaline 1 in 1,000, 1 mL | Injection | 5 | .. | AP | |
Amoxycillin Trihydrate | Tablet, chewable, equivalent to 250 mg amoxycillin | Oral | 20 | .. | GK | |
| Capsule equivalent to 250 mg amoxycillin | Oral | 20 | .. | AF, CH, CS, DG, DP, GK, GX, HX, SI, TW | |
| Capsule equivalent to 500 mg amoxycillin | Oral | 20 | .. | AF, CH, CS, DG, DP, GK, GX, HX, SI, TW | |
| Sachet containing oral powder equivalent to 3 g amoxycillin | Oral | 1 | .. | GK | |
Amoxycillin Trihydrate with Potassium Clavulanate | Tablet equivalent to 500 mg amoxycillin-125 mg clavulanic acid | Oral | 10 | .. | AL, AW, GK, HX, SL, SZ | |
| Tablet equivalent to 875 mg amoxycillin-125 mg clavulanic acid | Oral | 10 | .. | AL, AW, CH, GK, GX, HX, SL, SZ, TW | |
Amoxycillin Trihydrate with Potassium Clavulanate and Water - Purified BP | Powder for oral suspension equivalent to 125 mg amoxycillin-31.25 mg clavulanic acid per 5 mL, 75 mL | Oral | 1 | .. | AL, AW, GK, HX | |
| Powder for oral suspension equivalent to 400 mg amoxycillin-57 mg clavulanic acid per 5 mL, 60 mL | Oral | 1 | .. | AL, AW, GK, HX | |
Amoxycillin Trihydrate with Water - Purified BP | Powder for paediatric oral drops equivalent to 100 mg amoxycillin per mL, 20 mL | Oral | 1 | .. | GK | |
| Powder for oral suspension equivalent to 125 mg amoxycillin per 5 mL, 100 mL | Oral | 1 | .. | AF, CH, CS, DP, GK, GX, HX, SI, TW | |
| Powder for oral suspension equivalent to 250 mg amoxycillin per 5 mL, 100 mL | Oral | 1 | .. | AF, CH, CS, DP, GK, GX, HX, SI, TW | |
| Powder for oral suspension equivalent to 500 mg amoxycillin per 5 mL, 100 mL | Oral | 1 | .. | SZ | |
Amphotericin | Lozenge 10 mg | Oral | 20 | .. | BQ | |
Ampicillin Sodium | Powder for injection equivalent to 500 mg ampicillin | Injection | 5 | .. | CS, DP | |
| Powder for injection equivalent to 1 g ampicillin | Injection | 5 | .. | AS, CS, DP | |
Ampicillin Trihydrate | Capsule equivalent to 250 mg ampicillin | Oral | 24 | .. | AF | |
| Capsule equivalent to 500 mg ampicillin | Oral | 24 | .. | AF | |
Aspirin | Tablet, dispersible, 300 mg | Oral | 96 | .. | RC | |
Atropine Sulfate | Injection 600 micrograms in 1 mL ampoule | Injection | 10 | .. | AP | |
Benzathine Penicillin | Injection 900 mg in 2 mL cartridge-needle unit (for use with Tubex Injector) | Injection | 1 | .. | AS | |
| Powder for injection 900 mg | Injection | 1 | .. | AS | |
Benztropine Mesylate | Injection 2 mg in 2 mL ampoule | Injection | 5 | .. | MK | |
Benzydamine Hydrochloride | Mouth and throat rinse 22.5 mg per 15 mL, 500 mL | Oral application | 1 | .. | MM | |
Benzylpenicillin Sodium | Powder for injection equivalent to 600 mg benzylpenicillin | Injection | 10 | .. | CS | |
| Powder for injection equivalent to 3 g benzylpenicillin | Injection | 10 | .. | CS | |
Betamethasone Acetate with Betamethasone Sodium Phosphate | Injection 3 mg-3.9 mg in 1 mL ampoule | Injection | 5 | .. | SH | |
Carbamazepine | Tablet 100 mg | Oral | 200 | .. | BG, NV, SZ | |
| Tablet 200 mg | Oral | 200 | .. | AF, BG, NV, SZ | |
| Tablet 200 mg (controlled release) | Oral | 200 | .. | NV | |
| Tablet 400 mg (controlled release) | Oral | 200 | .. | NV | |
| Oral suspension 100 mg per 5 mL, 300 mL | Oral | 1 | .. | NV | |
Cefaclor Monohydrate | Tablet (sustained release) equivalent to 375 mg cefaclor | Oral | 10 | .. | AF, AS, CH, DG, DP, GX, LN, TW | |
Cefaclor Monohydrate with Water - Purified BP | Powder for oral suspension equivalent to 125 mg cefaclor per 5 mL, 100 mL | Oral | 1 | .. | AF, AS, AW, CH, GX, TW | |
| Powder for oral suspension equivalent to 250 mg cefaclor per 5 mL, 75 mL | Oral | 1 | .. | AF, AS, AW, CH, GX, TW | |
Cefotaxime Sodium | Powder for injection equivalent to 1 g cefotaxime | Injection | 10 | .. | MX, SZ | |
| Powder for injection equivalent to 2 g cefotaxime | Injection | 10 | .. | MX, SZ | |
Cefuroxime Axetil | Tablet equivalent to 250 mg cefuroxime | Oral | 14 | .. | GK | |
Cephalexin | Capsule 250 mg (anhydrous) | Oral | 20 | .. | AF, AS, CH, DP, GX, HX, LN, TW | |
| Capsule 500 mg (anhydrous) | Oral | 20 | .. | AF, AS, CH, DP, GX, HX, LN, TW | |
Cephalexin with Water - Purified BP | Granules for oral suspension 125 mg per 5 mL, 100 mL | Oral | 1 | .. | AF, AS, CH, DP, GX, LN, TW | |
| Granules for oral suspension 250 mg per 5 mL, 100 mL | Oral | 1 | .. | AF, AS, CH, DP, GX, LN, TW | |
Cephalothin Sodium | Powder for injection equivalent to 1 g cephalothin | Injection | 10 | .. | AS, MX | |
Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the eye | 1 | .. | PF, SI | |
Clindamycin Hydrochloride | Capsule equivalent to 150 mg clindamycin | Oral | 25 | .. | KR, PH | |
Codeine Phosphate | Tablet 30 mg | Oral | 20 | .. | FM | |
Codeine Phosphate with Paracetamol | Tablet 30 mg-500 mg | Oral | 20 | .. | AL, CO, DK, FM, GK, SW | |
Diazepam | Tablet 2 mg | Oral | 50 | .. | AF, AW, RO, SU | |
| Tablet 5 mg | Oral | 50 | .. | AF, AW, DP, RO, SU | |
| Injection 10 mg in 2 mL ampoule | Injection | 5 | .. | MX | |
Diclofenac Sodium | Tablet 25 mg (enteric coated) | Oral | 100 | .. | AF, AW, BG, CH, DP, GX, HX, NV, TW | |
| Tablet 50 mg (enteric coated) | Oral | 50 | .. | AF, AW, CH, DP, GX, HX, NV, TW | |
| Suppository 100 mg | Rectal | 40 | .. | NV | |
Dicloxacillin Sodium | Capsule equivalent to 250 mg dicloxacillin | Oral | 24 | .. | AF, BQ, SI | |
| Capsule equivalent to 500 mg dicloxacillin | Oral | 24 | .. | AF, BQ, SI | |
| Powder for injection equivalent to 500 mg dicloxacillin | Injection | 5 | .. | BQ | |
| Powder for injection equivalent to 1 g dicloxacillin | Injection | 5 | .. | BQ | |
Doxycycline Hydrochloride | Tablet equivalent to 100 mg doxycycline | Oral | 7 | .. | AF, DP, PF, SI | |
| Capsule equivalent to 100 mg doxycycline (containing enteric coated pellets) | Oral | 7 | .. | FA, MX | |
Doxycycline Monohydrate | Tablet equivalent to 100 mg doxycycline | Oral | 7 | .. | CH, GX, HX, TW | |
Erythromycin | Capsule 250 mg (containing enteric coated pellets) | Oral | 25 | .. | FA, MX | |
Erythromycin Ethyl Succinate | Tablet equivalent to 400 mg erythromycin | Oral | 25 | .. | AB, AF | |
Erythromycin Ethyl Succinate with Water - Purified BP | Powder for oral liquid equivalent to 200 mg erythromycin per 5 mL, 100 mL | Oral | 1 | .. | AB, AF | |
| Powder for oral liquid equivalent to 400 mg erythromycin per 5 mL, 100 mL | Oral | 1 | .. | AB, AF | |
Erythromycin Lactobionate | Powder for I.V. infusion equivalent to 1 g erythromycin, vial | Injection | 5 | .. | AB | |
Flucloxacillin Magnesium with Water - Purified BP | Powder for oral suspension equivalent to 125 mg flucloxacillin per 5 mL, 100 mL | Oral | 1 | .. | CS, GK | |
| Powder for oral suspension equivalent to 250 mg flucloxacillin per 5 mL, 100 mL | Oral | 1 | .. | CS, GK | |
Flucloxacillin Sodium | Capsule equivalent to 250 mg flucloxacillin | Oral | 24 | .. | AF, CS, GK, SI | |
| Capsule equivalent to 500 mg flucloxacillin | Oral | 24 | .. | AF, CS, GK, SI | |
|
|
|
|
|
| |
| Powder for injection equivalent to 500 mg flucloxacillin | Injection | 5 | .. | CS, DP | |
| Powder for injection equivalent to 1 g flucloxacillin | Injection | 5 | .. | AS, CS, DP, MX | |
Glucagon Hydrochloride | Injection set containing 1 mg (1 I.U.) and 1 mL solvent in disposable syringe | Injection | 1 | .. | NO | |
Glucose | I.V. infusion 278 mmol (anhydrous) per L, 1 L | Injection | 5 | .. | BX | |
Glyceryl Trinitrate | Tablets 600 micrograms, 100 | Oral | 1 | .. | FM, SI | |
Hydrocortisone Acetate | Cream 10 mg per g, 30 g | Application | 1 | .. | FM, SI | |
| Cream 10 mg per g, 50 g | Application | 1 | .. | DT, FM, SI | |
| Ointment 10 mg per g, 30 g | Application | 1 | .. | FM, SI | |
| Ointment 10 mg per g, 50 g | Application | 1 | .. | FM, SI | |
Hydrocortisone Sodium Succinate | Injection equivalent to 100 mg hydrocortisone with 2 mL solvent | Injection | 6 | .. | PH | |
| Injection equivalent to 250 mg hydrocortisone with 2 mL solvent | Injection | 6 | .. | PH | |
Hydromorphone Hydrochloride | Tablet 2 mg | Oral | 20 | .. | AB | |
| Tablet 4 mg | Oral | 20 | .. | AB | |
| Tablet 8 mg | Oral | 20 | .. | AB | |
| Oral liquid 1 mg per mL, 473 mL | Oral | 1 | .. | AB | |
| Injection 2 mg in 1 mL ampoule | Injection | 5 | .. | AB | |
| Injection 10 mg in 1 mL ampoule | Injection | 5 | .. | AB | |
| Injection 50 mg in 5 mL ampoule | Injection | 5 | .. | AB | |
Ibuprofen | Tablet 200 mg | Oral | 100 | .. | AF | |
| Tablet 400 mg | Oral | 100 | .. | AB | |
| Tablets 400 mg, 20 | Oral | 1 | .. | AB | |
Indomethacin | Capsule 25 mg | Oral | 100 | .. | AF, MK | |
| Suppository 100 mg | Rectal | 40 | .. | MK | |
Ketoprofen | Capsule 200 mg (sustained release) | Oral | 28 | .. | AV, HP | |
| Suppository 100 mg | Rectal | 40 | .. | AV | |
Lignocaine Hydrochloride | Injection 100 mg in 5 mL | Injection | 5 | .. | PF | |
Lincomycin Hydrochloride | Injection equivalent to 600 mg lincomycin in 2 mL vial | Injection | 5 | .. | PH | |
Methylprednisolone Acetate | Injection 40 mg in 1 mL vial | Injection | 5 | .. | KR, PH | |
Metoclopramide Hydrochloride | Tablet 10 mg | Oral | 25 | .. | AF, VT | |
| Oral solution 5 mg per 5 mL, 100 mL | Oral | 1 | .. | VT | |
| Injection 10 mg in 2 mL ampoule | Injection | 10 | .. | VT | |
Metronidazole | Tablet 200 mg | Oral | 21 | .. | AF, AV, HP | |
| Tablet 400 mg | Oral | 5 | .. | AF | |
| I.V. infusion 500 mg in 100 mL | Injection | 5 | .. | BX | |
| Suppositories 500 mg, 10 | Rectal | 1 | .. | AV | |
Metronidazole Benzoate | Oral suspension 320 mg per 5 mL, 100 mL | Oral | 1 | .. | AV | |
Morphine Hydrochloride | Oral solution 1 mg per mL, 500 mL | Oral | 1 | .. | VT | |
| Oral solution 2 mg per mL, 200 mL | Oral | 1 | .. | MF, PF | |
| Oral solution 5 mg per mL, 200 mL | Oral | 1 | .. | MF, PF | |
| Oral solution 5 mg per mL, 250 mL | Oral | 1 | .. | VT | |
| Oral solution 5 mg per mL, 500 mL | Oral | 1 | .. | VT | |
| Oral solution 10 mg per mL, 200 mL | Oral | 1 | .. | MF, PF | |
| Oral solution 10 mg per mL, 250 mL | Oral | 1 | .. | VT | |
Morphine Sulfate | Tablet 30 mg | Oral | 20 | .. | FM | |
| Tablet 5 mg (controlled release) | Oral | 20 | .. | MF | |
| Tablet 10 mg (controlled release) | Oral | 20 | .. | MF | |
| Tablet 15 mg (controlled release) | Oral | 20 | .. | MF | |
| Tablet 30 mg (controlled release) | Oral | 20 | .. | MF | |
| Tablet 60 mg (controlled release) | Oral | 20 | .. | MF | |
| Tablet 100 mg (controlled release) | Oral | 20 | .. | MF | |
| Capsule 10 mg (containing sustained release pellets) | Oral | 20 | .. | GK | |
| Capsule 20 mg (containing sustained release pellets) | Oral | 20 | .. | GK | |
| Capsule 30 mg (controlled release) | Oral | 10 | .. | MF | |
| Capsule 50 mg (containing sustained release pellets) | Oral | 20 | .. | GK | |
| Capsule 60 mg (controlled release) | Oral | 10 | .. | MF | |
| Capsule 90 mg (controlled release) | Oral | 10 | .. | MF | |
| Capsule 100 mg (containing sustained release pellets) | Oral | 20 | .. | GK | |
| Capsule 120 mg (controlled release) | Oral | 10 | .. | MF | |
| Sachet containing controlled release granules for oral suspension, 20 mg per sachet | Oral | 20 | .. | MF | |
| Sachet containing controlled release granules for oral suspension, 30 mg per sachet | Oral | 20 | .. | MF | |
| Sachet containing controlled release granules for oral suspension, 60 mg per sachet | Oral | 20 | .. | MF | |
| Sachet containing controlled release granules for oral suspension, 100 mg per sachet | Oral | 20 | .. | MF | |
| Injection 10 mg in 1 mL ampoule | Injection | 5 | .. | MX | |
| Injection 15 mg in 1 mL ampoule | Injection | 5 | .. | MX | |
| Injection 30 mg in 1 mL ampoule | Injection | 5 | .. | MX | |
Naloxone Hydrochloride | Injection 400 micrograms in 1 mL disposable injection set | Injection | 1 | .. | CS | |
| Injection 800 micrograms in 2 mL disposable injection set | Injection | 1 | .. | CS | |
| Injection 2 mg in 5 mL disposable injection set | Injection | 1 | .. | CS | |
Naproxen | Tablet 250 mg | Oral | 100 | .. | AF, RO | |
| Tablet 500 mg | Oral | 50 | .. | AF, RO | |
| Tablet 750 mg (sustained release) | Oral | 28 | .. | MD, RO | |
| Tablet 1 g (sustained release) | Oral | 28 | .. | MD, RO | |
Naproxen Sodium | Tablet 550 mg | Oral | 50 | .. | MD, RO | |
Nitrazepam | Tablet 5 mg | Oral | 25 | .. | AF, VT | |
Nystatin | Tablet 500,000 units | Oral | 50 | .. | SI | |
| Capsule 500,000 units | Oral | 50 | .. | SI | |
| Oral suspension 100,000 units per mL, 24 mL | Oral | 1 | .. | BQ, SI | |
Oxazepam | Tablet 15 mg | Oral | 25 | .. | AF, SI | |
| Tablet 30 mg | Oral | 25 | .. | AF, FM, SI | |
Oxycodone Hydrochloride | Tablet 5 mg | Oral | 20 | .. | SI | |
| Capsule 5 mg | Oral | 20 | .. | MF | |
| Capsule 10 mg | Oral | 20 | .. | MF | |
| Capsule 20 mg | Oral | 20 | .. | MF | |
| Oral solution 5 mg per 5 mL, 250 mL | Oral | 1 | .. | MF | |
| Tablet 5 mg (controlled release) | Oral | 20 | .. | MF | |
| Tablet 10 mg (controlled release) | Oral | 20 | .. | MF | |
| Tablet 20 mg (controlled release) | Oral | 20 | .. | MF | |
| Tablet 40 mg (controlled release) | Oral | 20 | .. | MF | |
| Tablet 80 mg (controlled release) | Oral | 20 | .. | MF | |
Oxycodone Pectinate | Suppository equivalent to 30 mg oxycodone | Rectal | 12 | .. | PL | |
Paracetamol | Tablet 500 mg | Oral | 100 | .. | AW, CH, DG, FM, HX, JT, PC, SW, TW | |
| Oral liquid 120 mg per 5 mL, 100 mL | Oral | 1 | .. | SW | |
| Oral liquid 240 mg per 5 mL, 200 mL | Oral | 1 | .. | SW | |
Pethidine Hydrochloride | Injection 100 mg in 2 mL ampoule | Injection | 5 | .. | MX | |
Phenoxymethylpenicillin Benzathine | Oral suspension equivalent to 125 mg phenoxymethylpenicillin per 5 mL, 100 mL | Oral | 2 | .. | FM, SI | |
| Oral suspension equivalent to 250 mg phenoxymethylpenicillin per 5 mL, 100 mL | Oral | 2 | .. | FM, SI | |
Phenoxymethylpenicillin Potassium | Tablet equivalent to 250 mg phenoxymethylpenicillin | Oral | 50 | .. | SI | |
| Tablet equivalent to 500 mg phenoxymethylpenicillin | Oral | 50 | .. | SI | |
| Capsule equivalent to 250 mg phenoxymethylpenicillin | Oral | 50 | .. | CS, DP, FM, HX | |
| Capsule equivalent to 500 mg phenoxymethylpenicillin | Oral | 50 | .. | CS, DP, FM, HX | |
Piroxicam | Dispersible tablet 10 mg | Oral | 50 | .. | AF, GX, HX, PF | |
| Dispersible tablet 20 mg | Oral | 25 | .. | AF, CH, GX, HX, PF, TW | |
| Capsule 10 mg | Oral | 50 | .. | AF, CH, GX, PF, TW | |
| Capsule 20 mg | Oral | 25 | .. | AF, CH, GX, PF, TW | |
Procaine Penicillin | Injection 1.5 g in disposable syringe | Injection | 5 | .. | SI | |
Prochlorperazine | Suppositories 3 mg, equivalent to 5 mg prochlorperazine maleate, 5 | Rectal | 1 | .. | AV | |
| Suppositories 15 mg, equivalent to 25 mg prochlorperazine maleate, 5 | Rectal | 1 | .. | AV | |
Prochlorperazine Maleate | Tablet 5 mg | Oral | 25 | .. | AV, HP | |
Prochlorperazine Mesylate | Injection 12.5 mg in 1 mL ampoule | Injection | 10 | .. | AV | |
Promethazine Hydrochloride | Injection 50 mg in 2 mL ampoule | Injection | 10 | .. | MX | |
Sodium Chloride | I.V. infusion 154 mmol per L, 1 L | Injection | 5 | .. | BX | |
| I.V. infusion 513 mmol per L, 1 L | Injection | 2 | .. | BX | |
Sodium Chloride with Glucose | I.V. infusion 31 mmol-222 mmol (anhydrous) per L, 1 L | Injection | 5 | .. | BX | |
| I.V. infusion 19 mmol-104 mmol (anhydrous) per 500 mL, 500 mL | Injection | 5 | .. | BX | |
| I.V. infusion 39 mmol-69 mmol (anhydrous) per 500 mL, 500 mL | Injection | 5 | .. | BX | |
Sulindac | Tablet 100 mg | Oral | 100 | .. | AF | |
| Tablet 200 mg | Oral | 50 | .. | AF | |
Temazepam | Tablet 10 mg | Oral | 25 | .. | AF, FM, SI | |
Ticarcillin Sodium with Potassium Clavulanate | Powder for injection equivalent to 3 g ticarcillin-100 mg clavulanic acid | Injection | 10 | .. | GK | |
Tramadol Hydrochloride | Capsule 50 mg | Oral | 20 | .. | AF, AW, CH, CS, GX, TW | |
| Tablet 100 mg (sustained release) | Oral | 20 | .. | AW, CS, HX | |
| Tablet 150 mg (sustained release) | Oral | 20 | .. | AW, CS, HX | |
| Tablet 200 mg (sustained release) | Oral | 20 | .. | AW, CS, HX | |
| Oral drops 100 mg per mL, 10 mL | Oral | 1 | .. | CS | |
| Injection 100 mg in 2 mL ampoule | Injection | 5 | .. | CS, HX | |
Triamcinolone Acetonide | Injection 10 mg in 1 mL ampoule | Injection | 5 | .. | BQ | |
Trimethoprim with Sulfamethoxazole | Tablet 80 mg-400 mg | Oral | 10 | .. | AF, SI | |
| Tablet 160 mg-800 mg | Oral | 10 | .. | AF, CH, GX, RO, SI, TW | |
| Paediatric oral suspension 40 mg-200 mg per 5 mL, 100 mL | Oral | 1 | .. | AF, RO, SI | |
Vancomycin Hydrochloride | Powder for injection equivalent to 500 mg (500,000 I.U.) vancomycin activity | Injection | 2 | .. | AS, MX | |
| ||||||
Metronidazole | Tablet 400 mg | Treatment of anaerobic infections | Oral | 21 | .. | AF, AV, HP | |
Paracetamol | Tablet 500 mg | Chronic arthropathies | Oral | 300 | .. | AW, CH, DG, FM, HX, JT, PC, SW, TW | |
| |||||||
Creams 100 g 1
Dusting Powders 100 g 1
Ear Drops 15 mL 2
Eye Drops containing Cocaine Hydrochloride BP 15 mL ..
Eye Drops, Other 15 mL 5
Eye Lotions 200 mL 2
Inhalations 50 mL 1
Linctuses containing Codeine Phosphate BP 100 mL ..
Linctuses, Other 100 mL 2
Lotions 200 mL 2
Mixtures containing Codeine Phosphate BP 200 mL ..
Mixtures, Other 200 mL 4
Mixtures for Children containing Codeine Phosphate BP 100 mL ..
Mixtures for Children, Other 100 mL 4
Mouth Washes 200 mL 1
Nasal Instillations 15 mL 2
Ointments and Waxes 100 g 1
Paints 25 mL 1
Pastes containing Cocaine Hydrochloride BP 25 g ..
Pastes, Other 100 g 1
Powders for Internal Use 100 g 2
Solutions 200 mL 2
|
Notes to the Determinations under Sections 85, 85A and 88 (No. PB 24 of 2006)
Note 1
The Determinations under Sections 85, 85A and 88 (No. PB 24 of 2006) (in force under subsection 85, 85A and 88 of the National Health Act 1953) as shown in this compilation is amended as indicated in the Tables below.
Table of Instruments
Title | Date of Registration | Date of | Application, saving or |
No. PB 24 of 2006 | 26 May 2006 (see F2006L01619) | 1 June 2006 |
|
No. PB 25 of 2006 | 19 June 2006 (see F2006L01880) | 20 June 2006 | — |
Table of Amendments
ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted | |
Provision affected | How affected |
First Schedule |
|
Part 1................ | am. No. PB 25 of 2006 |
Part 2................ | am. No. PB 25 of 2006 |
Third Schedule |
|
Part 1................ | am. No. PB 25 of 2006 |